EP2569276A1 - Nouveaux lipides cationiques et procédés d'utilisation de ceux-ci - Google Patents

Nouveaux lipides cationiques et procédés d'utilisation de ceux-ci

Info

Publication number
EP2569276A1
EP2569276A1 EP11731455A EP11731455A EP2569276A1 EP 2569276 A1 EP2569276 A1 EP 2569276A1 EP 11731455 A EP11731455 A EP 11731455A EP 11731455 A EP11731455 A EP 11731455A EP 2569276 A1 EP2569276 A1 EP 2569276A1
Authority
EP
European Patent Office
Prior art keywords
lipid
mol
particle
compound
moiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP11731455A
Other languages
German (de)
English (en)
Other versions
EP2569276B1 (fr
Inventor
James Heyes
Mark Wood
Alan Martin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arbutus Biopharma Corp
Original Assignee
Protiva Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protiva Biotherapeutics Inc filed Critical Protiva Biotherapeutics Inc
Publication of EP2569276A1 publication Critical patent/EP2569276A1/fr
Application granted granted Critical
Publication of EP2569276B1 publication Critical patent/EP2569276B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/08—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/46—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/30—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/02—Monothiocarboxylic acids
    • C07C327/04—Monothiocarboxylic acids having carbon atoms of thiocarboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C327/06—Monothiocarboxylic acids having carbon atoms of thiocarboxyl groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/22—Esters of monothiocarboxylic acids having carbon atoms of esterified thiocarboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Definitions

  • Therapeutic nucleic acids include, e.g., small interfering RNA (siRNA), microRNA (miRNA), antisense oligonucleotides, ribozymes, plasmids, and immune-stimulating nucleic acids. These nucleic acids act via a variety of mechanisms. In the case of interfering RNA molecules such as siRNA and miRNA, these nucleic acids can down-regulate intracellular levels of specific proteins through a process termed RNA interference (RNAi). Following introduction of interfering RNA into the cell cytoplasm, these double-stranded RNA constructs can bind to a protein termed RISC.
  • siRNA small interfering RNA
  • miRNA microRNA
  • antisense oligonucleotides e.g., antisense oligonucleotides, ribozymes, plasmids, and immune-stimulating nucleic acids.
  • RNAi RNA interference
  • the sense strand of the interfering RNA is displaced from the RISC complex, providing a template within RISC that can recognize and bind mRNA with a complementary sequence to that of the bound interfering RNA. Having bound the complementary mRNA, the RISC complex cleaves the mRNA and releases the cleaved strands. RNAi can provide down-regulation of specific proteins by targeting specific destruction of the corresponding mRNA that encodes for protein synthesis.
  • RNAi The therapeutic applications of RNAi are extremely broad, since interfering RNA constructs can be synthesized with any nucleotide sequence directed against a target protein.
  • siRNA constructs have shown the ability to specifically down-regulate target proteins in both in vitro and in vivo models.
  • siRNA constructs are currently being evaluated in clinical studies.
  • RNA constructs Two problems currently faced by interfering RNA constructs are, first, their susceptibility to nuclease digestion in plasma and, second, their limited ability to gain access to the intracellular compartment where they can bind RISC when administered systemically as free interfering RNA molecules.
  • These double-stranded constructs can be stabilized by the incorporation of chemically modified nucleotide linkers within the molecule, e.g., phosphothioate groups.
  • chemically modified linkers provide only limited protection from nuclease digestion and may decrease the activity of the construct.
  • Intracellular delivery of interfering RNA can be facilitated by the use of carrier systems such as polymers, cationic liposomes, or by the covalcni attachment of a cholesterol moiety to the molecule.
  • carrier systems such as polymers, cationic liposomes, or by the covalcni attachment of a cholesterol moiety to the molecule.
  • improved delivery systems are required to increase the potency of interfering NA molecules such as siRNA and miR A and to reduce or eliminate the requirement for chemically modified nucleotide linkers.
  • lipid-based carrier systems to deliver chemically modified or unmodified therapeutic nucleic acids.
  • Zelphati et al. J. Contr. ReL, 41 :99- 19 (1996) describes the use of anionic (conventional) liposomes, pH sensitive liposomes, immunoliposomes, fusogenic liposomes, and cationic lipid/antisense aggregates.
  • siRNA has been administered systemically in cationic liposomes, and these nucleic acid-lipid particles have been reported to provide improved down-regulation of target proteins in mammals including non-human primates (Zirnmermann et al. , Nature, 441 : 111-114 (2006)).
  • these compositions would encapsulate nucleic acids with high efficiency, have high drug:lipid ratios, protect the encapsulated nucleic acid from degradation and clearance in serum, be suitable for systemic delivery, and provide intracellular delivery of the
  • nucleic acid-lipid particles should be well- tolerated and provide an adequate therapeutic index, such that patient treatment at an effective dose of the nucleic acid is not associated with significant toxicity and/or risk to the patient.
  • present invention provides such compositions, methods of making the compositions, and methods of using the compositions to introduce nucleic acids into cells, including for the treatment of diseases.
  • the present invention provides novel cationic (audino) lipids and lipid particles comprising these lipids, which are advantageous for the in vivo delivery of active agents or therapeutic agents such as nucleic acids, as well as lipid particles such as nucleic acid-lipid particle compositions suitable for in vivo therapeutic use.
  • the present invention also provides methods of making these lipid compositions, as well as methods of introducing active agents or therapeutic agents such as nucleic acids into cells using these lipid compositions, e.g., for the treatment of various disease conditions.
  • the present invention provides a cationic lipid of Formula I having the following structure:
  • R 1 and R 2 are either the same or different and are independently hydrogen (H) or an optionally substituted CrC 6 alkyl, C 2 -Cs alkenyl, or C 2 -C 6 alkynyl, or R 1 and R 2 may join to form an optionally substituted heterocyclic ring;
  • R 3 is either absent or is hydrogen (H) or a C ⁇ -C alkyl to provide a quaternary amine
  • R 4 and R 5 are either the same or different and are independently an optionally substituted C 10 -C24 alkyl, Cio-C 2 4 alkenyl, Cio-C 2 4 alkynyl, or C 10 -C 2 4 acyl;
  • X is O, S, N(R 6 ), C(O), C(0)0, OC(O), C(0)N(R 6 ), N(R 6 )C(0), OC(0)N(R 6 ), N(R 6 )C(0)0, C(0)S, C(S)0, S(O), S(0)(0), C(S), or an optionally substituted heterocyclic ring, wherein R 6 is hydrogen (H) or an optionally substituted Ci-Cio alkyl, C 2 -C 10 alkenyl, or C 2 -C)o alkynyl; and
  • Y is either absent or is an optionally substituted Ci-Ce alkyl, C 2 -C1 ⁇ 2 alkenyl, or
  • R 1 and R 2 are independently selected from the group consisting of a methyl group and an ethyl group, i.e., R 1 and R 2 are both methyl groups, R 1 and R 2 are both ethyl groups, or R 1 and R 2 are a combination of one methyl group and one ethyl group.
  • R 1 and R 2 are joined to form an optionally substituted heterocyclic ring having from 2 to 5 carbon atoms (e.g., 2, 3, 4, or 5 carbon atoms, or from 2-5, 2-4, 2-3, 3-5, 3-4, or 4-5 carbon atoms) and from 1 to 3 heteroatoms ⁇ e.g., 1, 2, or 3 heteroatoms, or from 1-3, 1-2, or 2-3 heteroatoms) selected from the group consisting of nitrogen (N), oxygen (O), sulfur (S), and combinations thereof.
  • R 1 and R 2 are joined to form an optionally substituted diazole (e.g., an optionally substituted imidazole) or an optionally substituted triazole.
  • X is O, C(0)0, C(0)N(R 6 ), N(R 6 )C(0)0, or C(0)S.
  • R 6 is hydrogen (H)bond an optionally substituted methyl group, an optionally substituted ethyl group, or an optionally substituted C 3 -C
  • X is an optionally substituted heterocyclic ring having iroui 2 to 5 carbon atoms (e.g., 2, 3, 4, or 5 carbon atoms, or from 2-5, 2-4, 2-3, 3-5, 3-4, or 4-5 carbon atoms) and from 1 to 3 heteroatoms (e.g., 1, 2, or 3 heteroatoms, or from 1-3, 1-2, or 2-3 heteroatoms) selected from the group consisting of nitrogen (N), oxygen (O), sulfur (S), and combinations thereof.
  • X is an optionally substituted diazole (e.g., an optionally substituted imidazole) or an optionally substituted triazole.
  • Y is (03 ⁇ 4) ⁇ and n is 0, 1, 2, 3, 4, 5, or 6. In particular embodiments, n is 2, 3, or 4 (e.g., n is 2-4, 2-3, or 3-4).
  • R 4 and R 5 which can be independently optionally substituted, comprises at least one site of unsaturation.
  • R 4 and R 5 are independently selected from the group consisting of a dodecenyl moiety, a tetradecenyl (e.g., myristoleyl) moiety, a hexadecenyl (e.g., palmitoleyl) moiety, an octadecenyl (e.g., oleyl) moiety, and an icosenyl moiety.
  • one of R 4 or R s is an oleyl moiety or R 4 and R 5 are both oleyl moieties.
  • one of R 4 or R 5 comprises one site of unsaturation and the other side-chain comprises at least two or three sites of unsaturation as described herein.
  • R 4 and R 5 which can be independently optionally substituted, comprises at least two sites of unsaturation.
  • R 4 and R 5 are independently selected from the group consisting of a dodecadienyl moiety, a tetradecadienyl moiety, a hexadecadienyl moiety, an octadecadienyl moiety, and an icosadienyl moiety.
  • the octadecadienyl moiety is a linoleyl moiety.
  • one ofR 4 or R 5 is a linoleyl moiety or R 4 and R are both linoleyl moieties.
  • one of R 4 or R 5 comprises two sites of unsaturation and the other side-chain comprises at least three sites of unsaturation as described herein.
  • R ] and R 2 are not both methyl groups when X is C(0)0, Y is (C3 ⁇ 4) 2 or (CH 2 ) 3 , and R 4 and R 5 are both linoleyl moieties.
  • At least one of R 4 and R 5 (e.g., both R 4 and R 5 ), which can be independently optionally substituted, comprises at least three sites of unsaturation.
  • R 4 and R s are independently selected from the group consisting of a dodecatrienyl moiety, a tetradectrienyl moiety, a hexadecatrienyl moiety, an octadecatrienyl moiety, and an icosatrienyl moiety.
  • the octadecatrienyl moiety is a linolenyl moiety or a ⁇ -linolenyl moiety.
  • one of R 4 or R 5 is a linolenyl or ⁇ -linolenyl moiety, or R 4 and R 5 are both linolenyl or ⁇ -linolenyl moieties.
  • one of R 4 or R 5 comprises three sites of unsaturation and the other side- chain comprises at least four sites of unsaturation as described herein. [00151 Tn a further embodiment, at least one of R 4 and R 5 (e.g., both R 4 and R 5 ) comprises a substituted C 12 -C 2 4 alkyl.
  • the substituted C12-C2 alkyl comprises a C 12 -C 2 4 alkyl having at least 1-6 C1-C6 alkyl substituents.
  • one of R 4 or R 5 is a phytanyl moiety or R 4 and R 5 are both phytanyl moieties.
  • one of R 4 or R 5 comprises a substituted C 12 -C 2 4 alkyl and the other side-chain comprises at least one, two, or three sites of unsaturation as described herein.
  • one of R 4 or R 5 comprises at least one optionally substituted cyclic alkyl group.
  • the optionally substituted cyclic alkyl group comprises an optionally substituted saturated cyclic alkyl group, an optionally substituted unsaturated cyclic alkyl group, or a combination thereof.
  • the optionally substituted saturated cyclic alkyl group comprises an optionally substituted C 3-8 cycloalkyl group such as, for example, a cyclopropyl group.
  • the optionally substituted unsaturated cyclic alkyl group comprises an optionally substituted C 3-8 cycloalkenyl group.
  • one of R 4 or R 5 comprises at least one optionally substituted cyclic alkyl group and the other side-chain comprises any one of the optionally substituted Ci 0 -C 2 alkyl, Cto-C ⁇ alkenyl, C 10 -C24 alkynyl, or Cio-C 24 acyl groups described herein (e.g., a side-chain comprising at least one, two, or three sites of unsaturation).
  • each of the at least one, two, or three sites of unsaturation present in one or both R 4 and R 5 correspond to a cis double bond, a trans double bond, or combinations thereof at specific positions in one or both R 4 and R 5 .
  • one or both R 4 and R 5 are C 18 alkyl groups containing any combination of double bonds in the cis and/or trans configuration at one or more positions in the side-chain (e.g., cis and/or trans double bonds at position 9, at positions 6 and 9, at positions 3, 6, and 9, at positions 6, 9, and 12, or at positions 7 and 9 of a C )8 alkyl group).
  • the at least one, two, or three sites of unsaturation present in one or both R 4 and R 5 can also be characterized by either the "E" chemical notation and/or the "Z" chemical notation.
  • the cationic lipid of Formula I is selected from the group consisting of Compounds 4, 8, 10, 11 , 12, 13, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, and 45 as described herein.
  • the present invention provides a lipid particle comprising one or more of the above cationic lipids of Formula I or salts thereof.
  • the lipid particle further comprises one or more non-cationic lipids such as neutral lipids.
  • the lipid particle further comprises one or more conjugated lipids capable of reducing or inhibiting particle aggregation.
  • the lipid particle further comprises one or more active agents or therapeutic agents.
  • the non-cationic lipid component of the lipid particle may comprise a phospholipid, cholesterol (or cholesterol derivative), or a mixture thereof.
  • the phospholipid comprises dipalmitoylphosphatidylcholme (DPPC), distearoylphosphatidylcholine (DSPC), or a mixture thereof.
  • the conjugated lipid component of the lipid particle comprises a polyethyleneglycol (PEG)-lipid conjugate.
  • the PEG-lipid conjugate comprises a PEG-diacylglycerol (PEG-DAG) conjugate, a PEG-dialkyloxypropyl (PEG-DAA) conjugate, or a mixture thereof.
  • the lipid conjugate comprises a polyoxazoline (POZ)-lipid conjugate such as a POZ-DAA conjugate.
  • the active agent or therapeutic agent comprises a nucleic acid.
  • the nucleic acid comprises an interfering RNA molecule which includes any double-stranded RNA capable of mediating RNAi, such as, e.g., an siRNA, Dicer-substrate dsRNA, shRNA, aiRNA, pre-miRNA, or mixtures thereof.
  • the nucleic acid comprises single-stranded or double-stranded DNA, RNA, or a DNA/RNA hybrid such as, e.g., an antisense oligonucleotide, a ribozyme, a plasmid, an immunostimulatory oligonucleotide, or mixtures thereof.
  • the active agent or therapeutic agent is fully encapsulated within the lipid portion of the lipid particle such that the active agent or therapeutic agent in the lipid particle is resistant in aqueous solution to enzymatic degradation, e.g., by a nuclease or protease.
  • the lipid particle is substantially non-toxic to mammals such as humans.
  • the present invention provides serum-stable nucleic acid- lipid particles (SNALP) comprising: (a) one or more nucleic acids such as interfering RNA molecules; (b) one or more cationic lipids of Formula I or salts thereof; (c) one or more non- cationic lipids; and (d) one or more conjugated lipids that inhibit aggregation of particles.
  • SNALP serum-stable nucleic acid- lipid particles
  • the present invention provides nucleic acid-lipid particles (e.g., SNALP) comprising: (a) one or more nucleic acids; (b) one or more cationic lipids of Formula I or salts thereof comprising from about 50 mol % to about 85 mol % of the total lipid present in the particle; (c) one or more non-cationic lipids comprising from about 13 mol % to about 49.5 mol % of the total lipid present in the particle; and (d) one or more conjugated lipids that inhibit aggregation of particles comprising from about 0.5 mol % to about 2 mol % of the total lipid present in the particle.
  • SNALP nucleic acid-lipid particles
  • the nucleic acid-iipid particie comprises: (a) one or more nucleic acids; (b) one or more cationic lipids of Formula I or a salt thereof comprising from about 50 mol % to about 65 mol % of the total lipid present in the particle; (c) one or more non-cationic lipids comprising a mixture of one or more phospholipids and cholesterol or a derivative thereof, wherein the one or more phospholipids comprises from about 4 mol % to about 10 mol % of the total lipid present in the particle and the cholesterol or derivative thereof comprises from about 30 mol % to about 40 mol % of the total lipid present in the particle; and (d) one or more PEG-lipid conjugates comprising from about 0.5 mol % to about 2 mol % of the total lipid present in the particle.
  • This embodiment of nucleic acid-lipid particle is generally referred to herein as the "1 :57" formulation.
  • the 1 :57 formulation comprises: (a) one or more nucleic acids; (b) one or more cationic lipids of Formula I or a salt thereof comprising from about 52 mol % to about 62 mol % of the total lipid present in the particle; (c) a mixture of one or more phospholipids and cholesterol or a derivative thereof comprising from about 36 mol % to about 47 mol % of the total lipid present in the particle; and (d) one or more PEG-lipid conjugates comprising from about 1 mol % to about 2 mol % of the total lipid present in the particle.
  • the 1 : 57 formulation is a four-component system comprising about 1.4 mol % PEG-lipid conjugate (e.g., PEG2000-C-DMA), about 57.1 mol % cationic lipid of Formula I or a salt thereof, about 7.1 mol % DPPC (or DSPC), and about 34.3 mol % cholesterol (or derivative thereof).
  • PEG-lipid conjugate e.g., PEG2000-C-DMA
  • cationic lipid of Formula I or a salt thereof about 7.1 mol % DPPC (or DSPC)
  • 34.3 mol % cholesterol or derivative thereof.
  • the nucleic acid-lipid particle comprises: (a) one or more nucleic acids; (b) one or more cationic lipids of Formula I or a salt thereof comprising from about 56.5 mol % to about 66.5 mol % of the total lipid present in the particle; (c) cholesterol and/or one or more derivatives thereof comprising from about 31.5 mol % to about 42.5 mol % of the total lipid present in the particle; and (d) one or more PEG- lipid conjugates comprising from about 1 mol % to about 2 mol % of the total lipid present in the particle.
  • This embodiment of nucleic acid-lipid particle is generally referred to herein as the "1 :62" formulation.
  • the 1 :62 formulation is a three- component system which is phospholipid-free and comprises about 1.5 mol % PEG-lipid conjugate (e.g., PEG2000-C-DMA), about 61.5 mol % cationic lipid of Formula I or a salt thereof, and about 36.9 mol % cholesterol (or derivative thereof).
  • PEG-lipid conjugate e.g., PEG2000-C-DMA
  • 61.5 mol % cationic lipid of Formula I or a salt thereof e.g., a salt thereof
  • cholesterol or derivative thereof
  • the present invention provides nucleic acid-iipid particles (e.g., SNALP) comprising: (a) one or more nucleic acids; (b) one or more cationic lipids of Formula I or salts thereof comprising from about 2 mol % to about 50 mol % of the total lipid present in the particle; (c) one or more non-cationic lipids comprising from about 5 mol % to about 90 mol % of the total lipid present in the particle; and (d) one or more conjugated lipids that inhibit aggregation of particles comprising from about 0.5 mol % to about 20 mol % of the total lipid present in the particle.
  • SNALP nucleic acid-iipid particles
  • the nucleic acid-lipid particle comprises: (a) one or more nucleic acids; (b) one or more cationic lipids of Formula I or a salt thereof comprising from about 30 mol % to about 50 mol % of the total lipid present in the particle; (c) a mixture of one or more phospholipids and cholesterol or a derivative thereof comprising from about 47 mol % to about 69 mol % of the total lipid present in the particle; and (d) one or more PEG-lipid conjugates comprising from about 1 mol % to about 3 mol % of the total lipid present in the particle.
  • This embodiment of nucleic acid-lipid particle is generally referred to herein as the "2:40" formulation.
  • the 2:40 formulation is a four-component system which comprises about 2 mol % PEG-lipid conjugate (e.g., PEG2000-C-DMA), about 40 mol % cationic lipid of Formula I or a salt thereof, about 10 mol % DPPC (or DSPC), and about 48 mol % cholesterol (or derivative thereof).
  • PEG-lipid conjugate e.g., PEG2000-C-DMA
  • the 40 mol % cationic lipid of Formula I or a salt thereof about 10 mol % DPPC (or DSPC)
  • about 48 mol % cholesterol or derivative thereof.
  • the present invention provides nucleic acid-lipid particles (e.g., SNALP) comprising: (a) one or more nucleic acids; (b) one or more cationic lipids of Formula I or salts thereof comprising from about 50 mol % to about 65 mol % of the total lipid present in the particle; (c) one or more non-cationic lipids comprising from about 25 mol % to about 45 mol % of the total lipid present in the particle; and (d) one or more conjugated lipids that inhibit aggregation of particles comprising from about 5 mol % to about 10 mol % of the total lipid present in the particle.
  • SNALP nucleic acid-lipid particles
  • the nucleic acid-lipid particle comprises: (a) one or more nucleic acids; (b) one or more cationic lipids of Formula I or a salt thereof comprising from about 50 mol % to about 60 mol % of the total lipid present in the particle; (c) a mixture of one or more phospholipids and cholesterol or a derivative thereof comprising from about 35 mol % to about 45 mol % of the total lipid present in the particle; and (d) one or more PEG-lipid conjugates comprising from about 5 mol % to about 10 mol % of the total lipid present in the particle.
  • This embodiment of nucleic acid-lipid particle is generally referred to herein as the "7:54" formulation.
  • the non-cationic lipid mixture in the 7:54 formulation comprises: (i) a phospholipid of from about 5 mol % to about 10 mol % of the total lipid present in the particle; and (ii) cholesterol or a derivative thereof of from about 25 mol % tn about 35 rncl % of the total lipid pi cscal in the particle.
  • the 7:54 formulation is a four-component system which comprises about 7 mol % PEG-lipid conjugate (e.g., PEG750-C-DMA), about 54 mol % cationic lipid of Formula I or a salt thereof, about 7 mol % DPPC (or DSPC), and about 32 mol % cholesterol (or derivative thereof).
  • the nucleic acid-lipid particle comprises: (a) one or more nucleic acids; (b) one or more cationic lipids of Formula I or a salt thereof comprising from about 55 mol % to about 65 mol % of the total lipid present in the particle; (c) cholesterol and/or one or more derivatives thereof comprising from about 30 mol % to about 40 mol % of the total lipid present in the particle; and (d) one or more PEG-lipid conjugates comprising from about 5 mol % to about 10 mol % of the total lipid present in the particle.
  • This embodiment of nucleic acid-lipid particle is generally referred to herein as the "7:58" formulation.
  • the 7:58 formulation is a three-component system which is phospholipid-free and comprises about 7 mol % PEG-lipid conjugate (e.g., PEG750-C-DMA), about 58 mol % cationic lipid of Formula I or a salt thereof, and about 35 mol % cholesterol (or derivative thereof).
  • PEG-lipid conjugate e.g., PEG750-C-DMA
  • 58 mol % cationic lipid of Formula I or a salt thereof e.g., 58 mol % cationic lipid of Formula I or a salt thereof
  • 35 mol % cholesterol or derivative thereof.
  • the present invention also provides pharmaceutical compositions comprising a lipid particle such as a nucleic acid-lipid particle (e.g., SNALP) and a pharmaceutically acceptable carrier.
  • a lipid particle such as a nucleic acid-lipid particle (e.g., SNALP) and a pharmaceutically acceptable carrier.
  • the present invention provides methods for introducing one or more therapeutic agents such as nucleic acids into a cell, the method comprising contacting the cell with a lipid particle described herein (e.g., SNALP).
  • a lipid particle described herein e.g., SNALP
  • the cell is in a mammal and the mammal is a human.
  • the present invention provides methods for the in vivo delivery of one or more therapeutic agents such as nucleic acids, the method comprising administering to a mammal a lipid particle described herein (e.g., SNALP).
  • a lipid particle described herein e.g., SNALP
  • the lipid particles are administered by one of the following routes of administration: oral, intranasal, intravenous, intraperitoneal, intramuscular, intraarticular, intralesional, intratracheal, subcutaneous, and intradermal.
  • routes of administration oral, intranasal, intravenous, intraperitoneal, intramuscular, intraarticular, intralesional, intratracheal, subcutaneous, and intradermal.
  • the lipid particles are administered systemically, e.g., via enteral or parenteral routes of administration.
  • the mammal is a human.
  • the present invention provides methods for treating a disease or disorder in a mammal in need thereof, the method comprising administering to the mammal a therapeutically effective amount of a lipid particle (e.g., SNALP) comprising one or more therapeutic agents such as nucleic acids.
  • diseases or disorders include a viral infection, a liver disease or disorder, and cancer.
  • the mammal is a human.
  • the present invention provides methods for treating a liver disease or disorder by administering a nucleic acid such as an interfering RNA (e.g., siRNA) in nucleic acid-lipid particles (e.g., SNALP), alone or in combination with a lipid-lowering agent.
  • a nucleic acid such as an interfering RNA (e.g., siRNA) in nucleic acid-lipid particles (e.g., SNALP), alone or in combination with a lipid-lowering agent.
  • lipid diseases and disorders include, but are not limited to, dyslipidemia (e.g., hyperlipidemias such as elevated triglyceride levels (hypertriglyceridemia) and/or elevated cholesterol levels (hypercholesterolemia)), atherosclerosis, coronary heart disease, coronary artery disease, atherosclerotic cardiovascular disease (CVD), fatty liver disease (hepatic steatosis), abnormal lipid metabolism, abnormal cholesterol metabolism, diabetes (including Type 2 diabetes), obesity, cardiovascular disease, and other disorders relating to abnormal metabolism.
  • dyslipidemia e.g., hyperlipidemias such as elevated triglyceride levels (hypertriglyceridemia) and/or elevated cholesterol levels (hypercholesterolemia)
  • atherosclerosis e.g., coronary heart disease, coronary artery disease, atherosclerotic cardiovascular disease (CVD), fatty liver disease (hepatic steatosis), abnormal lipid metabolism, abnormal cholesterol metabolism, diabetes (including Type 2 diabetes), obesity, cardiovascular disease,
  • the present invention provides a method for lowering or reducing cholesterol levels in a mammal (e.g., human) in need thereof (e.g., a mammal with elevated blood cholesterol levels), the method comprising administering to the mammal a therapeutically effective amount of a nucleic acid-lipid particle (e.g., a SNALP formulation) described herein comprising one or more interfering RNAs (e.g., siRNAs) that target one or more genes associated with metabolic diseases and disorders.
  • a nucleic acid-lipid particle e.g., a SNALP formulation
  • interfering RNAs e.g., siRNAs
  • the present invention provides a method for lowering or reducing triglyceride levels in a mammal (e.g., human) in need thereof (e.g., a mammal with elevated blood triglyceride levels), the method comprising administering to the mammal a therapeutically effective amount of a nucleic acid-lipid particle (e.g., a SNALP formulation) described herein comprising one or more interfering RNAs (e.g., siRNAs) that target one or more genes associated with metabolic diseases and disorders.
  • a nucleic acid-lipid particle e.g., a SNALP formulation
  • interfering RNAs e.g., siRNAs
  • these methods can be carried out in vitro using standard tissue culture techniques or in vivo by administering the interfering RNA (e.g., siRNA) using any means known in the art.
  • the interfering RNA e.g., siRNA
  • the interfering RNA is delivered to a liver cell
  • the present invention provides methods for treating a cell proliferative disorder such as cancer by administering a nucleic acid such as an interfering RNA (e.g., siRNA) in nucleic acid-lipid particles (e.g., SNALP), alone or in combination with a chemotherapy drug.
  • a nucleic acid such as an interfering RNA (e.g., siRNA) in nucleic acid-lipid particles (e.g., SNALP), alone or in combination with a chemotherapy drug.
  • the methods can be carried out in vitro using standard tissue culture techniques or in vivo by administering the interfering RNA (e.g., siR A) using any means known in the art.
  • the interfering RNA e.g., siRNA
  • the interfering RNA is delivered to a cancer cell in a mammal such as a human, alone or in combination with a chemotherapy drug.
  • the nucleic acid-lipid particles and/or chemotherapy drugs may also be co-administered with conventional hormonal
  • the present invention provides methods for preventing or treating a viral infection such as an arenavirus (e.g., Lassa virus) or filo virus (e.g., Ebola virus, Marburg virus, etc.) infection which causes hemorrhagic fever or a hepatitis (e.g., Hepatitis C virus) infection which causes acute or chronic hepatitis by administering a nucleic acid such as an interfering RNA (e.g., siRNA) in nucleic acid-lipid particles (e.g., SNALP), alone or in combination with the administration of conventional agents used to treat or ameliorate the viral condition or any of the symptoms associated therewith.
  • a viral infection such as an arenavirus (e.g., Lassa virus) or filo virus (e.g., Ebola virus, Marburg virus, etc.) infection which causes hemorrhagic fever or a hepatitis (e.g., Hepatitis C virus) infection which causes acute or chronic hepatitis
  • the methods can be carried out in vitro using standard tissue culture techniques or in vivo by administering the interfering RNA using any means known in the art.
  • the interfering RNA e.g., siRNA
  • the interfering RNA is delivered to cells, tissues, or organs of a mammal such as a human that are infected and/or susceptible of being infected with the hemorrhagic fever virus, such as, e.g., cells of the reticuloendothelial system (e.g., monocytes, macrophages, etc.), endothelial cells, liver cells (e.g., hepatocytes), fibroblast cells, and/or platelet cells.
  • the reticuloendothelial system e.g., monocytes, macrophages, etc.
  • endothelial cells e.g., liver cells (e.g., hepatocytes), fibroblast cells, and/or platelet cells.
  • the interfering RNA (e.g., siRNA) is delivered to cells, tissues, or organs of a mammal such as a human that are infected and or susceptible of being infected with the hepatitis virus, such as, e.g., cells of the liver (e.g., hepatocytes).
  • a mammal such as a human that are infected and or susceptible of being infected with the hepatitis virus, such as, e.g., cells of the liver (e.g., hepatocytes).
  • the lipid particles of the invention comprising one or more cationic lipids of Formula I or salts thereof are particularly advantageous and suitable for use in the administration of nucleic acids such as interfering RNA to a subject (e.g., a mammal such as a human) because they are stable in circulation, of a size required for pharmacodynamic behavior resulting in access to extravascular sites, and are capable of reaching target cell populations.
  • the present invention is based, in part, upon the discovery of novel cationic (amino) lipids that provide advantages when used in lipid particles for the in vivo delivery of an active or therapeutic agent such as a nucleic acid into a cell of a mammal.
  • the present invention provides nucleic acid-lipid particle compositions comprising one or more of the novel cationic lipids described herein that provide increased activity of the nucleic acid (e.g., interfering RNA) and improved tolerability of the compositions in vivo, resulting in a significant increase in the therapeutic index as compared to nucleic acid-lipid particle compositions previously described.
  • the present invention provides novel cationic lipids that enable the formulation of improved compositions for the in vitro and in vivo delivery of interfering RNA such as siRNA. It is shown herein that these improved lipid particle compositions are effective in down-regulating (e.g., silencing) the protein levels and/or mRNA levels of target genes. Furthermore, it is shown herein that the activity of these improved lipid particle compositions is dependent on the presence of the novel cationic lipids of the invention.
  • the lipid particles and compositions of the present invention may be used for a variety of purposes, including the delivery of encapsulated or associated (e.g., complexed) therapeutic agents such as nucleic acids to cells, both in vitro and in vivo. Accordingly, the present invention further provides methods of treating diseases or disorders in a subject in need thereof by contacting the subject with a lipid particl that encapsulates or is associated with a suitable therapeutic agent, wherein the lipid particle comprises one or more of the novel cationic lipids described herein.
  • the lipid particles of the present invention are particularly useful for the delivery of nucleic acids, including, e.g., interfering RNA molecules such as siR A. Therefore, the lipid particles and compositions of the present invention may be used to decrease the expression of target genes and proteins both in vitro and in vivo by contacting cells with a lipid particle comprising one or more novel cationic lipids described herein, wherein the lipid particle encapsulates or is associated with a nucleic acid that reduces target gene expression (e.g., an siRNA).
  • a lipid particle comprising one or more novel cationic lipids described herein, wherein the lipid particle encapsulates or is associated with a nucleic acid that reduces target gene expression (e.g., an siRNA).
  • the lipid particles and compositions of the present invention may be used to increase the expression of a desired protein both in vitro and in vivo by contacting cells with a lipid particle comprising one or more novel cationic lipids described herein, wherein the lipid particle encapsulates or is associated with a nucleic acid that enhances expression of the desired protein ⁇ e.g., aplasmid encoding the desired protein).
  • cationic lipids of the present invention lipid particles and compositions comprising the same, and their use to deliver active or therapeutic agents such as nucleic acids to modulate gene and protein expression, are described in further detail below.
  • interfering RNA or "RNAi” or “interfering RNA sequence” as used herein includes single-stranded RNA (e.g., mature miRNA, ssRNAi oligonucleotides, ssDNAi oligonucleotides), double-stranded RNA (i.e., duplex RNA such as siRNA, Dicer- substrate dsRNA, shRNA, aiRNA, or pre-miRNA), a DNA-RNA hybrid (see, e.g., PCT Publication No. WO 2004/078941), or a DNA-DNA hybrid (see, e.g., PCT Publication No.
  • Interfering RNA thus refers to the single-stranded RNA that is complementary to a target mRNA sequence or to the double-stranded RNA formed by two complementary strands or by a single, self-complementary strand.
  • Interfering RNA may have substantial or complete identity to the target gene or sequence, or may comprise a region of mismatch (i.e., a mismatch motif).
  • the sequence of the interfering RNA can correspond to the full-length target gene, or a subsequence ihereof.
  • the interfering RNA molecules are chemically synthesized.
  • Interfering RNA includes "small-interfering RNA” or “siRNA,” e.g., interfering RNA of about 15-60, 15-50, or 15-40 (duplex) nucleotides in length, more typically about 15- 30, 15-25, or 19-25 (duplex) nucleotides in length, and is preferably about 20-24, 21-22, or 21-23 (duplex) nucleotides in length (e.g., each complementary sequence of the double- stranded siRNA is 15-60, 15-50, 15-40, 15-30, 15-25, or 19-25 nucleotides in length, preferably about 20-24, 21-22, or 21-23 nucleotides in length, and the double-stranded siRNA is about 15-60, 15-50, 15-40, 15-30, 15-25, or 19-25 base pairs in length, preferably about 18-22, 1 -20, or 19-21 base pairs in length).
  • siRNA duplexes may comprise 3' overhangs of about 1 to about 4 nucleotides or about 2 to about 3 nucleotides and 5' phosphate termini.
  • siRNA include, without limitation, a double-stranded polynucleotide molecule assembled from two separate stranded molecules, wherein one strand is the sense strand and the other is the complementary antisense strand; a double- stranded polynucleotide molecule assembled from a single stranded molecule, where the sense and antisense regions are linked by a nucleic acid-based or non-nucleic acid-based linker; a double-stranded polynucleotide molecule with a hairpin secondary structure having self-complementary sense and antisense regions; and a circular single-stranded
  • siRNA includes RNA-RNA duplexes as well as DNA-RNA hybrids (see, e.g., PCT Publication No. WO 2004/078941).
  • siRNA are chemically synthesized.
  • siRNA can also be generated by cleavage of longer dsRNA (e.g., dsRNA greater than about 25 nucleotides in length) with the E. coli RNase III or Dicer. These enzymes process the dsRNA into biologically active siRNA (see, e.g., Yang et al, Proc. Natl. Acad. Sci. USA, 99:9942-9947 (2002); Calegari et al, Proc. Natl. Acad. Sci. USA, 99: 14236 (2002); Byrom et al. , Ambion TechNotes, 10(l):4-6 (2003); Kawasaki et al.
  • dsRNA are at least 50 nucleotides to about 100, 200, 300, 400, or 500 nucleotides in length.
  • a dsRNA may be as long as 1000, 1 00, 2000, 5000 nucleotides in length, or longer.
  • the dsRNA can encode for an entire gene transcript or a partial gene transcript.
  • siRNA may be encoded by a plasmid (e.g. , transcribed as sequences that automatically fold into duplexes with hairpin loops).
  • mismatch motif or mismatch region refers to a portion of an interfering R A (e.g., siRNA) sequence that does not have 100% complementarity to its target sequence.
  • An interfering RNA may have at least one, two, three, four, five, six, or more mismatch regions.
  • the mismatch regions may be contiguous or may be separated by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more nucleotides.
  • the mismatch motifs or regions may comprise a single nucleotide or may comprise two, three, four, five, or more nucleotides.
  • the phrase "inhibiting expression of a target gene” refers to the ability of a nucleic acid such as an interfering RNA (e.g., siRNA) to silence, reduce, or inhibit the expression of a target gene.
  • a test sample e.g., a sample of cells in culture expressing the target gene
  • a test mammal e.g.
  • a mammal such as a human or an animal model such as a rodent (e.g., mouse) or a non-human primate (e.g., monkey) model
  • a nucleic acid such as an interfering RNA (e.g., siRNA) that silences, reduces, or inhibits expression of the target gene.
  • siRNA interfering RNA
  • Expression of the target gene in the test sample or test animal is compared to expression of the target gene in a control sample (e.g.
  • a sample of cells in culture expressing the target gene or a control mammal (e.g., a mammal such as a human or an animal model such as a rodent (e.g., mouse) or non-human primate (e.g., monkey) model) that is not contacted with or administered the nucleic acid (e.g., interfering RNA).
  • a control mammal e.g., a mammal such as a human or an animal model such as a rodent (e.g., mouse) or non-human primate (e.g., monkey) model
  • the expression of the target gene in a control sample or a control mammal may be assigned a value of 100%.
  • silencing, inhibition, or reduction of expression of a target gene is achieved when the level of target gene expression in the test sample or the test mammal relative to the level of target gene expression in the control sample or the control mammal is about 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, or 0%.
  • the nucleic acids are capable of silencing, reducing, or inhibiting the expression of a target gene by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% in a test sample or a test mammal relative to the level of target gene expression in a control sample or a control mammal not contacted with or administered the nucleic acid (e.g., interfering
  • RNA RNA
  • assays for determining the level of target gene expression include, without limitation, examination of protein or mRNA levels using techniques known to those of skill in the art, such as, e.g., dot blots, Northern blots, in situ hybridization, ELISA,
  • an "effective amount” or “therapeutically effective amouui” of an active agent or therapeutic agent such as a therapeutic nucleic acid is an amount sufficient to produce the desired effect, e.g., an inhibition of expression of a target sequence in comparison to the normal expression level detected in the absence of the nucleic acid (e.g., interfering RNA).
  • Inhibition of expression of a target gene or target sequence is achieved when the value obtained with a nucleic acid such as an interfering RNA (e.g., siRNA) relative to the control is about 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, or 0%.
  • a nucleic acid such as an interfering RNA (e.g., siRNA) relative to the control is about 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, or 0%.
  • Suitable assays for measuring expression of a target gene or target sequence include, e.g., examination of protein or RNA levels using techniques known to those of skill in the art such as dot blots, northern blots, in situ hybridization, ELISA, immunoprecipitation, enzyme function, as well as phenotypic assays known to those of skill in the art.
  • a nucleic acid such as an interfering RNA (e.g., siRNA) is intended to mean a detectable decrease of an immune response to a given nucleic acid (e.g. , a modified interfering RNA).
  • the amount of decrease of an immune response by a nucleic acid such as a modified interfering RNA may be determined relative to the level of an immune response in the presence of an unmodified interfering RNA.
  • a detectable decrease can be about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, or more lower than the immune response detected in the presence of the unmodified interfering RNA.
  • a decrease in the immune response to a nucleic acid is typically measured by a decrease in cytokine production (e.g.
  • IL-12 insulin-like growth factor
  • a responder cell in vitro or a decrease in cytokine production in the sera of a mammalian subject after administration of the nucleic acid (e.g., interfering RNA).
  • the nucleic acid e.g., interfering RNA
  • responder cell refers to a cell, preferably a mammalian cell, that produces a detectable immune response when contacted with an immunostimulatory nucleic acid such as an unmodified interfering RNA (e.g., unmodified siRNA).
  • an immunostimulatory nucleic acid such as an unmodified interfering RNA (e.g., unmodified siRNA).
  • exemplary responder cells include, without limitation, dendritic cells, macrophages, peripheral blood mononuclear cells (PBMCs), splenocytes, and the like.
  • Detectable immune responses include, e.g.
  • Detectable immune responses also include, e.g., induction of interferon-induced protein with tetratricopeptide repeats 1 (IFFT1) mRNA.
  • IFFT1 interferon-induced protein with tetratricopeptide repeats 1
  • nucleic acid refers to a polymer containing at least two deoxyribonucleotides or ribonucleotides in either single- or double-stranded form and includes DNA, RNA, and hybrids thereof.
  • DNA may be in the form of, e.g., antisense molecules, plasmid DNA, DNA-DNA duplexes, pre-condensed DNA, PCR products, vectors (PI, PAC, BAC, YAC, artificial chromosomes), expression cassettes, chimeric sequences, chromosomal DNA, or derivatives and combinations of these groups.
  • RNA may be in the form of small interfering RNA (siRNA), Dicer-substrate dsRNA, small hairpin RNA
  • Nucleic acids include nucleic acids containing known nucleotide analogs or modified backbone residues or linkages, which are synthetic, naturally occurring, and non-naturally occurring, and which have similar binding properties as the reference nucleic acid. Examples of such analogs include, without limitation, phosphorothioates, phosphoramidates, methyl phosphonates, chiral-methyl phosphonates, 2'-0-methyl ribonucleotides, and peptide-nucleic acids (PNAs).
  • PNAs peptide-nucleic acids
  • nucleic acids containing known analogues of natural nucleotides that have similar binding properties as the reference nucleic acid.
  • a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions), alleles, orthologs, SNPs, and complementary sequences as well as the sequence explicitly indicated.
  • degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed- base and/or deoxyinosine residues (Batzer et ah, Nucleic Acid Res., 19:5081 (1991); Ohtsuka et al., J. Biol. Chem., 260:2605-2608 (1985); Rossolini et al, Mol. Cell. Probes, 8:91-98 (1994)).
  • "Nucleotides” contain a sugar deoxyribose (DNA) or ribose (RNA), a base, and a phosphate group. Nucleotides are linked together through the phosphate groups.
  • Bases include purines and pyrimidines, which further include natural compounds adenine, thymine, guanine, cytosine, uracil, inosine, and natural analogs, and synthetic derivatives of purines and pyrimidines, which include, but are not limited to, modifications which place new reactive groups such as, but not limited to, amines, alcohols, thiols, carboxylates, and alkylhalides.
  • gene refers to a nucleic acid ⁇ e.g., DNA or RNA) sequence that comprises partial length or entire length coding sequences necessary for the production of a polypeptide or precursor polypeptide.
  • Gene product refers to a product of a gene such as an RNA transcript or a polypeptide.
  • ne i rm upiu reiers LO a gioup oi organic cuinpounas max lnciuue, DUI are nor limited to, esters of fatty acids and are characterized by being insoluble in water, but soluble in many organic solvents. They are usually divided into at least three classes: (1) "simple lipids,” which include fats and oils as well as waxes; (2) “compound lipids,” which include phospholipids and glycolipids; and (3) "derived lipids” such as steroids.
  • lipid particle includes a lipid formulation that can be used to deliver an active agent or therapeutic agent, such as a nucleic acid (e.g. , interfering RNA) to a target site of interest (e.g., cell, tissue, organ, tumor, and the like).
  • an active agent or therapeutic agent such as a nucleic acid (e.g. , interfering RNA)
  • a target site of interest e.g., cell, tissue, organ, tumor, and the like.
  • the lipid particle of the invention is a nucleic acid-lipid particle, which is typically formed from a cationic lipid, a non-cationic lipid, and optionally a conjugated lipid that prevents aggregation of the particle.
  • the active agent or therapeutic agent such as a nucleic acid (e.g., interfering RNA)
  • SNALP refers to a stable nucleic acid-lipid particle.
  • a SNALP represents a particle made from lipids (e.g., a cationic lipid, a non-cationic lipid, and optionally a conjugated lipid that prevents aggregation of the particle), wherein the nucleic acid (e.g., an interfering RNA) is fully encapsulated within the lipid.
  • lipids e.g., a cationic lipid, a non-cationic lipid, and optionally a conjugated lipid that prevents aggregation of the particle
  • SNALP are extremely useful, for systemic applications, as they can exhibit extended circulation lifetimes following intravenous (i.v.) injection, they can accumulate at distal sites (e.g., sites physically separated from the adrninistration site), and they can mediate silencing of target gene expression at these distal sites.
  • the nucleic acid may be complexed with a condensing agent and encapsulated vvdtihin a SNALP as set forth in PCT Publication No. WO 00/03683, the disclosure of which is herein incorporated by reference in its entirety for all purposes.
  • the lipid particles of the invention typically have a mean diameter of from about 30 nm to about 150 nm, from about 40 nm to about 150 nm, from about 50 nm to about 150 nm, from about 60 nm to about 130 nm, from about 70 nm to about 1 10 nm, from about 70 nm to about 100 nm, from about 80 nm to about 100 nm, from about 90 nm to about 100 nm, from about 70 to about 90 nm, from about 80 nm to about 90 nm, from about 70 nm to about 80 nm, or about 30 nm, 35 nm, 40 nm, 45 nm, 50 nm, 55 nm, 60 nm, 65 nm, 70 nm, 75 nm, 80 nm, 85 nm, 90 nm, 95 nm, 100 nm, 105 nm, 1 10
  • nucleic acids when present in the lipid particles of the present invention, are resistant in aqueous solution to degradation with a nuclease.
  • Nucleic acid-lipid particles and their method of preparation are disclosed in, e.g., U.S. Patent Publication Nos. 20040142025 and 20070042031, the disclosures of which arc herein incofpuiatcu by reference in their entirety for all purposes.
  • lipid encapsulated can refer to a lipid particle that provides an active agent or therapeutic agent, such as a nucleic acid (e.g., an interfering RNA such as an siRNA), with full encapsulation, partial encapsulation, or both.
  • a nucleic acid e.g., an interfering RNA such as an siRNA
  • the nucleic acid is fully encapsulated in the lipid particle (e.g. , to form a SNALP or other nucleic acid-lipid particle).
  • lipid conjugate refers to a conjugated lipid that inhibits aggregation of lipid particles.
  • lipid conjugates include, but are not limited to, PEG-lipid conjugates such as, e.g., PEG coupled to dialkyloxypropyls (e.g. , PEG-DAA conjugates), PEG coupled to diacylglycerols (e.g., PEG-DAG conjugates), PEG coupled to cholesterol, PEG coupled to phosphatidylethanolamines, and PEG conjugated to ceramides (see, e.g., U.S. Patent No.
  • POZ-lipid conjugates e.g., POZ-DAA conjugates; see, e.g., U.S. Application No. 13/006,277, filed January 13, 2011
  • polyamide oligomers e.g., ATTA-lipid conjugates
  • Additional examples of POZ- lipid conjugates are described in PCT Publication No. WO 2010/006282.
  • PEG or POZ can be conjugated directly to the lipid or may be linked to the lipid via a linker moiety.
  • linker moiety suitable for coupling the PEG or the POZ to a lipid can be used including, e.g., non-ester containing linker moieties and ester-containing linker moieties.
  • non-ester containing linker moieties such as amides or carbamates, are used.
  • amphipathic lipid refers, in part, to any suitable material wherein the hydrophobic portion of the lipid material orients into a hydrophobic phase, while the hydrophilic portion orients toward the aqueous phase.
  • Hydrophilic characteristics derive from the presence of polar or charged groups such as carbohydrates, phosphate, carboxylic, sulfato, amino, sulfhydryl, nitro, hydroxyl, and other like groups. Hydrophobicity can be conferred by the inclusion of apolar groups that include, but are not limited to, long-chain saturated and unsaturated aliphatic hydrocarbon groups and such groups substituted by one or more aromatic, cycloaliphatic, or heterocyclic group(s). Examples of amphipathic compounds include, but are not limited to, phospholipids, aminolipids, and sphingolipids.
  • phospholipids include, but are not limited to, phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidic acid, palmitoyloleoyl phosphatidylcholine, lysophosphatidylcholine, lysophosphatidylethanolamine, dipalnutoylphosphatidylcholine, dioleoylphosphatidylcholine, distearoylnhnsnhatidyich line, and dilinc!ecy!phcsphatidylchGlme.
  • amphipathic lipids Other compounds lacking in phosphorus, such as sphingolipid, glycosphingolipid families, diacylglycerols, and ⁇ -acyloxyacids, are also within the group designated as amphipathic lipids. Additionally, the amphipathic lipids described above can be mixed with other lipids including triglycerides and sterols.
  • neutral lipid refers to any of a number of lipid species that exist either in an uncharged or neutral zwitterionic form at a selected pH.
  • lipids include, for example, diacylphosphatidylcholine, diacylphosphatidylethanolamme, ceramide, sphingomyelin, cephalin, cholesterol, cerebrosides, and diacylglycerols.
  • non-cationic lipid refers to any amphipathic lipid as well as any other neutral lipid or anionic lipid.
  • anionic lipid refers to any lipid that is negatively charged at physiological pH. These lipids include, but are not limited to, phosphatidylglycerols, cardiolipins, diacylphosphatidylserines, diacylphosphatidic acids, N-dodecanoyl
  • phosphatidylethanolamines N-succinyl phosphatidylemanolamines, N- glutarylphosphatidylethanolamines, lysylphosphatidylglycerols,
  • POPG palmitoyloleyolphosphatidylglycerol
  • hydrophobic lipid refers to compounds having apolar groups that include, but are not limited to, long-chain saturated and unsaturated aliphatic hydrocarbon groups and such groups optionally substituted by one or more aromatic, cycloaliphatic, or heterocyclic group(s). Suitable examples include, but are not limited to, diacylglycerol, dialkylglycerol, N-N-dialkylamino, l,2-diacyloxy-3-aminopropane, and l,2-dialkyl-3- aminopropane.
  • the term "fusogenic” refers to the ability of a lipid particle, such as a SNALP, to fuse with the membranes of a cell.
  • the membranes can be either the plasma membrane or membranes surrounding organelles, e.g., endosome, nucleus, etc.
  • aqueous solution refers to a composition comprising in whole, or in part, water.
  • organic lipid solution refers to a composition comprising in whole, or in part, an organic solvent having a lipid.
  • distal site refers to a physically separated site, which is not limited to an adjacent capillary bed, but includes sites broadly distributed throughout an organism.
  • "Serum-stable” in relation to nucleic aeid-lipid particles su ii as SIN ALP means that the particle is not significantly degraded after exposure to a serum or nuclease assay that would significantly degrade free DNA or R A. Suitable assays include, for example, a standard serum assay, a DNAse assay, or an RNAse assay.
  • Systemic delivery refers to delivery of lipid particles that leads to a broad biodistribution of an active agent such as an interfering RNA (e.g., siRNA) within an organism. Some techniques of administration can lead to the systemic delivery of certain agents, but not others. Systemic delivery means that a useful, preferably therapeutic, amount of an agent is exposed to most parts of the body. To obtain broad biodistribution generally requires a blood lifetime such that the agent is not rapidly degraded or cleared (such as by first pass organs (liver, lung, etc.) or by rapid, nonspecific cell binding) before reaching a disease site distal to the site of administration.
  • Systemic delivery of lipid particles can be by any means known in the art including, for example, intravenous, subcutaneous, and intraperitoneal. In a preferred embodiment, systemic delivery of lipid particles is by intravenous delivery.
  • “Local delivery,” as used herein, refers to delivery of an active agent such as an interfering RNA (e.g., siRNA) directly to a target site within an organism.
  • an agent can be locally delivered by direct injection into a disease site such as a tumor, other target site such as a site of inflammation, or a target organ such as the liver, heart, pancreas, kidney, and the like.
  • mammal refers to any mammalian species such as a human, mouse, rat, dog, cat, hamster, guinea pig, rabbit, livestock, and the like.
  • cancer refers to any member of a class of diseases characterized by the uncontrolled growth of aberrant cells.
  • the term includes all known cancers and neoplastic conditions, whether characterized as malignant, benign, soft tissue, or solid, and cancers of all stages and grades including pre- and post-metastatic cancers.
  • cancers examples include, but are not limited to, liver cancer, lung cancer, colon cancer, rectal cancer, anal cancer, bile duct cancer, small intestine cancer, stomach (gastric) cancer, esophageal cancer; gallbladder cancer, pancreatic cancer, appendix cancer, breast cancer, ovarian cancer; cervical cancer, prostate cancer, renal cancer (e.g., renal cell carcinoma), cancer of the central nervous system, glioblastoma, skin cancer, lymphomas, choriocarcinomas, head and neck cancers, osteogenic sarcomas, and blood cancers.
  • liver cancer lung cancer, colon cancer, rectal cancer, anal cancer, bile duct cancer, small intestine cancer, stomach (gastric) cancer, esophageal cancer
  • gallbladder cancer pancreatic cancer, appendix cancer, breast cancer, ovarian cancer
  • cervical cancer prostate cancer
  • renal cancer e.g., renal cell carcinoma
  • cancer of the central nervous system glioblastoma
  • liver cancer examples include hepatocellular carcinoma (HCC), secondary liver cancer (e.g., caused by metastasis of some other non-liver cancer cell type), and hepatoblastoma.
  • HCC hepatocellular carcinoma
  • secondary liver cancer e.g., caused by metastasis of some other non-liver cancer cell type
  • hepatoblastoma e.g., hepatoblastoma
  • a "tumor” comprises one or more cancerous cells.
  • the present invention provides, inter alia, novel cationic (amino) lipids that can advantageously be used in the lipid particles described herein for the in vitro and/or in vivo delivery of therapeutic agents such as nucleic acids to cells.
  • novel cationic lipids of the present invention have the structure set forth in Formula I herein, and include the ( ) and/or (S) enantiomers thereof.
  • a lipid of the present invention comprises a racemic mixture. In other embodiments, a lipid of the present invention comprises a mixture of one or more diastereomers. In certain embodiments, a lipid of the present invention is enriched in one enantiomer, such that the lipid comprises at least about 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% enantiomeric excess. In certain other embodiments, a lipid of the present invention is enriched in one diastereomer, such that the lipid comprises at least about 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% diastereomeric excess.
  • a lipid of the present invention is chirally pure (e.g., comprises a single optical isomer).
  • a lipid of the present invention is enriched in one optical isomer (e.g., an optically active isomer), such that the lipid comprises at least about 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% isomeric excess.
  • the present invention provides the synthesis of the cationic lipids of Formula I as a racemic mixture or in optically pure form.
  • cationic lipid and “amino lipid” are used interchangeably herein to include those lipids and salts thereof having one, two, three, or more fatty acid or fatty alkyl chains and a pH-titratable amino head group (e.g., an alkylamino or dialkylamino head group).
  • the cationic lipid is typically protonated (i.e., positively charged) at a pH below the pK a of the cationic lipid and is substantially neutral at a pH above the pK B .
  • the cationic lipids of the invention may also be termed titratable cationic lipids.
  • salts includes any anionic and cationic complex, such as the complex formed between a cationic lipid disclosed herein and one or more anions.
  • anions include inorganic and organic anions, e.g., hydride, fluoride, chloride, bromide, iodide, oxalate (e.g., hemioxalate), phosphate, phosphonate, hydrogen phosphate, dihydrogen phosphate, oxide, carbonate, bicarbonate, nitrate, nitrite, nitride, bisulfite, sulfide, sulfite, bisulfate, sulfate, thiosulfate, hydrogen sulfate, borate, formate, acetate, benzoate, citrate, tartrate, lactate, acrylate, polyacrylate, fumarate, maleate, itaconate, glycolate, gluconate, malate, mandelate, tig
  • alkyl includes a straight chain or branched, noncyclic or cyclic, saturated aliphatic hydrocarbon containing from 1 to 24 carbon atoms.
  • Representative saturated straight chain alkyls include, but are not limited to, methyl, ethyl, n-propyl, n-butyl, w-pentyl, M-hexyl, and the like, while saturated branched alkyls include, without limitation, isopropyl, sec-butyl, isobutyl, tert-bu yl, isopentyl, and the like.
  • Representative saturated cyclic alkyls include, but are not limited to, the C3.8 cycloalkyls described herein, while unsaturated cyclic alkyls include, without limitation, the C3-8 cycloalkenyls described herein.
  • heteroalkyl includes a straight chain or branched, noncyclic or cyclic, saturated aliphatic hydrocarbon as defined above having from about 1 to about 5 heteroatoms (i.e., 1, 2, 3, 4, or 5 heteroatoms) such as, for example, O, N, Si, and/or S, wherein the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized.
  • the heteroalkyl group can be attached to the remainder of the molecule through a carbon atom or a heteroatom.
  • cyclic alkyl includes any of the substituted or unsubstituted cycloalkyl, heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl groups described below.
  • cycloalkyl includes a substituted or unsubstituted cyclic alkyl group having from about 3 to about 8 carbon atoms (i.e., 3, 4, 5, 6, 7, or 8 carbon atoms) as ring vertices.
  • Preferred cycloalkyl groups include those having from about 3 to about 6 carbon atoms as ring vertices.
  • C 3-8 cycloalkyl groups include, but are not limited to, cyclopropyl, methyl-cyclopropyl, dimethyl-cyclopropyl, cyclobutyl, methyl-cyclobutyl, cyclopentyl, methyl-cyclopentyl, cyclohexyl, methyl-cyclohexyl, dimethyl-cyclohexyl, cycloheptyl, and cyclooctyl, as well as other substituted C 3 . 8 cycloalkyl groups.
  • heterocycloalkyl includes a substituted or unsubstituted cyclic alkyl group as defined above having from about 1 to about 3 heteroatoms as ring members selected from the group consisting of O, N, Si and S, wherein the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized.
  • the heterocycloalkyl group can be attached to the remainder of the molecule through a carbon atom or a heteroatom.
  • cycloalkenyl includes a substituted or unsubstituted cyclic alkenyl group having from about 3 to about 8 carbon atoms (i.e., 3, 4, 5, 6, 7, or 8 carbon atoms) as ring vertices.
  • Preferred cycloalkenyl groups are those having from about 3 to about 6 carbon atoms as ring vertices.
  • C 3 .g cycloalkenyl groups include, but are not limited to, cyclopropenyl, methyl-cyclopropenyl, dimethyl-cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexeny!, cyclohepteny!, and cyelocctenyl, as well as oilier substituted C 3- 8 ycioaikenyl groups.
  • heterocycloalkenyl includes a substituted or unsubstituted cyclic alkenyl group as defined above having from about 1 to about 3 heteroatoms as ring members selected from the group consisting of O, N, Si and S, wherein the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized.
  • the heterocycloalkenyl group can be attached to the remainder of the molecule through a carbon atom or a heteroatom.
  • alkoxy includes a group of the formula alkyl-O-, wherein "alkyl” has the previously given definition.
  • Non-lirniting examples of alkoxy groups include methoxy, ethoxy, M-propoxy, wo-propoxy, n-butoxy, /so-butoxy, sec-butoxy and teri-butoxy.
  • alkenyl includes an alkyl, as defined above, containing at least one double bond between adjacent carbon atoms. Alkenyls include both cis and trans isomers.
  • Representative straight chain and branched alkenyls include, but are not limited to, ethylenyl, propylenyl, 1-butenyl, 2-butenyl, isobutylenyl, 1-pentenyl, 2-pentenyl, 3-methyl-l-butenyl, 2- methyl-2-butenyl, 2,3-dimethyl-2-butenyl, and the like.
  • Representative cyclic alkenyls are described above.
  • alkynyl includes any alkyl or alkenyl, as defined above, which additionally contains at least one triple bond between adjacent carbons.
  • Representative straight chain and branched alkynyls include, without limitation, acetylenyl, propynyl, 1- butynyl, 2-butynyl, 1-pentynyl, 2-pentynyl, 3-methyl-l butynyl, and the like.
  • aryl includes a polyunsaturated, typically aromatic, hydrocarbon group which can be a single ring or multiple rings (up to three rings) which are fused together or linked covalently, and which optionally carries one or more substituents, such as, for example, halogen, trifluoromethyl, amino, alkyl, alkoxy, alkylcarbonyl, cyano, carbamoyl, alkoxycarbamoyl, methylendioxy, carboxy, alkoxy carbonyl, aminocarbonyl,
  • alkylaminocarbonyl dialkylaminocarbonyl, hydroxy, nitro, and the like.
  • unsubstituted aryl groups include phenyl, naphthyl, and biphenyl.
  • substituted aryl groups include, but are not limited to, phenyl, chlorophenyl,
  • alkylthio alkylsulfonyl
  • alkylsulfinyl alkylsulfinyl
  • arylsulfonyl include groups having the formula -S-R', -S(0) 2 -R ⁇ -8(0)- ⁇ and -S(0) 2 R j , respectively, wherein R' is an alkyl group as previously defined and R J is an aryl group as previously defined.
  • alkenyloxy and alkynyloxy include groups having the formula -O-R 1 , wherein R' is an alkenyl or alkynyl group, respectively.
  • alkenylthio and "aikynylibio” include groups having the formula -S-R k , wherein R k is an alkenyl or alkynyl group, respectively.
  • alkoxycarbonyl includes a group having the formula -C(0)0-R', wherein R 1 is an alkyl group as defined above and wherein the total number of carbon atoms refers to the combined alkyl and carbonyl moieties.
  • acyl includes any alkyl, alkenyl, or alkynyl wherein the carbon at the point of attachment is substituted with an oxo group, as defined below.
  • heterocycle includes a 5- to 7-membered monocyclic, or 7- to 10- membered bicyclic, heterocyclic ring which is either saturated, unsaturated, or aromatic, and which contains one, two, three, or more heteroatoms independently selected from nitrogen (N), oxygen (O), and sulfur (S), and wherein the nitrogen and sulfur heteroatoms may be optionally oxidized, and the nitrogen heteroatom may be optionally quaternized, including bicyclic rings in which any of the above heterocycles are fused to a benzene ring.
  • the heterocycle may be attached via any heteroatom or carbon atom.
  • Heterocycles include, but are not limited to, heteroaryls as defined below, as well as morpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperi2ynyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyridinyl, tetrahydroprimidinyl,
  • heteroaryl includes an aromatic 5- to 10-membered heterocycle which contains one, two, three, or more heteroatoms selected from nitrogen (N), oxygen (O), and sulfur (S).
  • the heteroaryl can be substituted on one or more carbon atoms with substituents such as, for example, halogen, alkyl, alkoxy, cyano, haloalkyl (e.g., trifluoromethyl), heterocyclyl (e.g., morpholinyl or pyrrolidinyl), and the like.
  • substituents such as, for example, halogen, alkyl, alkoxy, cyano, haloalkyl (e.g., trifluoromethyl), heterocyclyl (e.g., morpholinyl or pyrrolidinyl), and the like.
  • Non-limiting examples of heteroaryls include pyridinyl and fur any 1.
  • halogen includes fluoro, chloro, bromo, and iodo.
  • the present invention provides a cationic lipid of Formula I having the following structure:
  • R 6 is hydrogen (H) or an optionally substituted C]-C 10 alkyl, C 2 -Ci 0 alkenyl, or C 2 -Cio alkynyl;
  • Y is either absent or is an optionally substituted Ci-Ce alkyl, C2-C6 alkenyl,
  • R 1 and R 2 are each independently hydrogen (H) or an optionally substituted Ci-C 2 alkyl, C C 3 alkyl, Q-C4 alkyl, C1-C 5 alkyl, C2-C3 alkyl, C 2 -C 4 alkyl, C 2 -C 5 alkyl, C 2 -C 6 alkyl, C 3 -C 4 alkyl, C3-C5 alkyl, C 3 -C 6 alkyl, C4-C5 alkyl, C 4 -C 6 alkyl, C 5 -C 6 alkyl, C 2 -C 3 alkenyl, C 2 -C 4 alkenyl, C 2 -C 5 alkenyl, C 2 -C 6 alkenyl, C 3 -C 4 alkenyl, C3-C5 alkenyl, C 3 -C6 alkenyl, C4-CS alkenyl, C4-C6 alkenyl, C5-C6
  • R 1 and R 2 are both methyl groups, both ethyl groups, or a combination of one methyl group and one ethyl group.
  • R 3 is absent when the pH is above the p a of the cationic lipid and R 3 is hydrogen (H) when the pK is below the pK a of the catioui lipid such that the amino head group is protonated.
  • R 3 is an optionally substituted C]-C 2 alkyl, C,-C 3 alkyl, C1-C4 alkyl, C1-C5 alkyl, C 2 -C 3 alkyl, C 2 -C alkyl, C 2 -C 5 alkyl, C 2 -C 6 alkyl, C 3 - C 4 alkyl, C 3 -C 5 alkyl, C 3 -C 6 alkyl, C4-C5 alkyl, C 4 -C 6 alkyl, or C 5 -C 6 alkyl to provide a quaternary amine.
  • R l and R 2 are joined to form an optionally substituted heterocyclic ring comprising 1, 2, 3, 4, 5, 6, or more carbon atoms and 1, 2, 3, 4, or more heteroatoms such as nitrogen (N), oxygen (O), sulfur (S), and mixtures thereof.
  • the optionally substituted heterocyclic ring comprises from 2 to 5 carbon atoms and from 1 to 3 heteroatoms such as nitrogen (N), oxygen (O), and/or sulfur (S).
  • the heterocyclic ring comprises an optionally substituted imidazole, triazole (e.g., 1,2,3-triazole, 1,2,4-triazole), pyrazole, thiazole, pyrrole, furan, oxazole, isoxazole, oxazoline, oxazolidine, oxadiazole, tetrazole, and the like.
  • the optionally substituted heterocyclic ring comprises 5 carbon atoms and 1 nitrogen atom, wherein the heterocyclic ring can be substituted with a substituent such as a hydroxyl (-OH) group at the ortho, meta, and/or para positions.
  • the heterocyclic ring comprises an optionally substituted imidazole group.
  • R 6 is hydrogen (H) or an optionally substituted Ci-C 2 alkyl, d-C 3 alkyl, C ! -C 4 alkyl, C]-C 3 alkyl, C]-C 6 alkyl, C C 7 alkyl, Ci-C 8 alkyl, C C 9 alkyl, C 2 - C 3 alkyl, C 2 -C 4 alkyl, C 2 -C 5 alkyl, C 2 -C 6 alkyl, C 2 -C 7 alkyl, C 2 -C 8 alkyl, C 2 -C 9 alkyl, C 2 -C 10 alkyl, C 3 -C 4 alkyl, C 3 -C 5 alkyl, C 3 -C 6 alkyl, C 3 -C 7 alkyl, C 3 -C 8 alkyl, C 3 -C 9 alkyl, C 3 -Cio alkyl, C4-C5 alkyl, C 4 -C
  • R 6 is selected from the group consisting of hydrogen (H), a Ci alkyl (methyl) group, and a C 2 , C 3 , C 4 , C5, Ce, C 7 , C 8) C 9 , and C 10 alkyl, alkenyl, and alkynyl group.
  • X is C(0)0. In another particular embodiment, X is O. In certain embodiments, X is C(0)N(R 6 ), N(R 6 )C(0)0, or C(0)S. In one particular embodiment, X is N(R 6 )C(0)0 and R 6 is hydrogen (H), a methyl group, or a C 2) C 3 , C 4 , C 5 , e, C 7 , Cg, ⁇ 3 ⁇ 4, or Cio alkyl, alkenyl, or alkynyl group. In certain other embodiments, X is an optionally substituted heterocyclic ring.
  • the heterocyclic ring comprises 1, 2, 3, 4, 5, 6, or more carbon atoms and 1, 2, 3, 4, or more heteroatoms such as nitrogen (N), oxygen (0), sulfur (S), and mixtures thereof.
  • the optionally substituted heterocyclic ring comprises from 2 to 5 carbon atoms and from 1 to 3 heteroatoms such as nitrogen ( ), oxygen (O), and/or sulfur (S).
  • the heterocyclic ring comprises an optionally substituted imidazole, triazole (e.g., 1 ,2,3-triazole, 1 ,2,4-triazole), pyrazole, thiazole, pyrrole, furan, oxazole, isoxazole, oxazoline, oxazolidine, oxadiazole, tetrazole, and the like.
  • R 1 and R 2 are not both methyl groups when X is C(0)0, Y is (CH 2 ) 2 or (CH 2 ) 3 , and R 4 and R 5 are both linoleyl moieties.
  • At least one or both R 4 and R 5 independently comprises an optionally substituted C 12 -C 2 4, C 12 -C 2 , C 12 -C 2 o, Ci 4 -C 24 , Q 4 -C 22 , Ci4-C 2 o, Ci -C 24 , 0 16 -0 2 2 5 or C16-C 20 alkyl, alkenyl, alkynyl, or acyl group (i.e., C 12 , C 13 , C 14 , C 15 , Ci6 3 C 17 , C l g , C19, C 20 , C 2] , C 22 , C 23 , or C 2 4 alkyl, alkenyl, alkynyl, or acyl group).
  • At least one or both R 4 and R 5 independently comprises at least 1 , 2, 3, 4, 5, or 6 sites of unsaturation (e.g., 1-2, 1 -3, 1-4, 1-5, 1-6, 2-3, 2-4, 2-5, or 2-6 sites of unsaturation) or a substituted alkyl or acyl group.
  • the unsaturated side-chain comprises a dodecenyl moiety, a tetradecenyl (e.g., myristoleyl) moiety, a hexadecenyl (e.g., palmitoleyl) moiety, an octadecenyl (e.g., oleyl) moiety, an icosenyl moiety, a dodecadienyl moiety, a tetradecadienyl moiety, a hexadecadienyl moiety, an octadecadienyl moiety, an icosadienyl moiety, a dodecatrienyl moiety, a tetradectrienyl moiety, a hexadecatrienyl moiety, an octadecatrienyl moiety, an icosatrienyl moiety, or an acyl derivative thereof (e.g., o
  • the octadecadienyl moiety is a linoleyl moiety.
  • R 4 and R 5 are both linoleyl moieties.
  • the octadecatrienyl moiety is a linolenyl moiety or a ⁇ -linolenyl moiety.
  • R 4 and R 5 are both linolenyl moieties or ⁇ -linolenyl moieties.
  • R 4 and R 5 independently comprises a branched alkyl or acyl group (e.g., a substituted alkyl or acyl group)
  • the branched alkyl or acyl group may comprise a C 12 -C 24 alkyl or acyl having at least 1-6 (e.g., 1, 2, 3, 4, 5, 6, or more) Q-Ce alkyl substituents.
  • the branched alkyl or acyl giuup comprises a C j2 - C 2 o or C14-C22 alkyl or acyl with 1-6 (e.g., 1, 2, 3, 4, 5, 6) C1-C4 alkyl (e.g., methyl, ethyl, propyl, or butyl) substituents.
  • the branched alkyl group comprises a phytanyl (3,7,11,15-tetramethyl-hexadecanyl) moiety and the branched acyl group comprises a phytanoyl (3,7, 1 1 , 15-tetramethyl-hexadecanoyl) moiety.
  • R 4 and R are both phytanyl moieties.
  • the 1 , 2, 3, 4, 5, 6, or more sites of unsaturation present in one or both R 4 and R 5 correspond to, in each instance, cis double bonds, trans double bonds, or combinations thereof, at specific positions in one or both of the unsaturated side-chains.
  • the chemical notation "E” refers to the trans double bond configuration
  • the chemical notation "Z” refers to the cis double bond configuration.
  • one or both R 4 and R 5 are Cig alkyl groups containing any
  • R 4 and R 5 are C 18 alkyl groups containing any combination of double bonds which can be characterized by either the "E” chemical notation and/or the "Z” chemical notation at one or more positions in the side-chain (e.g., "Z” and/or "E” double bonds at position 9, at positions 6 and 9, at positions 3, 6, and 9, at positions 6, 9, and 12, or at positions 7 and 9 of a Cis alkyl group).
  • one of R 4 or R s independently comprises at least 1, 2, 3, 4, 5, 6, or more optionally substituted cyclic alkyl groups (e.g., 1-2, 1-3, 1-4, 1-5, 1-6, 2-3, 2-4, 2- 5, or 2-6 optionally substituted cyclic alkyl groups).
  • optionally substituted cyclic alkyl groups e.g., 1-2, 1-3, 1-4, 1-5, 1-6, 2-3, 2-4, 2- 5, or 2-6 optionally substituted cyclic alkyl groups.
  • one of R 4 or R 5 independently comprises an optionally substituted Ci 2 -C 2 4, Ci 2 -C 22 , C) 2 -C 2 o, C 14 -C 24 , Ci 4 -C 22 , Ci4-C 20j C 16 -C 24 , Ci6-C 22 , or C ]6 -C 2 o alkyl, alkenyl, alkynyl, or acyl group (i.e., C )2 , C13, C ]4 , Cis, C 16 , On, C 18 , Ci9, C 20 , C 2 i, C 22 , C 23 , or C 24 alkyl, alkenyl, alkynyl, or acyl group), and the other of R 4 or R 5 comprises at least 1, 2, 3, 4, 5, or 6 optionally substituted cyclic alkyl groups (e.g., 1-2, 1 -3, 1-4, 1-5, 1-6, 2-3, 2-4, 2-5, or 2-6 optionally substituted cycl
  • one or mure of the optionally substituted cyclic alkyl groups present in one of R 4 and R 5 are independently selected from the group consisting of an optionally substituted saturated cyclic alkyl group, an optionally substituted unsaturated cyclic alkyl group, and combinations thereof.
  • the optionally substituted saturated cyclic alkyl group comprises an optionally substituted C 3-8 cycloalkyl group (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, etc.).
  • the optionally substituted saturated cyclic alkyl group comprises a cyclopropyl group, optionally containing one or more substituents and/or heteroatoms.
  • the optionally substituted unsaturated cyclic alkyl group comprises an optionally substituted C 3 . 8 cycloalkenyl group (e.g., cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, etc.).
  • one of R 4 or R 5 comprises at least 1, 2, 3, 4, 5, or 6 sites of unsaturation (e.g., 1-2, 1-3, 1-4, 1-5, 1-6, 2-3, 2-4, 2-5, or 2-6 sites of unsaturation) or a substituted alkyl or acyl group
  • the other side-chain comprises at least 1, 2, 3, 4, 5, or 6 optionally substituted cyclic alkyl groups (e.g., 1-2, 1-3, 1-4, 1-5, 1-6, 2-3, 2-4, 2-5, or 2-6 optionally substituted cyclic alkyl groups).
  • the unsaturated side-chain may comprise a myristoleyl moiety, a palmitoleyl moiety, an oleyl moiety, a dodecadienyl moiety, a tetradecadienyl moiety, a hexadecadienyl moiety, an octadecadienyl moiety, an icosadienyl moiety, a dodecatrienyl moiety, a tetradectrienyl moiety, a hexadecatrienyl moiety, an octadecatrienyl moiety, an icosatrienyl moiety, or an acyl derivative thereof (e.g., linoleoyl, linolenoyl, ⁇ -linolenoyl, etc.).
  • acyl derivative thereof e.g., linoleoyl, linolenoyl, ⁇ -linol
  • the octadecadienyl moiety is a linoleyl moiety. In other instances, the octadecatrienyl moiety is a linolenyl moiety or a ⁇ -linolenyl moiety.
  • the branched alkyl or acyl group may comprise a C 12 - C 24 alkyl or acyl having at least 1-6 (e.g., 1, 2, 3, 4, 5, 6, or more) Ci-C ⁇ alkyl substituents.
  • the branched alkyl or acyl group comprises a Cj 2 -C 2 o or C14-C22 alkyl or acyl with 1 -6 (e.g., 1 , 2, 3, 4, 5, 6) C 1 -C4 alkyl (e.g., methyl, ethyl, propyl, or butyl) substituents.
  • the branched alkyl group comprises a phytanyl moiety and the branched acyl group comprises a phytanoyl moiety.
  • the optionally substituted cyclic alkyl groups present in one of R 4 or R 5 are located at the site(s) of unsaturation in the corresponding unsaturated side-chain.
  • one of R 4 of R 5 is a C 18 alkyl group having 1, 2, or 3 optionally substituted cyclic alkyl groups, wherein the optionally substituted cyclic alkyl groups (e.g., independently selected cyclopropyl groups) are located at one or more (e.g., all) of the sites cf ⁇ .saturation present in a corresponding iinoieyi moiety, iinolenyi moiety, or ⁇ - linolenyl moiety.
  • R 4 and R 5 are different and are independently an optionally substituted CrC 2 4 alkyl, C 2 -C 24 alkenyl, C 2 -C 24 alkynyl, or Ci-C 2 4 acyl.
  • one of R 4 or R 5 comprises at least 1 , 2, 3, 4, 5, or 6 optionally substituted cyclic alkyl groups (e.g., 1-2, 1-3, 1-4, 1-5, 1-6, 2-3, 2-4, 2-5, or 2-6 optionally substituted cyclic alkyl groups).
  • R 4 and R 5 are different and are independently an optionally substituted C4-C 2 0 alkyl, C 4 -C 20 alkenyl, C 4 -C 2 o alkynyl, or C4-C 2 0 acyl.
  • R 4 is an optionally substituted C 12 -C 24 alkyl, Ci 2 -C 2 4 alkenyl, C 12 -C 24 alkynyl, or Ci 2 -C 24 acyl
  • R 5 is an optionally substituted C 4 -Cio alkyl, C 4 - C 10 alkenyl, C4-C 1 0 alkynyl, or C4-C1 0 acyl.
  • R 4 is an optionally substituted Ci 2 -C 20 or Ci4-C 22 alkyl, Ci 2 -C 20 or C I4 -C 22 alkenyl, Ci 2 -C 20 or Ci 4 -C 22 alkynyl, or Ci 2 -C 20 or Ci4-C 22 acyl
  • R 5 is an optionally substituted C4-C8 or C 6 alkyl, C 4 -C 8 or C 6 alkenyl, C 4 -C 8 or C6 alkynyl, or C4-C 8 or C 6 acyl.
  • R 4 is an optionally substituted C4-C 10 alkyl, C4-C 10 alkenyl, C4-C 0 alkynyl, or C 4 -Ci 0 acyl
  • R 5 is an optionally substituted C 12 - C 24 alkyl, C 12 -C 24 alkenyl, Ci 2 -C 24 alkynyl, or Ci 2 -C 2 4 acyl.
  • R 4 is an optionally substituted C4-C8 or C 6 alk> r l, C 4 -C 8 or Ce alkenyl, C 4 -Cg or e alkynyl, or C4- Cg or Cg acyl
  • R 5 is an optionally substituted C 12 -C 20 or C]4-C 22 alkyl, C ]2 -C 2 o or Ci4-C 22 alkenyl, C 1 2-C2 0 or Ci 4 -C 22 alkynyl, or C] 2 -C 2 o or C ⁇ -C ⁇ acyl.
  • one or more of the optionally substituted cyclic alkyl groups, when present in one of R 4 or R 5 are as described above.
  • R 4 and R 5 are either the same or different and are independently selected from the group consisting of:
  • Y is an optionally substituted Ci-C 2 alkyl, -C3 alkyl, C ⁇ - C 4 alkyl, Cj-Cs alkyl, C 2 -C 3 alkyl, C 2 -C 4 alkyl, C 2 -C 5 alkyl, C 2 -C 6 alkyl, C3-C4 alkyl, C 3 -C 5 alkyl, C 3 -C 6 alkyl, C 4 -C 5 alkyl, C 4 -C 6 alkyl, C 5 -C 6 alkyl, C 2 -C 3 alkenyl, C 2 -C 4 alkenyl, C 2 -C 5 alkenyl, C 2 -C 6 alkenyl, C3-C4 alkenyl, C3-C5 alkenyl, C3-C6 alkenyl, C4-C5 alkenyl, C 4 -Q alkenyl, C 5 -C 6 alkeny
  • Y is (CH 2 ) n and n is 0, 1, 2, 3, 4, 5, or 6 (e.g., 1-2, 1 -3, 1-4, 1-5, 1-6, 2-3, 2-4, 2-5, or 2-6). In a preferred embodiment, n is 2, 3, or 4.
  • the cationic lipid of Furmuia I has the following structure:
  • R 1 , R 2 , R 3 , R 4 , R 5 , X, and n are the same as described above.
  • the cationic lipid of Formula I forms a salt (preferably a crystalline salt) with one or more anions.
  • the cationic lipid of Formula I is the oxalate (e.g., hemioxalate) salt thereof, which is preferably a crystalline salt.
  • the cationic lipid of Formula I has one of the following
  • the compounds of the invention may be prepared by known organic synthesis techniques, including the methods described in the Examples.
  • the synthesis of the cationic lipids of the invention may require the use of protecting groups.
  • protecting group methodology is well known to those skilled in the art ⁇ see, e.g., PROTECTIVE GROUPS ⁇ ORGANIC SYNTHESIS, Green, T.W. et. al., Wiley-Interscience, New York City, 1999).
  • protecting groups wthin the context of this invention are any group that reduces or elirninates the unwanted reactivity of a functional group.
  • a protecting group can be added to a functional group to mask its reactivity during certain reactions and then removed to reveal the original functional group.
  • an "alcohol protecting group” is used.
  • An “alcohol protecting group” is any group which decreases or elirninates the unwanted reactivity of an alcohol functional group. Protecting groups can be added and removed using techniques well known in the art.
  • the cationic lipids of the present invention have at least one protonatable or deprotonatable group, such that the lipid is positively charged at a pH at or below physiological pH ⁇ e.g., pH 7.4), and neutral at a second pH, preferably at or above physiological pH.
  • a pH at or below physiological pH ⁇ e.g., pH 7.4 a pH at or below physiological pH ⁇ e.g. 7.4
  • a second pH preferably at or above physiological pH.
  • protonatable lipids according to the invention have a pK a of the protonatable group in the range of about 4 to about 1 1. Most preferred is a pK a of about 4 to about 7, because these lipids will be cationic at a lower pH formulation stage, while particles will be largely (though not completely) surface neutralized at physiological pH of around pH 7.4.
  • pK a of the protonatable group in the range of about 4 to about 1 1.
  • a pK a of about 4 to about 7 because these lipids will be cationic at a lower pH formulation stage, while particles will be largely (though not completely) surface neutralized at physiological pH of around pH 7.4.
  • One of the benefits of this p a is that at least some nucleic acid associated with the outside surface of the particle will lose its electrostatic uuci oiiun at physiological pH and be removed by simple dialysis, thus greatly reducing the particle's susceptibility to clearance.
  • Active agents include any molecule or compound capable of exerting a desired effect on a cell, tissue, tumor, organ, or subject. Such effects may be, e.g., biological, physiological, and/or cosmetic. Active agents may be any type of molecule or compound including, but not limited to, nucleic acids, peptides, polypeptides, small molecules, and mixtures thereof.
  • Non-limiting examples of nucleic acids include interfering R A molecules (e.g., dsRNA such as siRNA, Dicer-substrate dsRNA, shRNA, aiRNA, and/or miRNA), antisense oligonucleotides, plasmids, ribozymes, immunostimulatory oligonucleotides, and mixtures thereof.
  • dsRNA such as siRNA, Dicer-substrate dsRNA, shRNA, aiRNA, and/or miRNA
  • antisense oligonucleotides e.g., siRNA, Dicer-substrate dsRNA, shRNA, aiRNA, and/or miRNA
  • antisense oligonucleotides e.g., antisense oligonucleotides, plasmids, ribozymes, immunostimulatory oligonucleotides, and mixtures thereof.
  • peptides or polypeptides include, without limitation, antibodies (e.g., polyclonal antibodies, monoclonal antibodies, antibody fragments; humanized antibodies, recombinant antibodies, recombinant human antibodies, and/or PrimatizedTM antibodies), cytokines, growth factors, apoptotic factors, differentiation- inducing factors, cell-surface receptors and their ligands, hormones, and mixtures thereof.
  • antibodies e.g., polyclonal antibodies, monoclonal antibodies, antibody fragments; humanized antibodies, recombinant antibodies, recombinant human antibodies, and/or PrimatizedTM antibodies
  • cytokines cytokines
  • growth factors e.g., growth factor, apoptotic factors, differentiation- inducing factors, cell-surface receptors and their ligands, hormones, and mixtures thereof.
  • small molecules include, but are not limited to, small organic molecules or compounds such as any conventional agent or drug known to those of skill in the art.
  • the active agent is a therapeutic agent, or a salt or derivative thereof.
  • Therapeutic agent derivatives may be therapeutically active themselves or they may be prodrugs, which become active upon further modification.
  • a therapeutic agent derivative retains some or all of the therapeutic activity as compared to the unmodified agent, while in another embodiment, a therapeutic agent derivative is a prodrug that lacks therapeutic activity, but becomes active upon further modification.
  • the lipid particles described herein are associated with a nucleic acid, resulting in a nucleic acid-lipid particle (e.g., SNALP).
  • a nucleic acid-lipid particle e.g., SNALP.
  • Non-limiting exemplary embodiments related to selecting, synthesizing, and modifying nucleic acids such as siRNA, Dicer-substrate dsRNA, shRNA, aiRNA, miRNA, antisense oligonucleotides, ribozymes, and immunostimulatory oligonucleotides are described, for example, in U.S. Patent Publication No. 20070135372; in U.S. Patent Publication No. 201 10076335; and in PCT Publication No. WO 2010/105372 , the disclosures of which are each herein incorporated by reference in their entirety for all purposes.
  • the nucleic acid (e.g., interfering RNA) component of the nucleic acid-lipid particle (e.g., SNALP) comprises at least one modified nucleotide (e.g., at least 1. 2. 3, 4. , 6, 7, 8, 9, 10, 11, 12, cr mere modified nucleotides).
  • the nucleic acid (e.g., interfering RNA such as an siR A) comprises modified nucleotides including, but not limited to, 2'-0-methyl (2'OMe) nucleotides, 2 i -deoxy-2'-fluoro (2'F) nucleotides, 2'-deoxy nucleotides, 2'-0-(2-methoxyethyl) (MOE) nucleotides, locked nucleic acid (LNA) nucleotides, 5-C-methyl nucleotides, 4'-thio nucleotides, -amino nucleotides, 2'-C-allyl nucleotides, and mixtures thereof.
  • 2'-0-methyl (2'OMe) nucleotides 2 i -deoxy-2'-fluoro (2'F) nucleotides
  • 2'-deoxy nucleotides 2'-0-(2-methoxyethyl) (MOE) nucleotides
  • LNA
  • the modified interfering RNA (e.g., modified siR A) is generally less immunostimulatory than a corresponding unmodified interfering RNA (e.g., unmodified siRNA) sequence and retains RNAi activity against the target gene of interest.
  • the modified interfering RNA (e.g., modified siRNA) contains at least one 2'OMe purine or pyrimidine nucleotide such as a 2'OMe-guanosine, 2'OMe-uridine, 2'OMe-adenosine, and/or 2'OMe- cytosine nucleotide.
  • the modified nucleotides can be present in one strand (i.e., sense or antisense) or both strands of the interfering RNA (e.g., siRNA).
  • one or more of the uridine and/or guanosine nucleotides are modified (e.g., 2'OMe-modified) in one strand ( . e., sense or antisense) or both strands of the interfering RNA (e.g., siRNA).
  • the modified interfering RNA can further comprise one or more modified (e.g., 2'OMe-modified) adenosine and/or modified (e.g., 2'OMe-modified) cytosine nucleotides.
  • modified interfering RNA e.g., modified siRNA
  • adenosine and/or modified cytosine nucleotides e.g., 2'OMe-modified
  • only uridine and/or guanosine nucleotides are modified (e.g., 2'OMe-modified) in one strand (i.e., sense or antisense) or both strands of the interfering RNA (e.g., siRNA).
  • the interfering RNA (e.g., siRNA) sequences may have overhangs (e.g., 3' or 5' overhangs as described in Elbashir et al, Genes Dev., 15:188 (2001) or Nykanen et al, Cell, 107:309 (2001)), or may lack overhangs (i.e., have blunt ends).
  • the interfering RNA (e.g., siRNA) sequences may comprise one or more modified nucleotides in the double-stranded (duplex) region and/or in one or both of the overhangs (e.g. , 3' overhangs) when present.
  • the nucleic acid (e.g., interfering RNA) component of the nucleic acid-lipid particle (e.g., SNALP) can be used to downregulate or silence the translation (i.e., expression) of a gene of interest.
  • genes of interest include genes associated with metabolic diseases and disorders (e.g., liver diseases and disorders), genes associated with cell proliferation, tumorigenesis, and/or cell transformation (e.g. , a cell proliferative disorder such as cancer), angiogenic genes, receptor ligand genes, immunomodulator genes (e.g., those associated with inflammatory and autoimmune responses), genes associated with viral infection and survival, and genes associated with neurodegenerative disorders. See, e.g., U.S.
  • Patent Publication No. 20110076335 for a description of exemplary target genes (including their Genbank Accession os.) which may be do wur gulaie or sileu eu uy the nucieic acid (e.g., interfering RNA) of the nucleic acid-lipid particle (e.g., SNALP).
  • exemplary target genes including their Genbank Accession os.
  • the nucieic acid e.g., interfering RNA
  • the nucleic acid-lipid particle e.g., SNALP
  • Non-limiting examples of gene sequences associated with tumorigenesis or cell transformation include polo- like kinase 1 (PLK-1), cyclin-dependent kinase 4 (CD 4), COP1 , ring-box 1 (RBX1), WEE1, Eg5 (KSP, KIF1 1), forkhead box Ml (FOXM1), RAM2 (Rl, CDCA7L), XIAP, CSN5 (JAB 1), and HDAC2.
  • Non-limiting examples of gene sequences associated with metabolic diseases and disorders include apolipoprotein B
  • APOB apolipoprotein CIII
  • APOE apolipoprotein E
  • PCSK9 proprotein convertase subtilisin/kexin type 9
  • DGAT1 diacylglycerol O-acyltransferase type 1
  • DGAT2 diacylglyerol O-acyltransferase type 2
  • Non-limiting examples of gene sequences associated with viral infection and survival include host factors such as tissue factor (TF) or nucleic acid sequences from Filoviruses such as Ebola virus and Marburg virus (e.g., VP30, VP35, nucleoprotein (NP), polymerase protein (L-pol), VP40, glycoprotein (GP), and VP24); Arenaviruses such as Lassa virus (e.g., NP, GP, L, and/or Z genes), Junin virus, Machupo virus, Guanarito virus, and Sabia virus; Hepatitis viruses such as Hepatitis A, B, C, D, and E viruses; Influenza viruses such as Influenza A, B, and C viruses; Human Immunodeficiency Virus (HTV); Herpes viruses; and Human Papilloma Viruses (HPV).
  • host factors such as tissue factor (TF) or nucleic acid sequences from Filoviruses such as Ebola virus and Marburg virus (e.g.,
  • the active agent associated with the lipid particles of the invention may comprise one or more therapeutic proteins, polypeptides, or small organic molecules or compounds.
  • therapeutically effective agents or drugs include oncology drugs (e.g., chemotherapy drugs, hormonal therapaeutic agents, immunotherapeutic agents, radiotherapeutic agents, etc.), lipid-lowering agents, anti- viral drugs, anti-inflammatory compounds, antidepressants, stimulants, analgesics, antibiotics, birth control medication, antipyretics, vasodilators, anti-angiogenics, cytovascular agents, signal transduction inhibitors, cardiovascular drugs such as anti-arrhythmic agents, hormones, vasoconstrictors, and steroids.
  • oncology drugs e.g., chemotherapy drugs, hormonal therapaeutic agents, immunotherapeutic agents, radiotherapeutic agents, etc.
  • lipid-lowering agents e.g., anti- viral drugs, anti-inflammatory compounds, antidepressants, stimulants, analgesics, antibiotics, birth control medication, antipyretics, vasodilators
  • active agents may be adniinistered alone in the lipid particles of the invention, or in combination (e.g., co-administered) with lipid particles of the invention comprising nucleic acid such as interfering RNA.
  • Non-limiting examples of these types of active agents are described, e.g., in U.S. Patent Publication No. 201 10076335, the disclosure of which is herein incorporated by reference in its entirety for all purposes.
  • the present invention provides lipid particles comprising one or more of the cationic (amino) lipids or salts thereof described herein.
  • the lipid particles of the invention further comprise one or more non-cationic lipids.
  • the lipid pai ii ies further comprise one or more conjugated lipids capable of reducing or inhibiting particle aggregation.
  • the lipid particles further comprise one or more active agents or therapeutic agents such as therapeutic nucleic acids (e.g., interfering RNA such as siRNA).
  • Lipid particles include, but are not limited to, lipid vesicles such as liposomes.
  • a lipid vesicle includes a structure having lipid-containing membranes enclosing an aqueous interior.
  • lipid vesicles comprising one or more of the cationic lipids described herein are used to encapsulate nucleic acids within the lipid vesicles.
  • lipid vesicles comprising one or more of the cationic lipids described herein are complexed with nucleic acids to form lipoplexes.
  • the lipid particles of the invention typically comprise an active agent or therapeutic agent, a cationic lipid, a non-cationic lipid, and a conjugated lipid that inhibits aggregation of particles.
  • the active agent or therapeutic agent is fully encapsulated within the lipid portion of the lipid particle such that the active agent or therapeutic agent in the lipid particle is resistant in aqueous solution to enzymatic degradation, e.g., by a nuclease or protease.
  • the lipid particles described herein are substantially nontoxic to mammals such as humans.
  • the lipid particles of the invention typically have a mean diameter of from about 30 nm to about 150 nm, from about 40 nm to about 150 nm, from about 50 nm to about 150 nm, from about 60 nm to about 130 nm, from about 70 nm to about 110 nm, or from about 70 to about 90 nm.
  • the lipid particles of the invention also typically have a lipid:therapeutic agent (e.g., lipid:nucleic acid) ratio (mass/mass ratio) of from about 1 : 1 to about 100: 1, from about 1 : 1 to about 50: 1 , from about 2:1 to about 25: 1 , from about 3: 1 to about 20: 1 , from about 5: 1 to about 15: 1, or from about 5:1 to about 10:1.
  • lipid:therapeutic agent e.g., lipid:nucleic acid
  • ratio mass/mass ratio
  • the lipid particles of the invention are serum-stable nucleic acid-lipid particles (SNALP) which comprise an interfering RNA (e.g., dsRNA such as siRNA, Dicer-substrate dsRNA, shRNA, aiRNA, and/or miRNA), a cationic lipid (e.g. , one or more cationic lipids of Formula I or salts thereof as set forth herein), a non-cationic lipid (e.g., mixtures of one or more phospholipids and cholesterol), and a conjugated lipid that inhibits aggregation of the particles (e.g., one or more PEG-lipid conjugates).
  • SNALP serum-stable nucleic acid-lipid particles
  • the SNALP may comprise at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more unmodified and/or modified interfering RNA molecules (e.g., siRNA).
  • RNA molecules e.g., siRNA
  • Nucleic acid-lipid particles and their method of preparation are described in, e.g., U.S. Patent Nos. 5,753,613; 5,785,992; 5,705,385;
  • the nucleic acid may be fully encapsulated within the lipid portion of the particle, thereby protecting the nucleic acid from nuclease degradation.
  • a SNALP comprising a nucleic acid such as an interfering RNA is fully encapsulated within the lipid portion of the particle, thereby protecting the nucleic acid from nuclease degradation.
  • the nucleic acid in the SNALP is not substantially degraded after exposure of the particle to a nuclease at 37°C for at least about 20, 30, 45, or 60 minutes. In certain other instances, the nucleic acid in the SNALP is not substantially degraded after incubation of the particle in serum at 37°C for at least about 30, 45, or 60 minutes or at least about 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, or 36 hours. In other embodiments, the nucleic acid is complexed with the lipid portion of the particle.
  • the nucleic acid-lipid particle compositions are substantially nontoxic to mammals such as humans.
  • nucleic acid in the nucleic acid- lipid particle is not significantly degraded after exposure to serum or a nuclease assay that would significantly degrade free DNA or RNA.
  • a fully encapsulated system preferably less than about 25% of the nucleic acid in the particle is degraded in a treatment that would normally degrade 100% of free nucleic acid, more preferably less than about 10%, and most preferably less than about 5% of the nucleic acid in the particle is degraded.
  • “Fully encapsulated” also indicates that the nucleic acid-lipid particles are serum-stable, that is, that they do not rapidly decompose into their component parts upon in vivo administration.
  • full encapsulation may be determined by performing a membrane-impermeable fluorescent dye exclusion assay, which uses a dye that has enhanced fluorescence when associated with nucleic acid.
  • Specific dyes such as OliGreen ® and RiboGreen ® (Invitrogen Corp.; Carlsbad, CA) are available for the quantitative determination of plasmid DNA, single-stranded deoxyribonucleotides, and or single- or double-stranded ribonucleotides.
  • Encapsulation is determined by adding the dye to a liposomal formulation, measuring the resulting fluorescence, and comparing it to the fluorescence observed upon addition of a small amount of nonionic detergent.
  • the present invention provides a nucleic acid-lipid particle (e.g. , SNALP) composition comprising a plurality of nucleic acid-lipid particles.
  • the SN ALP composition comprises nucleic acid that is fully encapsulated vvdtbin the lipid portion of the particles, such that from about 30% to about 100%, from about 40% to about 100%, from about 50% to about 100%, from about 60% to about 100%, from about 70% to about 100%, from about 80% to about 100%, from about 90% to about 100%, from about 30% to about 95%, from about 40% to about 95%, from about 50% to about 95%, from about 60% to about 95%, from about 70% to about 95%, from about 80% to about 95%, from about 85% to about 95%, from about 90% to about 95%, from about 30% to about 90%, from about 40% to about 90%, from about 50% to about 90%, from about 60% to about 90%, from about 70% to about 90%, from about 80% to about 90%, or at least
  • the SNALP composition comprises nucleic acid that is fully encapsulated within the lipid portion of the particles, such that from about 30% to about 100%, from about 40% to about 100%, from about 50% to about 100%, from about 60% to about 100%, from about 70% to about 100%, from about 80% to about 100%, from about 90% to about 100%, from about 30% to about 95%, from about 40% to about 95%, from about 50% to about 95%, from about 60% to about 95%, from about 70% to about 95%, from about 80% to about 95%, from about 85% to about 95%, from about 90% to about 95%, from about 30% to about 90%, from about 40% to about 90%, from about 50% to about 90%, from about 60% to about 90%, from about 70% to about 90%, from about 80% to about 90%, or at least about 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%
  • the proportions of the components can be varied and the delivery efficiency of a particular formulation can be measured using, e.g., an endosomal release parameter (ERP) assay.
  • ERP endosomal release parameter
  • the present invention provides a lipid particle (e.g. , SNALP) composition comprising a plurality of lipid particles described herein and an antioxidant.
  • the antioxidant in the lipid particle composition reduces, prevents, and/or inhibits the degradation of a cationic lipid (e.g., a polyunsaturated cationic lipid) present in the lipid particle.
  • the antioxidant in the lipid particle composition reduces, prevents, and/or inhibits the degradation of the nucleic acid payload, e.g., by reducing, preventing, and/or inhibiting the oxidation of the cationic lipid, by reducing, preventing, and/or inhibiting the degradation of the nucleic acid payload, by reducing, preventing, and/or inhibiting the desulfurization of a phophorothioate (PS)- modified nucleic acid payload, and/or by stabilizing both the lipid and nucleic acid components.
  • PS phophorothioate
  • antioxidants include, but are not limited to, metal chelators (e.g., e&ylenediaminetetraacetic acid (EDTA), citrate, and the like), primary antioxidants (e.g., vitamin E isomers such as a-tocopherol or a salt thereof, butylated hydroxyanisole (BHA), butylhydroxytoluene (BHT), fert-butylhydroquinone (TBHQ), and the like), secondary antioxidants (e.g., ascorbic acid, ascorbyl palmitate, cysteine, glutathione, a-lipoic acid, and the like), salts thereof, and mixtures thereof.
  • metal chelators e.g., e&ylenediaminetetraacetic acid (EDTA), citrate, and the like
  • primary antioxidants e.g., vitamin E isomers such as a-tocopherol or a salt thereof, butylated hydroxyanisole (BHA), butylhydroxyto
  • the antioxidant is typically present in an amount sufficient to prevent, inhibit, and/or reduce the degradation of the cationic lipid and/or active agent present in the lipid particle.
  • the antioxidant comprises EDTA or a salt thereof (e.g., from about 20 mM to about 100 mM), alone or in combination with a primary antioxidant such as a-tocopherol or a salt thereof (e.g., from about 0.02 mol % to about 0.5 mol %) and/or secondary antioxidant such as ascorbyl palmitate or a salt thereof (e.g., from about 0.02 mol % to about 5.0 mol %).
  • An antioxidant such as EDTA may be included at any step or at multiple steps in the lipid particle formation process described in Section VI (e.g., prior to, during, and/or after lipid particle formation).
  • the lipid particles of the invention may include a targeting lipid.
  • the targeting lipid comprises a GalNAc moiety (i.e., an N-galactosamine moiety).
  • a targeting lipid comprising a GalNAc moiety can include those described in US Application No. 12/328,669, filed December 4, 2008, the disclosure of which is herein incorporated by reference in its entirety for all purposes.
  • a targeting lipid can also include any other lipid (e.g., targeting lipid) known in the art, for example, as described in US Application No. 12/328,669 or PCT Publication No.
  • the targeting lipid includes a plurality of GalNAc moieties, e.g., two or three GalNAc moieties. In some embodiments, the targeting lipid contains a plurality, e.g., two or three N-acetylgalactosamine (GalNAc) moieties. In some embodiments, the lipid in the targeting lipid is l ⁇ -Di-O-hexadecyl-sn-glyceride (i.e., DSG).
  • the targeting lipid includes a PEG moiety (e.g., a PEG moiety having a molecular weight of at least about 500 Da, such as about 1000 Da, 1500 Da, 2000 Da or greater), for example, the targeting moiety is connected to the lipid via a PEG moiety.
  • PEG moiety e.g., a PEG moiety having a molecular weight of at least about 500 Da, such as about 1000 Da, 1500 Da, 2000 Da or greater
  • Examples of GalNAc targeting lipids include, but are not limited to, (GalNAc) 3 -PEG-DSG, (GaTNAc) 3 -PEG-LCO, and mixtures thereof.
  • the targeting lipid includes a folate moiety.
  • a targeting lipid comprising a folate moiety can include those described in US Application No. 12/328,669, the disclosure of which is herein incorporated by reference in its entirety for all purposes.
  • folate targeting lipids include, but are not limited to, 1,2-distearoyl- sn-g]ycero-3-phosphoemanolaniine-N-[folate(polyethylene glycol)-2000] (ammonium salt) (Folate-PEG-DSPE), Folate-PEG2000-DSG, Folate-PEG3400-DSG, and mixtures thereof.
  • the lipid particles of the invention may further comprise one or more apolipoproteins.
  • apolipoprotein or “lipoprotein” refers to apolipoproteins known to those of skill in the art and variants and fragments thereof and to apolipoprotein agonists, analogues, or fragments thereof described in, e.g., PCT Publication No. WO 2010/0088537, the disclosure of which is herein incorporated by reference in its entirety for all purposes.
  • Suitable apolipoproteins include, but are not limited to, ApoA-I, ApoA-II, ⁇ - ⁇ , ApoA-V, and ApoE (e.g., ApoE2, ApoE3, etc.), and active polymorphic forms, isoforms, variants, and mutants as well as fragments or truncated forms thereof.
  • ApoE and/or active fragments and polypeptide analogues thereof, including recombinanfly produced forms thereof, are described in US Patent Nos. 5,672,685;
  • any of the novel cationic lipids of Formula I or salts thereof as set forth herein may be used in the lipid particles of the present invention (e.g., S ALP), either alone or in combination with one or more other cationic lipid species or non-cationic lipid species.
  • cationic lipids or salts thereof which may also be included in the lipid particles of the present invention include, but are not limited to, one or more of the cationic lipids of Formulas I-XXII or salts thereof as described in U.S. Application No. 13/077,856, filed March 31 , 201 1 , one or more of the cationic lipids of Formulas I-XFX or salts thereof as described in PCT Application No. PCT/CA2010/001919, filed December 1 , 2010, and/or one or more of the cationic lipids of Formulas I-III or salts thereof as described in PCT Application ⁇ .
  • PCi ⁇ JB2 11/ entitled “Novel Cyclic Cationic Lipids and Methods of Use Thereof," bearing Attorney Docket No. 86399-0101 lOPC (805953) and/or Reference No. N.l 14015 PJC/JRN, filed May 12, 2011, the disclosures of which are herein incorporated by reference in their entirety for all purposes.
  • Non-lirniting examples of additional suitable cationic lipids include l,2-dilinoleyloxy-N,N-dimethylaminopropane (DLinDMA), 1,2- dilinolenyloxy-N,N-dirnethylarninopropane (DLenDMA), 2,2-dilinoleyl-4-(2- dimethylaminoethyl)-[l,3]-dioxolane (DLin-K-C2-DMA; "XTC2" or "C2K”), 2,2-dilinoleyl- 4-dirnethylaminomethyl-[l,3]-dioxolane (DLin-K-DMA), 2,2-dilinoleyl-4-(3- dimethylaminopropyl)-[l,3]-dioxolane (DLin-K-C3-DMA; "C3K”), 2,2-dilinoleyl-4-(4- dhriethy
  • Examples of yet additional cationic lipids include, but are not limited to, 1,2- dioeylcarbamoyloxy-3-dimethylaminopropane (DO-C-DAP), 1 ,2-dimyristoleoyl-3- drmethylaminopropane (DMDAP), 1, 2-dioleoyl -3 -trimethylaminopropane chloride
  • DOTAP.Cl l,2-dilinoleylcarbamoyloxy-3-dimemylarninopropane
  • DLin-C-DAP 1,2- dilinoleyoxy-3 -(dimethylamino)acetoxypropane
  • DLin-D AC 1,2-dilinoleyoxy-3 - morpholinopropane
  • DLin-MA l,2-dilinoleoyl-3-dimethylaminopropane
  • DLin-S-DMA 1,2- dilinoleylthio-3-dimethylaminopropane
  • DLin-2-DMAP 1,2-dilinoleyloxy-3-trimethylaminopropane chioride salt
  • DLin-TMA.Cl l,2-dilinoleoyl-3-trimethylaminopropane chioride salt
  • DLin-TMA.Cl l,2-dilinoleoyl-3
  • DOGS dioctadecylamidoglycyl spermine
  • the additional cationic lipid forms a salt (preferably a crystalline salt) with one or more anions.
  • the additional cationic lipid is the oxalate (e.g., hemioxalate) salt thereof, which is preferably a crystalline salt.
  • cationic lipids such as ⁇ -DLenDMA, DLen-C2K-DMA, ⁇ -DLen- C2K-DMA, DPan-C2K-DMA, DPan-C3K-DMA 3 DLen-C2K-DMA, Y-DLen-C2K-DMA, DPan-C2K-DMA, TLinDMA, C2-TLinDMA, C3-TLinD A, C2-DLinDMA, and C2- DLinDAP, as well as additional cationic lipids, is described in PCT Publication No. WO 201 1/000106, the disclosure of which is herein incorporated by reference in its entirety for all purposes.
  • cationic lipids such as CP-LenMC3, CP-y-LenMC3, CP-MC3, CP- DLen-C2K-DMA, CP-YDLen-C2K-DMA, CP-C2K-DMA, CP-DODMA, CP-DPetroDMA, CP-DLinD A, CP-DLenDMA, and CP-yDLenDMA is described in PCT Application No.
  • the cationic lipid comprises from about 45 mol % to about 90 mol %, from about 45 mol % to about 85 mol %, from about 45 mol % to about 80 mol %, from about 45 mol % to about 75 mol %, from about 45 mol % to about 70 mol %, from about 45 mol % to about 65 mol %, from about 45 mol % to about 60 mol %, from about 45 mol % to about 55 mol %, from about 50 mol % to about 90 mol %, from about 50 mol % to about 85 mol %, from about 50 mol % to about 80 mol %, from about 50 mol % to about 75 mol %, from about 50 mol % to about 70 mol %, from about 50 mol % to about 65 mol %, from about 50 mol % to about 60 mol %, from about 55 mol % to about 65 %, from about 50 mol % to about
  • the cationic lipid comprises from about 50 mol % to about 58 mol %, from about 51 mol % to about 59 mol %, from about 51 mol % to about 58 mol %, from about 51 mol % to about 57 mol %, from about 52 mol % to about 58 mol %, from about 52 mol % to about 57 mol %, from about 52 mol % to about 56 mol %, or from about 53 mol % to about 55 mol % (or any fraction thereof or range therein) of the total lipid present in the particle.
  • the cationic lipid comprises about 50 mol %, 51 mol %, 52 mol %, 53 mol %, 54 mol %, 55 mol %, 56 mol %, 57 mol %, 58 mol %, 59 mol %, 60 mol %, 61 mol %, 62 mol %, 63 mol %, 64 mol %, or 65 mol % (or any fraction thereof or range therein) of the total lipid present in the particle.
  • the cationic lipid comprises (at least) about 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, or 90 mol % (or any fraction thereof or range therein) of the total lipid present in the particle.
  • the cationic lipid comprises from about 2 mol % to about 60 mol %, from about 5 mol % to about 50 mol %, from about 10 mol % to about 50 mol %, from about 20 mol % to about 50 mol %, from about 20 mol % to about 40 mol %, from about 30 mol % to about 40 mol %, or about 40 mol % (or any fraction thereof or range therein) of the total lipid present in the particle.
  • the percentage of cationic lipid present in the lipid particles of the invention is a target amount, and that the actual amount of cationic lipid present in the formulation may vary, for example, by ⁇ 5 mol %.
  • the target amount of cationic lipid is 57.1 mol %, but the actual amount of cationic lipid may be ⁇ 5 mol %, ⁇ 4 mol %, ⁇ 3 mol %, ⁇ 2 mol %, ⁇ 1 mol %, ⁇ 0.75 mol %, ⁇ 0.5 mol %, ⁇ 0.25 mol %, or ⁇ 0.1 mol % of that target amount, with the balance of the formulation being made up of other lipid components (adding up to 100 moi % of total lipids present in the particle).
  • the target amount of cationic lipid is 54.06 mol %, but the actual amount of cationic lipid may be ⁇ 5 mol %, ⁇ 4 mol %, ⁇ 3 mol %, ⁇ 2 mol %, ⁇ 1 mol %, ⁇ 0.75 mol %, ⁇ 0.5 mol %, ⁇ 0.25 mol %, or ⁇ 0.1 mol % of that target amount, with the balance of the formulation being made up of other lipid components (adding up to 100 mol % of total lipids present in the particle).
  • the non-cationic lipids used in the lipid particles of the invention can be any of a variety of neutral uncharged, zwittenonic, or anionic lipids capable of producing a stable complex.
  • Non-limiting examples of non-cationic lipids include phospholipids such as lecithin, phosphatidylethanolamine, lysolecithin, lysophosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin, egg sphingomyelin (ESM), cephalin, cardiolipin, phosphatide acid, cerebrosides, dicetylphosphate, distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalrnitoylphosphatidylcholine (DPPC),
  • phospholipids such as lecithin, phosphatidylethanolamine, lysolecithin, lysophosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin, egg sphingomyelin
  • dioleoylphosphatidylglycerol DOPG
  • dipalmitoylphosphatidylglycerol DPPG
  • dioleoylphosphatidylemanolamine DOPE
  • palmitoyloleoyl-phosphatidylcholine POPC
  • palrmtoyloleoyl-phosphatidylethanolamine POPE
  • palmitoyloleyol-phosphatidylglycerol POPG
  • acyl groups in these lipids are preferably acyl groups derived from fatty acids having Cio-C 24 carbon chains, e.g., lauroyl, myristoyl, palmitoyl, stearoyl, or oleoyl.
  • non-cationic lipids include sterols such as cholesterol and derivatives thereof.
  • cholesterol derivatives include polar analogues such as 5a-cholestanol, 5p-coprostanol, cholesteryl-(2'-hydroxy)-ethyl ether, cholesteryl-(4'- hydroxy)-butyl ether, and 6-ketocholestanol; non-polar analogues such as 5a-cholestane, cholestenone, 5a-cholestanone, 5P-cholestanone, and cholesteryl decanoate; and mixtures thereof.
  • the cholesterol derivative is a polar analogue such as cholesteryl-(4'-hydroxy)-butyl ether.
  • cholesteryl-(2'-hydroxy)-ethyl ether is described in PCT Publication No. WO 09/127060, the disclosure of which is herein incorporated by reference in its entirety for all purposes.
  • the non-cationic lipid present in the lipid particles comprises or consists of a mixture of one or more phospholipids and cholesterol or a derivative thereof.
  • the non-cationic lipid present in the lipid particles comprises or consists of one or more phospholipids, e.g., a cholesterol-free lipid particle formulation.
  • the non-cationic lipid present in the lipid particles comprises or consists of cholesterol or a derivative thereof, e.g., a phospholipid-free lipid particle formulation.
  • non-cationic lipids suitable for use in the present invention include nonphosphorous containing lipids such as, e.g., stearylamine, dodecylarnine, hexadecylamine, acetyl palmitate, glycerolricinoleate, hexadecyl stereate, isopropyl myristate, amphoteric acrylic polymers, triethanolamine-lauryl sulfate, alkyl-aryl sulfate polyethyloxylated fatty acid amides, dioctadecyldimethyl ammonium bromide, ceramide, sphingomyelin, and the like.
  • nonphosphorous containing lipids such as, e.g., stearylamine, dodecylarnine, hexadecylamine, acetyl palmitate, glycerolricinoleate, hexadecyl
  • the non-cationic lipid comprises from about 10 mol % to about 60 mol %, from about 20 mol % to about 55 mol %, from about 20 mol % to about 45 mol %, from about 20 mol % to about 40 mol %, from about 25 mol % to about 50 mol %, from about 25 mol % to about 45 mol %, from about 30 mol % to about 50 mol %, from about 30 mol % to about 45 mol %, from about 30 mol % to about 40 mol %, from about 35 mol % to about 45 mol %, from about 37 mol % to about 42 mol %, or about 35 mol %, 36 mol %, 37 mol %, 38 mol %, 39 mol %, 40 mol %, 41 mol %, 42 mol %, 43 mol %, 44 mol %, or 45 mol % (or any fraction thereof
  • the lipid particles contain a mixture of phospholipid and cholesterol or a cholesterol derivative
  • the mixture may comprise up to about 40 mol %, 45 mol %, 50 mol %, 55 mol %, or 60 mol % of the total lipid present in the particle.
  • the phospholipid component in the mixture may comprise from about 2 mol % to about 20 mol %, from about 2 mol % to about 15 mol %, from about 2 mol % to about 12 mol %, from about 4 mol % to about 15 mol %, or from about 4 mol % to about 10 mol % (or any fraction thereof or range therein) of the total lipid present in the particle.
  • the phospholipid component in the mixture comprises from about 5 mol % to about 10 mol %, from about 5 mol % to about 9 mol %, from about 5 mol % to about 8 mol %, from about 6 mol % to about 9 mol %, from about 6 mol % to about 8 mol %, or about 5 mol %, 6 mol %, 7 mol %, 8 mol %, 9 mol %, or 10 mol % (or any fraction thereof or range therein) of the total lipid present in the particle.
  • a 1:57 lipid particle formulation comprising a mixture of phospholipid and cholesterol may comprise a phospholipid such as DPPC or DSPC at about 7 mol % (or any fraction thereof), e.g., in a mixture with cholesterol or a cholesterol derivative at about 34 mol % (or any fraction thereof) of the total lipid present in the particle.
  • a phospholipid such as DPPC or DSPC at about 7 mol % (or any fraction thereof), e.g., in a mixture with cholesterol or a cholesterol derivative at about 34 mol % (or any fraction thereof) of the total lipid present in the particle.
  • a 7:54 lipid particle formulation comprising a mixture of phospholipid and cholesterol may comprise a phospholipid such as DPPC or DSPC at about 7 mol % (or any fraction thereof), e.g., in a mixture with cholesterol or a cholesterol derivative at about 32 mol % (or any fraction thereof) of the total lipid present in the particle.
  • the cholesterol component in the mixture may comprise from about 25 mol % to about 45 mol %, from about 25 mol % to about 40 mol %, from about 30 mol % to about 45 mol %, from about 30 mol % to about 40 mol %, from about 27 mol % to about 37 mol %, from about 25 mol % to about 30 mol %, or from about 35 mol % to about 40 mol % (or any fraction thereof or range therein) of the total lipid present in the particle.
  • the cholesterol component in the mixture comprises from about 25 mol % to about 35 mol %, from about 27 mol % to about 35 mol %, from about 29 mol % to about 35 mol %, from about 30 mol % to about 35 mol %, from about 30 mol % to about 34 mol %, from about 31 mol % to about 33 mol %, or about 30 mol %, 31 mol %, 32 mol %, 33 mol %, 34 mol %, or 35 mol % (or any fraction thereof or range therein) of the total lipid present in the particle.
  • the cholesterol component in the mixture comprises about 36, 37, 38, 39, 40, 41, 42, 43, 44, or 45 mol % (or any fraction thereof or range therein) of the total lipid present in the particle.
  • a 1 :57 lipid particle formulation comprising a mixture of phospholipid and cholesterol may comprise cholesterol or a cholesterol derivative at about 34 mol % (or any fraction thereof), e.g., in a mixture with a phospholipid such as DPPC or DSPC at about 7 mol % (or any fraction thereof) of the total lipid present in the particle.
  • a 7:54 lipid particle formulation comprising a mixture of phospholipid and cholesterol may comprise cholesterol or a cholesterol derivative at about 32 mol % (or any fraction thereof), e.g., in a mixture with a phospholipid such as DPPC or DSPC at about 7 mol % (or any fraction thereof) of the total lipid present in the particle.
  • the cholesterol or derivative thereof may comprise up to about 25 mol %, 30 mol %, 35 mol %, 40 mol %, 45 mol %, 50 mol %, 55 mol %, or 60 mol % of the total lipid present in the particle.
  • the cholesterol or derivative thereof in the phospholipid-free lipid particle formulation may comprise from about 25 mol % to about 45 mol %, from about 25 nvcl % to about 40 moi %, from about 30 mol % to about 45 mol %, from about 30 mol % to about 40 mol %, from about 31 mol % to about 39 mol %, from about 32 mol % to about 38 mol %, from about 33 mol % to about 37 mol %, from about 35 mol % to about 45 mol %, from about 30 mol % to about 35 mol %, from about 35 mol % to about 40 mol %, or about 30 mol %, 31 mol %, 32 mol %, 33 mol %, 34 mol %, 35 mol %, 36 mol %, 37 mol %, 38 mol %, 39 mol %, 40 mol %, 41 mol %, 42
  • a 1 :62 lipid particle formulation may comprise cholesterol at about 37 mol % (or any fraction thereof) of the total lipid present in the particle.
  • a 7:58 lipid particle formulation may comprise cholesterol at about 35 mol % (or any fraction thereof) of the total lipid present in the particle.
  • the non-cationic lipid comprises from about 5 mol % to about 90 mol %, from about 10 mol % to about 85 mol %, from about 20 mol % to about 80 mol %, about 10 mol % (e.g., phospholipid only), or about 60 mol % (e.g., phospholipid and cholesterol or derivative thereof) (or any fraction thereof or range therein) of the total lipid present in the particle.
  • the percentage of non-cationic lipid present in the lipid particles of the invention is a target amount, and that the actual amount of non-cationic lipid present in the formulation may vary, for example, by ⁇ 5 mol %.
  • the target amount of phospholipid is 7.1 mol % and the target amount of cholesterol is 34.3 mol %, but the actual amount of phospholipid may be ⁇ 2 mol %, ⁇ 1.5 mol %, ⁇ 1 mol %, ⁇ 0.75 mol %, ⁇ 0.5 mol %, ⁇ 0.25 mol %, or ⁇ 0.1 mol % of that target amount, and the actual amount of cholesterol may be ⁇ 3 mol %, ⁇ 2 mol %, ⁇ 1 mol %, ⁇ 0.75 mol %, ⁇ 0.5 mol %, ⁇ 0.25 mol %, or ⁇ 0.1 mol % of that target amount, with the balance of the formulation being made up of other lipid components (adding up to 100 mol % of total lipids present in the particle).
  • the target amount of phospholipid is 6.75 mol % and the target amount of cholesterol is 32.43 mol %, but the actual amount of phospholipid may be ⁇ 2 mol %, ⁇ 1.5 mol %, ⁇ 1 mol %, ⁇ 0.75 mol %, ⁇ 0.5 mol %, ⁇ 0.25 mol %, or ⁇ 0.1 mol % of that target amount, and the actual amount of cholesterol may be ⁇ 3 mol %, ⁇ 2 mol %, ⁇ 1 mol %, ⁇ 0.75 mol %, ⁇ 0.5 mol %, ⁇ 0.25 mol %, or ⁇ 0.1 mol % of that target amount, with the balance of the formulation being made up of other lipid components (adding up to 100 mol % of total lipids present in the particle).
  • the lipid particles of the invention may further comprise a lipid conjugate.
  • the conjugated lipid is useful in that it prevents the aggregation of particles.
  • Suitable conjugated lipids include, but are not limited to, PEG-lipid conjugates, POZ-lipid conjugates, ATTA-lipid conjugates, cationic-polymer- lipid conjugates (CPLs), and mixtures thereof.
  • the lipid particles comprise either a PEG-lipid conjugate or an ATTA-lipid conjugate together with a CPL.
  • ATT A or "polyamide” includes, without limitation, compounds described in U.S. Patent Nos. 6,320,017 and 6,586,559, the disclosures of which are herein incorporated by reference in their entirety for all purposes.
  • the lipid conjugate is a PEG-lipid.
  • PEG-lipids include, but are not limited to, PEG coupled to dialkyloxypropyls (PEG-DAA) as described in, e.g., PCT Publication No. WO 05/026372, PEG coupled to diacylglycerol (PEG-DAG) as described in, e.g., U.S. Patent Publication Nos. 20030077829 and
  • PEG coupled to phospholipids such as phosphatidylemanolarnine (PEG-PE), PEG conjugated to ceramides as described in, e.g., U.S. Patent No. 5,885,613, PEG conjugated to cholesterol or a derivative thereof, and mixtures thereof.
  • PEG-PE phosphatidylemanolarnine
  • ceramides as described in, e.g., U.S. Patent No. 5,885,613, PEG conjugated to cholesterol or a derivative thereof, and mixtures thereof.
  • the disclosures of these patent documents are herein incorporated by reference in their entirety for all purposes.
  • PEG-lipids suitable for use in the invention include, without limitation, mPEG2000-l ,2-di-O-alkyl-in3-carbomoylglyceride (PEG-C-DOMG).
  • PEG-C-DOMG mPEG2000-l ,2-di-O-alkyl-in3-carbomoylglyceride
  • PEG-lipid conjugates include, without limitation, l-[8'-(l,2-dimyristoyl-3-propanoxy)- carboxamido-3',6'-dioxaoctanyl]carbamoyI-ro-methyl-poIy(ethylene glycol) (2KPEG-DMG).
  • 2KPEG-DMG l-[8'-(l,2-dimyristoyl-3-propanoxy)- carboxamido-3',6'-dioxaoctanyl]carbamoyI-ro-methyl-poIy(ethylene glycol)
  • PEG is a linear, water-soluble polymer of ethylene PEG repeating units with two terminal hydroxyl groups. PEGs are classified by their molecular weights; for example, PEG 2000 has an average molecular weight of about 2,000 daltons, and PEG 5000 has an average molecular weight of about 5,000 daltons. PEGs are commercially available from Sigma Chemical Co. and other companies and include, but are not limited to, the following:
  • MePEG-OH monomethoxypolyethylene glycol
  • MePEG-S monomethoxypolyethylene glycol- succinate MePEG-S
  • MePEG-S monomethoxypolyethylene glycol-succinirnidyl succinate
  • MePEG-S monomethoxypolyethylene glycol-succinirnidyl succinate
  • MePEG-S monomethoxypolyethylene glycol-amine
  • MePEG-TRES monomethoxypolyethylene glycol-tresylate
  • ePEG-IM monomethoxypolyethylene glycol-irnidazolyl-carbonyl
  • ePEG-IM monomethoxypolyethylene glycol-irnidazolyl-carbonyl
  • PEGs such as those described in U.S. Patent Nos. 6,774,180 and 7,053,150 (e.g., mPEG (20 KDa) amine) are also useful for preparing the PEG-lipid conjugates of the present invention.
  • mPEG (20 KDa) amine e.g., mPEG (20 KDa) amine
  • monomethoxypolyethyleneglycol-acetic acid ePEG-CH 2 COOH
  • PEG-DAA conjugates e.g., PEG-DAA conjugates.
  • the PEG moiety of the PEG-lipid conjugates described herein may comprise an average molecular weight ranging from about 550 daltons to about 10,000 daltons. In certain instances, the PEG moiety has an average molecular weight of from about 750 daltons to about 5,000 daltons (e.g., from about 1,000 daltons to about 5,000 daltons, from about 1,500 daltons to about 3,000 daltons, from about 750 daltons to about 3,000 daltons, from about 750 daltons to about 2,000 daltons, etc.).
  • the PEG moiety has an average molecular weight of from about 550 daltons to about 1000 daltons, from about 250 daltons to about 1000 daltons, from about 400 daltons to about 1000 daltons, from about 600 daltons to about 900 daltons, from about 700 daltons to about 800 daltons, or about 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, or 1000 daltons. In preferred embodiments, the PEG moiety has an average molecular weight of about 2,000 daltons or about 750 daltons.
  • the PEG can be optionally substituted by an alkyl, alkoxy, acyl, or aryl group.
  • the PEG can be conjugated directly to the lipid or may be linked to the lipid via a linker moiety.
  • Any linker moiety suitable for coupling the PEG to a lipid can be used including, e.g., non-ester containing linker moieties and ester-containing linker moieties.
  • the linker moiety is a non-ester containing linker moiety.
  • non-ester containing linker moiety refers to a linker moiety that does not contain a carboxylic ester bond (-OC(O)-).
  • Suitable non-ester containing linker moieties include, but are not limited to, amido (-C(O)NH-), amino (-NR-), carbonyl (-C(O)-), carbamate (-NHC(O)O-), urea (-NHC(O)NH-), disulphide (-S-S-), ether (-0-), succinyl (- (0)CCH 2 CH 2 C(0)-), succinamidyl (-NHC(0)CH 2 CH 2 C(0) H-), ether, disulphide, as well as combinations thereof (such as a linker containing both a carbamate linker moiety and an amido linker moiety).
  • a carbamate linker is used to couple the PEG to the lipid.
  • an ester containing linker moiety is used to couple the PEG to the lipid.
  • Suitable ester containing linker moieties include, e.g., carbonate (-OC(O)O-), succinoyl, phosphate esters (-O-(O)POH-O-), sulfonate esters, and combinations thereof.
  • Phosphatidylethanolamines having a variety of acyl chain groups of varying chain lengths and degrees of saturation can be conjugated to PEG to form the lipid conjugate.
  • Such phosphatidylethanolamines are commercially available, or can be isolated or synthesized using conventional techniques known to those of skilled in the art.
  • Phosphatidylethanolamines containing saturated or unsaturated fatty acids with carbon chain lengths in the range of Cio to C 20 are preferred.
  • Phosphatidylethanolamines with mono- or diunsaturated fatty acids and mixtures of saturated and unsaturated fatty acids can also be used.
  • Suitable phosphatidylemanolamines include, but are not limited to, dimyristoyl- phosphatidylethanolamine (DMPE), dipalmitoyl-phosphatidylemanolamine (DPPE), dioleoylphosphatidylethanolaniine (DOPE), and distearoyl-phosphatidylethanolamine (DSPE).
  • DMPE dimyristoyl- phosphatidylethanolamine
  • DPPE dipalmitoyl-phosphatidylemanolamine
  • DOPE dioleoylphosphatidylethanolaniine
  • DSPE distearoyl-phosphatidylethanolamine
  • diacylglycerol or "DAG” includes a compound having 2 fatty acyl chains, R 1 and R 2 , both of which have independently between 2 and 30 carbons bonded to the 1- and 2-position of glycerol by ester linkages.
  • the acyl groups can be saturated or have varying degrees of unsaturation. Suitable acyl groups include, but are not limited to, lauroyl (C12), myristoyl (C14), palmitoyl (C 16 ), stearoyl (Qg), and icosoyl (C 20 ).
  • R 1 and R 2 are the same, i.e., R 1 and R 2 are both myristoyl (i.e., dimyristoyl), R and R 2 are both stearoyl (i.e., distearoyl), etc.
  • Diacylglycerols have the following general formula:
  • dialkyloxypropyl includes a compound having 2 alkyl chains, R l and R 2 , both of which have independently between 2 and 30 carbons.
  • the alkyl groups can be saturated or have varying degrees of unsaturation.
  • Dialkyloxypropyls have the following general formula:
  • the PEG-lipid is a PEG-DAA conjugate having the following formula:
  • R 1 and R 2 are independently selected and are long-chain alkyl groups having from about 10 to about 22 carbon atoms; PEG is a polyetbyleneglycol; and L is a non-ester containing linker moiety or an ester containing linker moiety as described above.
  • the long- chain alkyl groups can be saturated or unsaturated. Suitable alkyl groups include, but are not limited to, decyl (Ci 0 ), lauryl (C 12 ), myristyl (C 14 ), palmityl (C 16 ), stearyl (Cjs), and icosyl (C 2 o).
  • R 1 and R 2 are the same, i.e., R 1 and R 2 are both myristyl ⁇ i.e., dimyristyl), R 1 and R 2 are both stearyl ⁇ i.e., distearyl), etc.
  • the PEG has an average molecular weight ranging from about 550 daltons to about 10,000 daltons. In certain instances, the PEG has an average molecular weight of from about 750 daltons to about 5,000 daltons ⁇ e.g., from about 1,000 daltons to about 5,000 daltons, from about 1 ,500 daltons to about 3,000 daltons, from about 750 daltons to about 3,000 daltons, from about 750 daltons to about 2,000 daltons, etc.).
  • the PEG moiety has an average molecular weight of from about 550 daltons to about 1000 daltons, from about 250 daltons to about 1000 daltons, from about 400 daltons to about 1000 daltons, from about 600 daltons to about 900 daltons, from about 700 daltons to about 800 daltons, or about 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, or 1000 daltons. In preferred embodiments, the PEG has an average molecular weight of about 2,000 daltons or about 750 daltons.
  • the PEG can be optionally substituted with alkyl, alkoxy, acyl, or aryl groups. In certain embodiments, the terminal hydroxyl group is substituted with a methoxy or methyl group.
  • L is a non-ester containing linker moiety.
  • Suitable non-ester containing linkers include, but are not limited to, an amido linker moiety, an amino linker moiety, a carbonyl linker moiety, a carbamate linker moiety, a urea linker moiety, an ether linker moiety, a disulphide linker moiety, a succinamidyl linker moiety, and
  • the non-ester containing linker moiety is a carbamate linker moiety (i.e., a PEG-C-DAA conjugate). In another preferred embodiment, the non-ester containing linker moiety is an amido linker moiety (i.e., a PEG- ⁇ 4-DAA conjugate). In yet another preferred embodiment, the non-ester containing linker moiety is a succinamidyl linker moiety (i.e., a PEG-S-DAA conjugate).
  • the PEG-lipid conjugate is selected from:
  • the PEG-DAA conjugates are synthesized using standard techniques and reagents known to those of skill in the art. It will be recognized that the PEG-DAA conjugates will contain various amide, amine, ether, thio, carbamate, and urea linkages. Those of skill in the art will recognize that methods and reagents for forming these bonds are well known and readily available. See, e.g., March, ADVANCED ORGANIC CHEMISTRY (Wiley 1992); Larock, COMPREHENSIVE ORGANIC TRANSFORMATIONS (VCH 1989); and Furniss, VOGEL'S TEXTBOOK OF PRACTICAL ORGANIC CHEMISTRY, 5th ed. (Longman 1989).
  • the PEG-DAA conjugate is a PEG-didecyloxypropyl (Ci 0 ) conjugate, a PEG-dilauryloxypropyl (C] 2 ) conjugate, a PEG-dimyristyloxypropyl (CM) conjugate, a PEG- dipalmityloxypropyl (C 16 ) conjugate, or a PEG-distearyloxypropyl (Ci 3 ⁇ 4 ) conjugate.
  • the PEG preferably has an average molecular weight of about 750 or about 2,000 daltons.
  • the PEG-lipid conjugate comprises PEG2000-C-DMA, wherein the "2000” denotes the average molecular weight of the PEG, the “C” denotes a carbamate linker moiety, and the “DMA” denotes dimyristyloxypropyl.
  • the PEG-lipid conjugate comprises PEG750-C- DMA, wherein the "750” denotes the average molecular weight of the PEG, the "C” denotes a carbamate linker moiety, and the "DMA” denotes dimyristyloxypropyl.
  • the terminal hydroxyl group of the PEG is substituted with a methyl group.
  • hydrophilic polymers can be used in place of PEG.
  • suitable polymers include, but are not limited to, polyvinylpyrrolidone, polymethyloxazoline, polyethyloxazoline, polyhydroxypropyl methacrylamide,
  • polymethacrylamide and polydimethylacrylamide polylactic acid, polyglycolic acid, and derivatized celluloses such as hydroxymethylcellulose or hydroxyethylcellulose.
  • the lipid particles (e.g., SNALP) of the present invention can further comprise cationic poly(ethylene glycol) (PEG) lipids or CPLs (see, e.g., Chen et l, Bioconj. Chem., 1 1:433-437 (2000); U.S. Patent No. 6,852,334; PCT Publication No. WO 00/62813, the disclosures of which are herein incorporated by reference in their entirety for all purposes).
  • PEG poly(ethylene glycol)
  • the lipid conjugate (e.g., PEG-lipid) comprises from about 0.1 mol % to about 2 mol %, from about 0.5 mol % to about 2 mol %, from about 1 mol % to about 2 mol %, from about 0.6 mol % to about 1.9 mol %, from about 0.7 mol % to about 1.8 mol %, from about 0.8 mol % to about 1.7 mol %, from about 0.9 mol % to about 1.6 mol %, from about 0.9 mol % to about 1.8 mol %, from about 1 mol % to about 1.8 mol %, from about 1 mol % to about 1.7 mol %, from about 1.2 mol % to about 1.8 mol %, from about 1.2 mol % to about 1.7 mol %, from about 1.3 mol % to about 1.6 mol %, from about 1.4 mol % to about 1.5 mol %, from about 0.7 mol
  • the lipid conjugate (e.g., PEG-lipid) comprises from about 0 mol % to about 20 mol %, from about 0.5 mol % to about 20 mol %, from about 2 mol % to about 20 mol %, from about 1.5 mol % to about 18 mol %, from about 2 mol % to about 15 mol %, from about 4 mol % to about 15 mol %, from about 2 mol % to about 12 mol %, from about 5 mol % to about 12 mol %, or about 2 mol % (or any fraction thereof or range therein) of the total lipid present in the particle.
  • PEG-lipid comprises from about 0 mol % to about 20 mol %, from about 0.5 mol % to about 20 mol %, from about 2 mol % to about 20 mol %, from about 1.5 mol % to about 18 mol %, from about 2 mol % to about 15 mol %, from about 4
  • the lipid conjugate (e.g., PEG-lipid) comprises from about 4 mol % to about 10 mol %, from about 5 mol % to about 10 mol , from about 5 mol % to about 9 mol %, from about 5 mol % to about 8 mol %, from about 6 mol % to about 9 mol %, from about 6 mol % to about 8 mol %, or about 5 mol %, 6 mol %, 7 mol %, 8 mol %, 9 mol %, or 10 mol % (or any fraction thereof or range therein) of the total lipid present in the particle.
  • PEG-lipid comprises from about 4 mol % to about 10 mol %, from about 5 mol % to about 10 mol , from about 5 mol % to about 9 mol %, from about 5 mol % to about 8 mol %, from about 6 mol % to about 9 mol %, from about 6 mol %, or
  • the percentage of lipid conjugate (e.g., PEG-lipid) present in the lipid particles of the invention is a target amount, and that the actual amount of lipid conjugate present in the formulation may vary, for example, by ⁇ 2 mol %.
  • the target amount of lipid conjugate is 1.4 mol %, but the actual amount of lipid conjugate may be ⁇ 0.5 mol %, ⁇ 0.4 mol %, ⁇ 0.3 mol %, ⁇ 0.2 mol %, ⁇ 0.1 mol %, or ⁇ 0.05 mol % of that target amount, with the balance of the formulation being made up of other lipid components (adding up to 100 mol % of total lipids present in the particle).
  • the target amount of lipid conjugate is 6.76 mol %, but the actual amount of lipid conjugate may be ⁇ 2 mol %, ⁇ 1.5 mol %, ⁇ 1 mol %, ⁇ 0.75 mol %, ⁇ 0.5 mol %, ⁇ 0.25 mol %, or ⁇ 0.1 mol % of that target amount, with the balance of the formulation being made up of other lipid components (adding up to 100 mol % of total lipids present in the particle).
  • concentration of the lipid conjugate can be varied depending on the lipid conjugate employed and the rate at which the lipid particle is to become fusogenic.
  • the rate at which the lipid conjugate exchanges out of the lipid particle can be controlled, for example, by varying the concentration of the lipid conjugate, by varying the molecular weight of the PEG, or by varying the chain length and degree of saturation of the alkyl groups on the PEG-DAA conjugate.
  • the rate at which the lipid particle becomes fusogemc can be varied, for example, by varying the concentration of the lipid conjugate, by varying the molecular weight of the PEG, or by varying the chain length and degree of saturation of the alkyl groups on the PEG-DAA conjugate.
  • other variables including, for example, pH, temperature, ionic strength, etc.
  • lipid particle e.g., SNALP
  • vX preparation of Lipid Particles can be used to vary and/or control the rate at which the lipid particle becomes fusogenic. Other methods which can be used to control the rate at which the lipid particle becomes fusogenic will become apparent to those of skill in the art upon reading this disclosure. Also, by controlling the composition and concentration of the lipid conjugate, one can control the lipid particle (e.g., SNALP) size.
  • the lipid particles of the present invention e.g., SNALP, in which an active agent such as a nucleic acid (e.g., an interfering RNA such as an siR A) is entrapped within the lipid portion of the particle and is protected from degradation, can be formed by any method known in the art including, but not limited to, a continuous mixing method, a direct dilution process, and an in-line dilution process.
  • one or more antioxidants such as metal chelators (e.g., EDTA), primary antioxidants, and/or secondary antioxidants may be included at any step or at multiple steps in the process (e.g., prior to, during, and/or after lipid particle formation) as described in PCT Application No. PCT/CA2010/001919, the disclosure of which is herein incorporated by reference in its entirety for all purposes.
  • metal chelators e.g., EDTA
  • primary antioxidants e.g., EDTA
  • secondary antioxidants may be included at any step or at multiple steps in the process (e.g., prior to, during, and/or after lipid particle formation) as described in PCT Application No. PCT/CA2010/001919, the disclosure of which is herein incorporated by reference in its entirety for all purposes.
  • the cationic lipids may comprise at least one, two, three, four, five, or more cationic lipids such as those set forth in Formula I or salts thereof, alone or in combination with other cationic lipid species.
  • the non-cationic lipids may comprise one, two, or more lipids including egg sphingomyelin (ESM), distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), l-palrnitoyl-2- oleoyl-phosphatidylcholine (POPC), dipalmitoyl-phosphatidylcholine (DPPC), monomethyl- phosphatidylemanolamine, dimemyl-phosphatidylemanolamine, 14:0 PE (1,2-dimyristoyl- phosphatidylemanolamine (DMPE)), 16:0 PE (1,2-dipalmitoyl-phosphatidylemanolamine (DPPE)), 18:0 PE (1,2-distearoyl-phosphatidylemanolarnine (DSPE)), 18:1 PE (1,2-dioleoyl- phosphatidylethanol
  • ESM
  • the present invention provides nucleic acid-lipid particles (e.g., SNALP) produced via a continuous mixing method, e.g ., a process that includes providing an aqueous solution comprising a nucleic acid (e.g.
  • interfering RNA in a first reservoir, providing an organic lipid solution in a second reservoir (wherein the lipids present in the organic lipid solution are solubilized in an organic solvent, e.g., a lower alkanol such as ethanol), and mixing the aqueous solution with the organic lipid solution such that the organic lipid solution mixes with the aqueous solution so as to substantially instantaneously produce a lipid vesicle (e.g., liposome) encapsulating the nucleic acid within the lipid vesicle.
  • an organic solvent e.g., a lower alkanol such as ethanol
  • the nucleic acid-lipid particles formed using the continuous mixing method typically have a size of from about 30 nm to about 150 nm, from about 40 nm to about 150 nm, from about 50 nm to about 150 nm, from about 60 nm to about 130 nm, from about 70 nm to about 110 nm, from about 70 nm to about 100 nm, from about 80 nm to about 100 nm, from about 90 nm to about 100 nm, from about 70 to about 90 nm, from about 80 nm to about 90 nm, from about 70 nm to about 80 nm, less than about 120 nm, 110 nm, 100 nm, 90 nm, or 80 nm, or about 30 nm, 35 nm, 40 nm, 45 nm, 50 nm, 55 nm, 60 nm, 65 nm, 70 nm, 75 nm, 80 nm, 85 run, 90 nm,
  • the present invention provides nucleic acid-lipid particles ⁇ e.g., SNALP) produced via a direct dilution process that includes forming a lipid vesicle ⁇ e.g., liposome) solution and immediately and directly introducing the lipid vesicle solution into a collection vessel containing a controlled amount of dilution buffer.
  • the collection vessel includes one or more elements configured to stir the contents of the collection vessel to facilitate dilution.
  • the amount of dilution buffer present in the collection vessel is substantially equal to the volume of lipid vesicle solution introduced thereto.
  • a lipid vesicle solution in 45% ethanol when introduced into the collection vessel containing an equal volume of dilution buffer will advantageously yield smaller particles.
  • the present invention provides nucleic acid-lipid particles (e.g., SNALP) produced via an in-line dilution process in which a third reservoir containing dilution buffer is fluidly coupled to a second mixing region.
  • the lipid vesicle (e.g., liposome) solution formed in a first mixing region is immediately and directly mixed with dilution buffer in the second mixing region.
  • the second mixing region includes a T-corwecior arranged so that the lipid vesicle solution and the dilution buffer flows meet as opposing 180° flows; however, connectors providing shallower angles can be used, e.g., from about 27° to about 180° (e.g., about 90°).
  • a pump mechanism delivers a controllable flow of buffer to the second mixing region.
  • the flow rate of dilution buffer provided to the second mixing region is controlled to be substantially equal to the flow rate of lipid vesicle solution introduced thereto from the first mixing region.
  • This embodiment advantageously allows for more control of the flow of dilution buffer mixing with the lipid vesicle solution in the second mixing region, and therefore also the concentration of lipid vesicle solution in buffer throughout the second mixing process.
  • control of the dilution buffer flow rate advantageously allows for small particle size formation at reduced concentrations.
  • the nucleic acid-lipid particles formed using the direct dilution and in-line dilution processes typically have a size of from about 30 nm to about 150 nm, from about 40 nm to about 150 nm, from about 50 nm to about 150 nm, from about 60 nm to about 130 nm, from about 70 run to about 1 10 nm, from about 70 nm to about 100 nm, from about 80 nm to about 100 nm, from about 90 nm to about 100 nm, from about 70 to about 90 nm, from about 80 nm to about 90 nm, from about 70 nm to about 80 nm, less than about 120 nm, 1 10 nm, 100 nm, 90 nm, or 80 nm, or about 30 nm, 35 nm, 40 nm, 45 nm, 50 nm, 55 nm, 60 nm, 65 nm, 70 nm, 75 nm
  • the lipid particles of the invention can be sized by any of the methods available for sizing liposomes.
  • the sizing may be conducted in order to achieve a desired size range and relatively narrow distribution of particle sizes.
  • Extrusion of the particles through a small-pore polycarbonate membrane or an asyrnmetric ceramic membrane is also an effective method for reducing particle sizes to a relatively well-defined size distribution.
  • the suspension is cycled through the membrane one or more times until the desired particle size distribution is achieved.
  • the particles may be extruded through successively smaller-pore membranes, to achieve a gradual reduction in size.
  • the nucleic acids present in the particles are precondensed as described in, e.g. , U.S. Patent Application No. 09/744,103, the disclosure of which is herein incorporated by reference in its entirety for all purposes.
  • the methods may further comprise adding non-lipid poly cations which are useful to effect the lipofection of cells using the present compositions.
  • suitable non-lipid polycations include, hexadimethrine bromide (sold under the brand name POLYBRENE ® , from Aldrich Chemical Co., Milwaukee, Wisconsin, USA) or other salts of hexadimethrine.
  • suitable polycations include, for example, salts of poly- L-ormthine, poly-L-arginine, poly-L-lysine, poly-D-lysine, polyallylamine, and
  • the nucleic acid to lipid ratios (mass/mass ratios) in a formed nucleic acid-lipid particle will range from about 0.01 to about 0.2, from about 0.05 to about 0.2, from about 0.02 to about 0.1 , from about 0.03 to about 0.1, or from about 0.01 to about 0.08.
  • the ratio of the starting materials (input) also falls within this range.
  • the particle preparation uses about 400 ⁇ g nucleic acid per 10 mg total lipid or a nucleic acid to lipid mass ratio of about 0.01 to about 0.08 and, more preferably, about 0.04, which corresponds to 1.25 mg of total lipid per 50 ⁇ g of nucleic acid.
  • the particle has a nucleic acid:lipid mass ratio of about 0.08.
  • the lipid to nucleic acid ratios (mass/mass ratios) in a formed nucleic acid-lipid particle will range from about 1 (1 :1) to about 100 (100:1), from about 5 (5: 1) to about 100 (100: 1), from about 1 (1 :1) to about 50 (50: 1), from about 2 (2: 1) to about 50 (50: 1), from about 3 (3: 1) to about 50 (50: 1), from about 4 (4:1) to about 50 (50:1), from about 5 (5: 1) to about 50 (50: 1), from about 1 (1 : 1) to about 25 (25: 1), from about 2 (2: 1) to about 25 (25: 1), from about 3 (3:1) to about 25 (25: 1), from about 4 (4: 1) to about 25 (25: 1), from about 5 (5:1) to about 25 (25: 1), from about 5 (5: 1) to about 20 (20: 1), from about 5 (5: 1) to about 15 (15: 1), from about 5 (5: 1) to
  • the conjugated lipid may further include a CPL.
  • CPL-containing SNALP A variety of general methods for making SNALP-CPLs (CPL-containing SNALP) are discussed herein. Two general techniques include the "post-insertion” technique, that is, insertion of a CPL into, for example, a pre-formed SNALP, and the "standard” technique, wherein the CPL is included in the lipid mixture during, for example, the SNALP formation steps.
  • the post- insertion technique results in SNALP having CPLs mainly in the external face of the SNALP bilayer membrane, whereas standard techniques provide SNALP having CPLs on both internal and external faces.
  • the method is especially useful for vesicles made from phospholipids (which can contain cholesterol) and also for vesicles containing PEG-lipids (such as PEG-DAAs and PEG-DAGs).
  • PEG-lipids such as PEG-DAAs and PEG-DAGs.
  • the present invention also provides lipid particles (e.g., SNALP) in kit form.
  • the kit comprises a container which is compartmentalized for holding the various elements of the lipid particles (e.g., the active agents or therapeutic agents such as nucleic acids and the individual lipid components of the particles).
  • the kit comprises a container (e.g., a vial or ampoule) which holds the lipid particles of the invention (e.g., SNALP), wherein the particles are produced by one of the processes set forth herein.
  • the kit may further comprise one or more antioxidants such as metal chelators (e.g., EDTA), primary antioxidants, and/or secondary antioxidants.
  • the kit may further comprise an endosomal membrane destabilizer (e.g., calcium ions).
  • an endosomal membrane destabilizer e.g., calcium ions.
  • the kit typically contains the particle compositions of the present invention, either as a suspension in a pharmaceutically acceptable carrier or in dehydrated form, with instructions for their rehydration (if lyophilized) and administration.
  • the lipid particles of the present invention can be tailored to preferentially target particular tissues, organs, or tumors of interest.
  • preferential targeting of lipid particles such as SNALP may be carried out by controlling the composition of the particle itself.
  • the 1 :57 lipid particle (e.g., SNALP) formulation can be used to preferentially target the liver (e.g., normal liver tissue).
  • the 7:54 lipid particle (e.g., SNALP) formulation can be used to preferentially target solid tumors such as liver tumors and tumors outside of the liver.
  • the kits of the invention comprise these liver-directed and/or tumor-directed lipid particles, wherein the particles are present in a container as a suspension or in dehydrated form.
  • a targeting moiety attached to the surface of the lipid particle to further enhance the targeting of the particle.
  • Methods of attaching targeting moieties e.g., antibodies, proteins, etc.
  • lipids such as those used in the present particles
  • the lipid particles of the invention are useful for the introduction of active agents or therapeutic agents (e.g., nucleic acids such as interfering RNA) into cells.
  • the present invention also provides methods for introducing an active agent or therapeutic agent such as a nucleic acid (e.g., interfering RNA) into a cell.
  • the cell is a liver cell such as, e.g., a hepatocyte present in liver tissue.
  • the cell is a tumor cell such as, e.g., a tumor cell present in a solid tumor.
  • the methods are carried out in vitro or in vivo by first forming the particles as described above and then contacting the particles with the cells for a period of time sufficient for delivery of the active agent or therapeutic agent to the cells to occur.
  • the lipid particles of the invention can be adsorbed to almost any cell type with which they are mixed or contacted. Once adsorbed, the particles can either be endocytosed by a portion of the cells, exchange lipids with cell membranes, or fuse with the cells. Transfer or incorporation of the active agent or therapeutic agent (e.g., nucleic acid) portion of the particle can take place via any one of these pathways. In particular, when fusion takes place, the particle membrane is integrated into the cell membrane and the contents of the particle combine with the intracellular fluid.
  • the active agent or therapeutic agent e.g., nucleic acid
  • the lipid particles of the invention can be administered either alone or in a mixture with a pharmaceutically acceptable carrier (e.g., physiological saline or phosphate buffer) selected in accordance with the route of administration and standard pharmaceutical practice.
  • a pharmaceutically acceptable carrier e.g., physiological saline or phosphate buffer
  • physiological saline or phosphate buffer e.g., physiological saline or phosphate buffer
  • suitable carriers include, e.g., water, buffered water, 0.4% saline, 0.3% glycine, and the like, including glycoproteins for enhanced stability, such as albumin, lipoprotein, globulin, etc. Additional suitable carriers are described in, e.g.
  • carrier includes any and all solvents, dispersion media, vehicles, coatings, diluents, antibacterial and antifungal agents, isotonic and absorption delaying agents, buffers, carrier solutions, suspensions, colloids, and the like.
  • pharmaceutically acceptable refers to molecular entities and compositions that do not produce an allergic or similar untoward reaction when administered to a human.
  • the pharmaceutically acceptable carrier is generally added following lipid particle formation.
  • the lipid particle e.g., SNALP
  • the particle can be diluted into pharmaceutically acceptable carriers such as normal buffered saline.
  • the concentration of particles in the pharmaceutical formulations can vary widely, i.e., from less than about 0.05%, usually at or at least about 2 to 5%, to as much as about 10 to 90% by weight, and will be selected primarily by fluid volumes, viscosities, etc. , in accordance with the particular mode of administration selected.
  • the concentration may be increased to lower the fluid load associated with treatment. This may be particularly desirable in patients having atherosclerosis-associated congestive heart failure or severe hypertension.
  • particles composed of irritating lipids may be diluted to low concentrations to lessen inflammation at the site of administration.
  • compositions of the present invention may be sterilized by conventional, well-known sterilization techniques.
  • Aqueous solutions can be packaged for use or filtered under aseptic conditions and lyophilized, the lyophilized preparation being combined with a sterile aqueous solution prior to administration.
  • the compositions can contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, and calcium chloride.
  • the particle suspension may include lipid- protective agents which protect lipids against free-radical and lipid-peroxidative damages on storage. Lipophilic free-radical quenchers, such as alphatocopherol, and water-soluble iron- specific chelators, such as ferrioxamine, are suitable.
  • the lipid particles of the invention are particularly useful in methods for the therapeutic delivery of one or more nucleic acids comprising an interfering RNA sequence (e.g., siR A).
  • an interfering RNA sequence e.g., siR A
  • the methods of the invention ar useful for in viw delivery of interfering RNA (e.g., siRNA) to the liver and/or tumor of a mammalian subject.
  • interfering RNA e.g., siRNA
  • the disease or disorder is associated with expression and/or overexpression of a gene and expression or overexpression of the gene is reduced by the interfering RNA (e.g., siRNA).
  • a therapeutically effective amount of the lipid particle may be administered to the mammal.
  • an interfering RNA e.g., siRNA
  • cells are removed from a patient, the interfering RNA is delivered in vitro (e.g., using a SNALP described herein), and the cells are reinjected into the patient.
  • nucleic acid-lipid particles such as those described in PCT Publication Nos. WO 05/007196, WO 05/121348, WO 05/120152, and WO 04/002453, the disclosures of which are herein incorporated by reference in their entirety for all purposes.
  • the present invention also provides fully encapsulated lipid particles that protect the nucleic acid from nuclease degradation in serum, are non-immunogenic, are small in size, and are suitable for repeat dosing.
  • administration can be in any manner known in the art, e.g., by injection, oral administration, inhalation (e.g. , intransal or intratracheal), transdermal application, or rectal administration. Administration can be accomplished via single or divided doses.
  • the pharmaceutical compositions can be administered parenterally, i.e., intraarticularly, intravenously, intraperitoneally, subcutaneously, or intramuscularly. In some embodiments, the pharmaceutical compositions are administered intravenously or intraperitoneally by a bolus injection (see, e.g. , U.S. Patent No. 5,286,634).
  • Intracellular nucleic acid delivery has also been discussed in Straubringer et al, Methods Enzymol, 101 :512 (1983); Mannino et al, Biotechniques, 6:682 (1988); Nicolau et al, Crit. Rev. Ther. Drug Carrier Syst., 6:239 (1989); and Behr, Acc. Chem. Res., 26:274 (1993). Still other methods of administering lipid-based therapeutics are described in, for example, U.S. Patent Nos. 3,993,754; 4,145,410; 4,235,871; 4,224,179; 4,522,803; and 4,588,578.
  • the lipid particles can be administered by direct injection at the site of disease or by injection at a site distal from the site of disease (see, e.g., Culver, HUMAN GENE THERAPY, Mary Ann Liebert, Inc., Publishers, New York. pp.70-71(1 94)).
  • the disclosures of the above- described references are herein incorporated by reference in their entirety for all purposes.
  • the lipid particles of the present invention ⁇ e.g., SNALP
  • at least about 5%, 10%, 15%, 20%, or 25% of the total injected dose of the particles is present in plasma about 8, 12, 24, 36, or 48 hours after injection.
  • more than about 20%, 30%, 40% and as much as about 60%, 70% or 80%) of the total injected dose of the lipid particles is present in plasma about 8, 12, 24, 36, or 48 hours after injection. In certain instances, more than about 10% of a plurality of the particles is present in the plasma of a mammal about 1 hour after administration. In certain other instances, the presence of the lipid particles is detectable at least about 1 hour after administration of the particle. In certain embodiments, the presence of a therapeutic agent such as a nucleic acid is detectable in cells of the lung, liver, tumor, or at a site of a therapeutic agent such as a nucleic acid is detectable in cells of the lung, liver, tumor, or at a site of
  • downregulation of expression of a target sequence by an interfering RNA is detectable at about 8, 12, 24, 36, 48, 60, 72 or 96 hours after administration.
  • downregulation of expression of a target sequence by an interfering RNA occurs preferentially in liver cells (e.g., hepatocytes), tumor cells, or in cells at a site of inflarnmation.
  • the presence or effect of an interfering RNA in cells at a site proximal or distal to the site of administration or in cells of the lung, liver, or a tumor is detectable at about 12, 24, 48, 72, or 96 hours, or at about 6, 8, 10, 12, 14, 16, 18, 19, 20, 22, 24, 26, or 28 days after administration.
  • the lipid particles e.g., SNALP
  • the invention are administered parenterally or
  • compositions of the present invention can be made into aerosol formulations (i.e., they can be "nebulized") to be administered via inhalation (e.g., intranasally or intratracheally) (see, Brigham et al. , Am. J. Sci., 298:278 (1989)). Aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like.
  • the pharmaceutical compositions may be delivered by intranasal sprays, inhalation, and/or other aerosol delivery vehicles.
  • Methods for delivering nucleic acid compositions directly to the lungs via nasal aerosol sprays have been described, e.g., in U.S. Patent Nos. 5,756,353 and 5,804,212.
  • the delivery of drugs using intranasal microparticle resins and lysophosphatidyl-glycerol compounds (U.S. Patent 5,725,871) are also well-known in the pharmaceutical arts.
  • transmucosal drug delivery in the form of a polytetrafluoroetheylene support matrix is described in U.S. Patent No. 5,780,045.
  • Formulations suitable for pareuierai administration such as, for example, by intraarticular (in the joints), intravenous, intramuscular, intradermal, intraperitoneal, and subcutaneous routes, include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives.
  • compositions are preferably aaministered, for example, by intravenous infusion, orally, topically, intraperitoneally, intravesically, or intrathecally.
  • the lipid particle formulations are formulated with a suitable pharmaceutical carrier.
  • a suitable pharmaceutical carrier may be employed in the compositions and methods of the present invention. Suitable formulations for use in the present invention are found, for example, in REMINGTON'S PHARMACEUTICAL SCIENCES, Mack Publishing Company, Philadelphia, PA, 17th ed. (1985).
  • a variety of aqueous carriers may be used, for example, water, buffered water, 0.4% saline, 0.3% glycine, and the like, and may include glycoproteins for enhanced stability, such as albumin, lipoprotein, globulin, etc.
  • compositions can be sterilized by conventional liposomal sterilization techniques, such as filtration.
  • the compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents, wetting agents and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate, etc.
  • These compositions can be sterilized using the techniques referred to above or, alternatively, they can be produced under sterile conditions.
  • the resulting aqueous solutions may be packaged for use or filtered under aseptic conditions and lyophilized, the lyophilized preparation being combined with a sterile aqueous solution prior to administration.
  • the lipid particles disclosed herein may be delivered via oral administration to the individual.
  • the particles may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, pills, lozenges, elixirs, mouthwash, suspensions, oral sprays, syrups, wafers, and the like ⁇ see, e.g., U.S. Patent Nos. 5,641,515, 5,580,579, and 5,792,451, the disclosures of which are herein incorporated by reference in their entirety for all purposes).
  • These oral dosage forms may also contain the following: binders, gelatin; excipients, lubricants, and/or flavoring agents. When the unit dosag p .
  • any material used in preparing any unit dosage form should be pharmaceutically pure and substantially non-toxic in the amounts employed.
  • these oral formulations may contain at least about 0.1% of the lipid particles or more, although the percentage of the particles may, of course, be varied and may conveniently be between about 1% or 2% and about 60% or 70% or more of the weight or volume of the total formulation.
  • the amount of particles in each therapeutically useful composition may be prepared is such a way that a suitable dosage will be obtained in any given unit dose of the compound. Factors such as solubility, bioavailability, biological half-life, route of administration, product shelf life, as well as other pharmacological considerations will be contemplated by one skilled in the art of preparing such
  • Formulations suitable for oral administration can consist of: (a) liquid solutions, such as an effective amount of a packaged therapeutic agent such as nucleic acid (e.g., interfering RNA) suspended in diluents such as water, saline, or PEG 400; (b) capsules, sachets, or tablets, each containing a predetermined amount of a therapeutic agent such as nucleic acid (e.g., interfering RNA), as liquids, solids, granules, or gelatin; (c) suspensions in an appropriate liquid; and (d) suitable emulsions.
  • a packaged therapeutic agent such as nucleic acid (e.g., interfering RNA) suspended in diluents such as water, saline, or PEG 400
  • capsules, sachets, or tablets each containing a predetermined amount of a therapeutic agent such as nucleic acid (e.g., interfering RNA), as liquids, solids, granules,
  • Tablet forms can include one or more of lactose, sucrose, mannitol, sorbitol, calcium phosphates, corn starch, potato starch, microcrystalline cellulose, gelatin, colloidal silicon dioxide, talc, magnesium stearate, stearic acid, and other excipients, colorants, fillers, binders, diluents, buffering agents, moistening agents, preservatives, flavoring agents, dyes, disintegrating agents, and pharmaceutically compatible carriers.
  • Lozenge forms can comprise a therapeutic agent such as nucleic acid (e.g., interfering RNA) in a flavor, e.g., sucrose, as well as pastilles comprising the therapeutic agent in an inert base, such as gelatin and glycerin or sucrose and acacia emulsions, gels, and the like containing, in addition to the therapeutic agent, carriers known in the art.
  • a therapeutic agent such as nucleic acid (e.g., interfering RNA) in a flavor, e.g., sucrose, as well as pastilles comprising the therapeutic agent in an inert base, such as gelatin and glycerin or sucrose and acacia emulsions, gels, and the like containing, in addition to the therapeutic agent, carriers known in the art.
  • lipid particles can be incorporated into a broad range of topical dosage forms.
  • a suspension containing nucleic acid-lipid particles such as SNALP can be formulated and administered as gels, oils, emulsions, topical creams, pastes, ointments, lotions, foams, mousses, and the like.
  • the methods of the present invention may be practiced in a variety of hosts.
  • Preferred hosts include mammalian species, such as primates (e.g., humans and chimpanzees as well as other nonhuman primates), canines, felines, equines, bovines, ovines, caprines, rodents (e.g., rats and mice), lagomorphs, and swine.
  • the amount of particles administered will depend upon the ratio of therapeutic agent (e.g., nucleic acid) to lipid, the particular therapeutic agent (e.g., nucleic acid) used, the disease or disorder being treated, the age, weight, and condition of the patient, and the judgment of the clinician, but will generally be between about 0.01 and about 50 mg per kilogram of body weight, preferably between about 0.1 and about 5 mg/kg of body weight, or about 10 8 -10 10 particles per administration (e.g., injection).
  • therapeutic agent e.g., nucleic acid
  • lipid lipid
  • therapeutic agent e.g., nucleic acid
  • the delivery of therapeutic agents such as nucleic acids can be to any cell grown in culture, whether of plant or animal origin, vertebrate or invertebrate, and of any tissue or type.
  • the cells are animal cells, more preferably mammalian cells, and most preferably human cells (e.g., tumor cells or hepatocytes).
  • a lipid particle suspension is added to 60- 80% confluent plated cells having a cell density of from about 10 3 to about 10 5 cells/ml, more preferably about 2 x 10 4 cells/ml.
  • the concentration of the suspension added to the cells is preferably of from about 0.01 to 0.2 ⁇ g/ml, more preferably about 0.1 ⁇ g/ml.
  • tissue culture of cells may be required, it is well-known in the art. For example, Freshney, Culture of Animal Cells, a Manual of Basic Technique, 3rd Ed., Wiley-Liss, New York (1994), Kuchler et al, Biochemical Methods in Cell Culture and Virology, Dowden, Hutchinson and Ross, Inc. (1 77), and the references cited therein provide a general guide to the culture of cells. Cultured cell systems often will be in the form of monolayers of cells, although cell suspensions are also used. [0256] Using an Endosomal Release Parameter (ERP) assay, the delivery efficiency of the SNALP or other lipid particle of the invention can be optimized.
  • ERP Endosomal Release Parameter
  • an ERP assay is described in detail in U.S. Patent Publication No. 20030077829, the disclosure of which is herein incorporated by reference in its entirety for all purposes. More particularly, the purpose of an ERP assay is to distinguish the effect of various cationic lipids and helper lipid components of SNALP or other lipid particle based on their relative effect on binding/uptake or fusion with/destabilization of the endosomal membrane. This assay allows one to determine quantitatively how each component of the SNALP or other lipid particle affects delivery efficiency, thereby optimizing the SNALP or other lipid particle. Usually, an ERP assay measures expression of a reporter protein (e.g.
  • an ERP assay can be adapted to measure downregulation of transcription or translation of a target sequence in the presence or absence of an interfering RNA (e.g., siRNA). By comparing the ERPs for each of the various SNALP or other lipid particles, one can readily determine the optimized system, e.g. , the SNALP or other lipid particle that has the greatest uptake in the cell.
  • compositions and methods of the present invention are used to treat a wide variety of cell types, in vivo and in vitro.
  • Suitable cells include, but are not limited to, hepatocytes, reticuloendothelial cells (e.g., monocytes, macrophages, etc.), fibroblast cells, endothelial cells, platelet cells, other cell types infected and/or susceptible of being infected with viruses, hematopoietic precursor (stem) cells, keratinocytes, skeletal and smooth muscle cells, osteoblasts, neurons, quiescent lymphocytes, tenninally differentiated cells, slow or noncycling primary cells, parenchymal cells, lymphoid cells, epithelial cells, bone cells, and the like.
  • hematopoietic precursor (stem) cells keratinocytes, skeletal and smooth muscle cells, osteoblasts, neurons, quiescent lymphocytes, tenninally differentiated cells, slow or noncycling primary cells, parenchymal
  • an active agent or therapeutic agent such as a nucleic acid (e.g., an interfering RNA) is delivered to cancer cells (e.g., cells of a solid tumor) including, but not limited to, liver cancer cells, lung cancer cells, colon cancer cells, rectal cancer cells, anal cancer cells, bile duct cancer cells, small intestine cancer cells, stomach (gastric) cancer cells, esophageal cancer cells, gallbladder cancer cells, pancreatic cancer cells, appendix cancer cells, breast cancer cells, ovarian cancer cells, cervical cancer cells, prostate cancer cells, renal cancer cells, cancer cells of the central nervous system, glioblastoma tiic or ceils, skin cancer cells, lymphoma cells, choriocarcinoma tumor cells, head and neck cancer cells, osteogenic sarcoma tumor cells, and blood cancer cells.
  • cancer cells e.g., cells of a solid tumor
  • cancer cells e.g., cells of a solid tumor
  • cancer cells e.g.,
  • lipid particles such as SNALP encapsulating a nucleic acid (e.g., an interfering RNA) is suited for targeting cells of any cell type.
  • the methods and compositions can be employed with cells of a wide variety of vertebrates, including mammals, such as, e.g, canines, felines, equines, bovines, ovines, caprines, rodents (e.g., mice, rats, and guinea pigs), lagomorphs, swine, and primates (e.g. monkeys, chimpanzees, and humans).
  • the lipid particles of the present invention are detectable in the subject at about 1, 2, 3, 4, 5, 6, 7, 8 or more hours. In other embodiments, the lipid particles of the present invention (e.g., SNALP) are detectable in the subject at about 8, 12, 24, 48, 60, 72, or 96 hours, or about 6, 8, 10, 12, 14, 16, 18, 19, 22, 24, 25, or 28 days after administration of the particles.
  • the presence of the particles can be detected in the cells, tissues, or other biological samples from the subject.
  • the particles may be detected, e.g. , by direct detection of the particles, detection of a therapeutic nucleic acid such as an interfering R A (e. g. , siRNA) sequence, detection of the target sequence of interest (/. e. , by detecting expression or reduced expression of the sequence of interest), or a combination thereof.
  • a therapeutic nucleic acid such as an interfering R A (e. g. , siRNA) sequence
  • detection of the target sequence of interest /. e. , by detecting
  • Lipid particles of the invention such as SNALP can be detected using any method known in the art.
  • a label can be coupled directly or indirectly to a component of the lipid particle using methods well-known in the art.
  • a wide variety of labels can be used, with the choice of label depending on sensitivity required, ease of conjugation with the lipid particle component, stability requirements, and available instrumentation and disposal provisions.
  • Suitable labels include, but are not limited to, spectral labels such as fluorescent dyes (e.g., fluorescein and derivatives, such as fluorescein isothiocyanate (FITC) and Oregon GreenTM; rhodamine and derivatives such Texas red, tetrarhodimine isothiocynate (TRITC), etc., digoxigenin, biotin, phycoerythrin, AMCA, CyDyesTM, and the like; radiolabels such as 3 H, 125 1, 35 S, 14 C, 32 P, 33 P, etc.; enzymes such as horse radish peroxidase, alkaline
  • fluorescent dyes e.g., fluorescein and derivatives, such as fluorescein isothiocyanate (FITC) and Oregon GreenTM
  • rhodamine and derivatives such Texas red, tetrarhodimine isothiocynate (TRITC), etc.
  • digoxigenin biotin,
  • ucieic Acids such as colloidal gold or colored glass or plastic beads such as polystyrene, polypropylene, latex, etc.
  • the label can be detected using any means known in the art.
  • Nucleic acids are detected and quantified herein by any of a number of means well-known to those of skill in the art.
  • the detection of nucleic acids may proceed by well-known methods such as Southern analysis, Northern analysis, gel electrophoresis, PCR, radiolabeling, scintillation counting, and affinity chromatography. Additional analytic biochemical methods such as spectrophotometry, radiography, electrophoresis, capillary electrophoresis, high performance liquid chromatography (HPLC), thin layer chromatography (TLC), and hyperdiffusion chromatography may also be employed.
  • HPLC high performance liquid chromatography
  • TLC thin layer chromatography
  • nucleic acid hybridization format The selection of a nucleic acid hybridization format is not critical.
  • a variety of nucleic acid hybridization formats are known to those skilled in the art.
  • common formats include sandwich assays and competition or displacement assays.
  • Hybridization techniques are generally described in, e.g., "Nucleic Acid Hybridization, A Practical Approach,” Eds. Hames and Higgins, IRL Press (1985).
  • the sensitivity of the hybridization assays may be enhanced through the use of a nucleic acid amplification system which multiplies the target nucleic acid being detected.
  • a nucleic acid amplification system which multiplies the target nucleic acid being detected.
  • In vitro amplification techniques suitable for amplifying sequences for use as molecular probes or for generating nucleic acid fragments for subsequent subcloning are known. Examples of techniques sufficient to direct persons of skill through such in vitro amplification methods, including the polymerase chain reaction (PCR), the ligase chain reaction (LCR), QP-replicase amplification, and other RNA polymerase mediated techniques (e.g., NASBATM) are found in Sambrook et al. , In Molecular Cloning: A Laboratory Manual, Cold Spring Harbor
  • nucleic acid sequence based amplification NASBATM, Cangene, Mississauga, Ontario
  • Qp-replicase systems can be used to directly identify mutants where the PCR or LCR primers are designed to be. extended or ligaied only when a select sequence is present.
  • the select sequences can be generally amplified using, for example, nonspecific PCR primers and the amplified target region later probed for a specific sequence indicative of a mutation.
  • Nucleic acids for use as probes are typically synthesized chemically according to the solid phase phosphoramidite triester method described by Beaucage et al. , Tetrahedron Letts., 22:1859 1862 (1981), e.g., using an automated synthesizer, as described in Needham VanDevanter et al., Nucleic Acids Res., 12:6159 (1984).
  • Purification of polynucleotides, where necessary, is typically performed by either native acrylamide gel electrophoresis or by anion exchange HPLC as described in Pearson et al., J.
  • In situ hybridization assays are well-known and are generally described in Angerer et al, Methods Enzymol., 152:649 (1987).
  • an in situ hybridization assay cells are fixed to a solid support, typically a glass slide. If DNA is to be probed, the cells are denatured with heat or alkali. The cells are then contacted with a hybridization solution at a moderate temperature to permit annealing of specific probes that are labeled.
  • the probes are preferably labeled with radioisotopes or fluorescent reporters.
  • LenMC3 (Compound 4) and CP-LenMC3 (Compound 5) having the structures shown below were synthesized as described in Scheme 2 below.
  • LenMC3 is also known as linolenyl-MC3 and DLen-MC3.
  • CP-LenMC3 is also known as CP-linolenyl-MC3 and CP- DLen-MC
  • y-LenMC3 (Compound 8) and CP-y-LenMC3 (Compound 9) having the structures shown below were synthesized as described in Scheme 3 below.
  • y-LenMC3 is also known as ylinolenyl-MC3, yDLen-MC3, and D-y-Len-MC3.
  • CP-y-LenMC3 is also known as CP- ylinolenyl-MC3 , CP-yDLen-MC3 , and CP-D-y-Len-MC3.
  • y-LenMC3 (Compound 8) (1.28 g, 2.0 mmol), a stirbar and anhydrous DCM (40 mL).
  • the flask was flushed with N 2 and cooled to 0°C, then a 1M solution of diethylzinc in hexanes added (30 mL, 30 mmol, ⁇ 5 equivalents per olefin).
  • the solution was stirred for 1 hour ai 0°C, then diiodomethane (2.4 mL 50 mmol) added and the reaction stirred overnight at RT.
  • the reaction mixture was concentrated and then redissolved in EtOAc (50 mL).
  • MC3MC (Compound 10) having the structure shown below was synthesized as described in Schemes 4 and 5 below.
  • the aqueous layer was back-extracted with diethyl ether (200 mL).
  • the combined diethyl ether extracts were dried on MgSC>4, filtered, and concentrated.
  • the resulting oil was purified by column chromatography (column 10"L x 2"W; eluted with 100% hexanes) to afford the product as a pale yellow oil (16.3 g, 90%).
  • the resulting pale yellow oil was purified by column chromatography (column 12"L x 2"W; eluted with a gradient of 100% hexanes ⁇ 2% ⁇ 4% ethyl ether in hexanes) to afford the product as a pale yellow oil (6.4 g, 49%).
  • Ethyl 6-(dimethylamino')hexanoate was allowed to react in a 5.6M solution of dirnethylamine in ethanol (lOOmL) for 17 hours. The solution was then concentrated in vacuo to dryness. The resulting bright orange paste was purified by column chromatography (column 5"L x 2"W; eluted with a gradient of 100% dichloromethane ⁇ l%/0.25% ⁇ 2%/0.5% MeOH/NHtOH in dichloromethane) to afford the product as a yellow oil.
  • the reaction mixture was filtered through celite with ether rinses (400 mL).
  • the filtrate (-400-500 mL) was stirred vigorously with saturated ammonium chloride (300 mL) for 16 hours.
  • the ether/toluene layer was separated and washed with brine (1 x 100 mL).
  • the organic layer was dried on magnesium sulfate, filtered and concentrated in vacuo to dryness.
  • the yellow oil was purified by column chromatography (gradient: 100% Hexanes to 5% EtOAc in hexanes) to afford the title compound as a pale yellow oil (4.8 g, 56%).
  • dioleyl mesylate was obtained as a pale yellow oil (51.7 g, 97%).
  • Example 30 Lipid Encapsulation of siRNA.
  • siRNA molecules used in these studies were chemically synthesized and annealed using standard procedures.
  • siRNA molecules were encapsulated into serum-stable nucleic acid-lipid particles (SNALP) composed of the following lipids: (1) the lipid conjugate PEG2000-C-DiviA (3-N-[(-methoxypoly(ethylene glycol)2000)carbamoyl]-l,2- diniyristyloxypropylaxnine); (2) one or more cationic lipids or salts thereof (e.g., cationic lipids of Formula I of the invention and/or other cationic lipids described herein); (3) the phospholipid DPPC (l,2-dipalmitoyl-sn-glycero-3-phosphocholine) (Avanti Polar Lipids; Alabaster, AL); and (4) synthetic cholesterol (Sigma- Aldrich Corp.; St.
  • SNALP serum-stable nucleic acid-lipid particles
  • siRNA molecules were encapsulated into SNALP of the following "1 :57" formulation: 1.4% PEG2000-C-DMA; 57.1% cationic lipid; 7.1% DPPC; and 34.3% cholesterol.
  • 1 :57 formulation is a target formulation, and that the amount of lipid (both cationic and non- cationic) present and the amount of lipid conjugate present in the formulation may vary.
  • the amount of cationic lipid will be 57.1 mol % ⁇ 5 mol %, and the amount of lipid conjugate will be 1.4 mol % ⁇ 0.5 mol %, with the balance of the 1 :57 formulation being made up of non-cationic lipid (e.g., phospholipid, cholesterol, or a mixture of the two).
  • non-cationic lipid e.g., phospholipid, cholesterol, or a mixture of the two.
  • siRNA were encapsulated into SNALP composed of the following lipids: (1) the lipid conjugate PEG750-C-DMA (3 -N-[(-Methoxypoly (ethylene glycol)750)carbamoyl]-l ,2-dimyristyloxypropylamine); (2) one or more cationic lipids or salts thereof (e.g., cationic lipids of Formula I of the invention and/or other cationic lipids described herein); (3) the phospholipid DPPC; and (4) synthetic cholesterol in the molar ratio 6.76:54.06:6.75:32.43, respectively.
  • PEG750-C-DMA 3 -N-[(-Methoxypoly (ethylene glycol)750)carbamoyl]-l ,2-dimyristyloxypropylamine
  • one or more cationic lipids or salts thereof e.g., cationic lipids of Formula I of the invention and/or other cationic
  • siRNA were encapsulated into SNALP of the following "7:54" formulation: 6.76 mol % PEG750-C-DMA; 54.06 mol % cationic lipid; 6.75 mol % DPPC; and 32.43 mol % cholesterol.
  • the amount of cationic lipid will be 54.06 mol % ⁇ 5 mol %, and the amount of lipid conjugate will be 6.76.mol % ⁇ 1 mol %, with the balance of the 7:54 formulation being made up of non-cationic lipid (e.g. , phospholipid, cholesterol, or a mixture of the two).
  • empty particles with identical lipid composition may be formed in the absence of siRNA.
  • This example demonstrates the efficacy of 1 :57 SNALP formulations containing various novel cationic lipids of Formula I described herein with an siRNA targeting ApoB in a mouse liver model.
  • the ApoB siRNA sequence used in this study is provided in Table 1.
  • the number after "ApoB” refers to the nucleotide position of the 5' base of the sense strand relative to the human ApoB mRNA sequence NM_000384.
  • Column 2 2'OMe nucleotides are indicated in bold and underlined.
  • the 3 '-overhangs on one or both strands of the siRNA molecule may alternatively comprise 1-4 deoxythymidine (dT) nucleotides, 1-4 modified and/or unmodified uridine (U) ribonucleotides, or 1-2 additional ribonucleotides having complementarity to the target sequence or the complementary strand thereof.
  • dT deoxythymidine
  • U unmodified uridine
  • 1-2 additional ribonucleotides having complementarity to the target sequence or the complementary strand thereof.
  • Table 2 shows a comparison of the liver ApoB mRNA knockdown activity of each of these SNALP formulations.
  • Table 2 illustrates that a SNALP formulation containing Compound 1, 4, 8, 13, 15, 27, 28, or 35 displayed unexpectedly improved ApoB silencing activity compared to a SNALP formulation containing the C2K benchmark cationic lipid when administered at the same dose.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des compositions et des procédés utiles pour l'apport d'agents thérapeutiques à des cellules. Ces compositions comprennent en particulier de nouveaux lipides cationiques et des particules d'acide nucléique-lipides qui permettent une encapsulation efficace d'acides nucléiques et l'apport efficace de l'acide nucléique encapsulé à des cellules in vivo. Les compositions de l'invention, qui sont très puissantes, permettent d'inactiver efficacement une protéine voulue spécifique à l'aide de doses relativement faibles. De plus, les compositions et procédés de l'invention sont moins toxiques et permettent d'obtenir un indice thérapeutique supérieur par rapport à des compositions et à des procédés connus à ce jour.
EP11731455.9A 2010-05-12 2011-05-12 Nouveaux lipides cationiques et procédés d'utilisation de ceux-ci Active EP2569276B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33410410P 2010-05-12 2010-05-12
US38405010P 2010-09-17 2010-09-17
PCT/GB2011/000723 WO2011141705A1 (fr) 2010-05-12 2011-05-12 Nouveaux lipides cationiques et procédés d'utilisation de ceux-ci

Publications (2)

Publication Number Publication Date
EP2569276A1 true EP2569276A1 (fr) 2013-03-20
EP2569276B1 EP2569276B1 (fr) 2021-02-24

Family

ID=44483991

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11731455.9A Active EP2569276B1 (fr) 2010-05-12 2011-05-12 Nouveaux lipides cationiques et procédés d'utilisation de ceux-ci

Country Status (5)

Country Link
US (3) US20130123338A1 (fr)
EP (1) EP2569276B1 (fr)
JP (5) JP2013527856A (fr)
CA (1) CA2799091A1 (fr)
WO (1) WO2011141705A1 (fr)

Families Citing this family (206)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2743265B1 (fr) 2008-10-09 2017-03-15 Arbutus Biopharma Corporation Lipides aminés améliorés et procédés d'administration d'acides nucléiques
EP3284482B1 (fr) 2008-11-10 2020-06-03 Arbutus Biopharma Corporation Nouveaux lipides et compositions d'administration d'agents thérapeutiques
HUE038039T2 (hu) 2009-12-01 2018-09-28 Translate Bio Inc mRNS bejuttatása fehérjék és enzimek kiegészítésére humán genetikai betegségekben
US20130323269A1 (en) * 2010-07-30 2013-12-05 Muthiah Manoharan Methods and compositions for delivery of active agents
WO2012019168A2 (fr) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Acides nucléiques modifiés et leurs procédés d'utilisation
DE19177059T1 (de) 2010-10-01 2021-10-07 Modernatx, Inc. N1-methyl-pseudouracile enthältendes ribonucleinsäuren sowie ihre verwendungen
WO2012075040A2 (fr) 2010-11-30 2012-06-07 Shire Human Genetic Therapies, Inc. Arnm pour l'utilisation dans le traitement de maladies génétiques humaines
CA2831613A1 (fr) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Administration et formulation d'acides nucleiques genetiquement modifies
KR20240135871A (ko) 2011-06-08 2024-09-12 샤이어 휴먼 지네틱 테라피즈 인크. Mrna 전달을 위한 지질 나노입자 조성물 및 방법
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2763701B1 (fr) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Nucléosides, nucléotides et acides nucléiques modifiés, et leurs utilisations
CN107266391B (zh) * 2011-10-18 2020-04-17 迪克纳制药公司 胺阳离子脂质及其用途
EP2788006A1 (fr) 2011-12-07 2014-10-15 Alnylam Pharmaceuticals, Inc. Lipides biodégradables pour l'administration d'agents actifs
CA3170051A1 (fr) * 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Lipides biodegradables ramifies a terminaisons alkyle et cycloalkyle destines a l'administration d'agents actifs
AU2012352180A1 (en) 2011-12-16 2014-07-31 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
UA120026C2 (uk) * 2012-02-24 2019-09-25 Арбутус Біофарма Корпорейшн Триалкілкатіонні ліпіди і способи їх застосування
WO2013149140A1 (fr) 2012-03-29 2013-10-03 Shire Human Genetic Therapies, Inc. Lipides cationiques ionisables
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
WO2013151663A1 (fr) 2012-04-02 2013-10-10 modeRNA Therapeutics Polynucléotides modifiés pour la production de protéines membranaires
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
JP6232416B2 (ja) * 2012-04-19 2017-11-15 サーナ・セラピューティクス・インコーポレイテッドＳｉｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． オリゴヌクレオチド送達のための、新規なジエステルおよびトリエステルベースの低分子量、生分解性カチオン性脂質
EP3884949A1 (fr) 2012-06-08 2021-09-29 Translate Bio, Inc. Administration pulmonaire d'arnm à des cellules cibles autres que pulmonaires
WO2013185067A1 (fr) 2012-06-08 2013-12-12 Shire Human Genetic Therapies, Inc. Polynucléotides résistant à la nucléase et leurs utilisations
JP6108197B2 (ja) * 2012-07-02 2017-04-05 日油株式会社 三級アミノ基含有脂質の製造方法
RS63237B1 (sr) 2012-11-26 2022-06-30 Modernatx Inc Terminalno modifikovana rnk
AU2014236396A1 (en) 2013-03-14 2015-08-13 Shire Human Genetic Therapies, Inc. Methods for purification of messenger RNA
EP2971010B1 (fr) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation et administration de compositions de nucléosides, de nucléotides, et d'acides nucléiques modifiés
EP3932947A1 (fr) 2013-03-14 2022-01-05 Translate Bio MA, Inc. Procédés et compositions de délivrance d'anticorps codés par arnm
IL305374A (en) 2013-03-14 2023-10-01 Ethris Gmbh CFTR mRNA Assemblies and Related Methods and Uses
RS57316B1 (sr) 2013-03-15 2018-08-31 Translate Bio Inc Sinergističko poboljšanje isporuke nukleinskih kiselina pomoću mešavina formulacija
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US20160151284A1 (en) * 2013-07-23 2016-06-02 Protiva Biotherapeutics, Inc. Compositions and methods for delivering messenger rna
AU2014315287A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2015034925A1 (fr) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Polynucléotides circulaires
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
BR112016007255A2 (pt) 2013-10-03 2017-09-12 Moderna Therapeutics Inc polinucleotídeos que codificam receptor de lipoproteína de baixa densidade
CN105658242A (zh) 2013-10-22 2016-06-08 夏尔人类遗传性治疗公司 用于苯丙酮尿症的mrna疗法
EA201690588A1 (ru) 2013-10-22 2016-09-30 Шир Хьюман Дженетик Терапис, Инк. Доставка мрнк в цнс и ее применение
EP3060257B1 (fr) 2013-10-22 2021-02-24 Translate Bio, Inc. Compositions des lipides pour l'administation arnm
ES2707966T3 (es) 2013-10-22 2019-04-08 Translate Bio Inc Terapia de ARNm para la deficiencia en síntesis de argininosuccinato
SG10201912038TA (en) 2014-04-23 2020-02-27 Modernatx Inc Nucleic acid vaccines
KR102470198B1 (ko) 2014-04-25 2022-11-22 샤이어 휴먼 지네틱 테라피즈 인크. 메신저 rna 의 정제 방법
MA48050A (fr) 2014-05-30 2020-02-12 Translate Bio Inc Lipides biodégradables pour l'administration d'acides nucléiques
US10138213B2 (en) 2014-06-24 2018-11-27 Translate Bio, Inc. Stereochemically enriched compositions for delivery of nucleic acids
CA2953341C (fr) 2014-06-25 2023-01-24 Acuitas Therapeutics Inc. Lipides et formulations de nanoparticules de lipides pour l'administration d'acides nucleiques
WO2016004318A1 (fr) 2014-07-02 2016-01-07 Shire Human Genetic Therapies, Inc. Encapsulation d'arn messager
EP3171895A1 (fr) 2014-07-23 2017-05-31 Modernatx, Inc. Polynucléotides modifiés destinés à la production d'anticorps intracellulaires
US9765333B2 (en) 2014-08-21 2017-09-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing marburg virus gene expression
JP6767976B2 (ja) 2014-12-05 2020-10-14 トランスレイト バイオ， インコーポレイテッド 関節疾患の治療のためのメッセンジャーｒｎａ治療法
US10172924B2 (en) 2015-03-19 2019-01-08 Translate Bio, Inc. MRNA therapy for pompe disease
LT3313829T (lt) * 2015-06-29 2024-08-12 Acuitas Therapeutics Inc. Lipidai ir lipidų nanodalelių sudėtys, skirtos nukleorūgščių tiekimui
LT3350157T (lt) 2015-09-17 2022-02-25 Modernatx, Inc. Junginiai ir kompozicijos terapinei medžiagai teikti intraceliuliniu būdu
MA56219A (fr) 2015-10-14 2022-04-20 Translate Bio Inc Modification d'enzymes apparentées à l'arn pour une production améliorée
JP6921833B2 (ja) 2015-10-22 2021-08-18 モデルナティーエックス， インコーポレイテッド ヒトサイトメガロウイルスワクチン
FI3368507T3 (fi) 2015-10-28 2023-03-21 Acuitas Therapeutics Inc Uusia lipidejä ja lipidinanopartikkeliformulaatioita nukleiinihappojen annostelemiseksi
EP3964200A1 (fr) 2015-12-10 2022-03-09 ModernaTX, Inc. Compositions et procédés permettant d'administrer des agents thérapeutiques
LT3394030T (lt) 2015-12-22 2022-04-11 Modernatx, Inc. Junginiai ir kompozicijos terapinei medžiagai teikti intraceliuliniu būdu
RS63135B1 (sr) 2015-12-23 2022-05-31 Modernatx Inc Postupci upotrebe polinukleotida koji kodiraju ox40 ligand
WO2017120612A1 (fr) 2016-01-10 2017-07-13 Modernatx, Inc. Arnm thérapeutiques codant pour des anticorps anti-ctla-4
EP3440206B1 (fr) 2016-04-08 2020-10-28 Translate Bio, Inc. Acide nucléique codant multimère et ses utilisations
AU2017283479B2 (en) 2016-06-13 2023-08-17 Translate Bio, Inc. Messenger RNA therapy for the treatment of ornithine transcarbamylase deficiency
EP3532103A1 (fr) 2016-10-26 2019-09-04 Acuitas Therapeutics, Inc. Formulations de nanoparticules lipidiques
EP3538067A1 (fr) 2016-11-08 2019-09-18 Modernatx, Inc. Formulations stabilisées de nanoparticules lipidiques
AU2018224326B2 (en) 2017-02-27 2024-01-04 Translate Bio, Inc. Novel codon-optimized CFTR mRNA
JP7220154B2 (ja) 2017-03-15 2023-02-09 モデルナティエックス インコーポレイテッド アミノ脂質の結晶形態
JP7332478B2 (ja) 2017-03-15 2023-08-23 モデルナティエックス インコーポレイテッド 脂質ナノ粒子製剤
LT3596041T (lt) 2017-03-15 2023-01-25 Modernatx, Inc. Terapinių medžiagų, skirtų intraląsteliniam tiekimui, junginys ir sudėtys
US11357856B2 (en) 2017-04-13 2022-06-14 Acuitas Therapeutics, Inc. Lipids for delivery of active agents
WO2018191719A1 (fr) 2017-04-13 2018-10-18 Acuitas Therapeutics, Inc. Administration lipidique d'agents thérapeutiques au tissu adipeux
EP3615510B1 (fr) 2017-04-28 2024-03-27 Acuitas Therapeutics, Inc. Nouveaux lipides carbonyles et formulations nanoparticulaires lipidiques pour l'administration d'acides nucléiques
EP3624824B1 (fr) 2017-05-16 2024-07-10 Translate Bio, Inc. D'arnm à codons optimisés codant pour la cftr pour l'utilisation dans le traitement de la fibrose kystique
WO2018213731A1 (fr) 2017-05-18 2018-11-22 Modernatx, Inc. Polynucléotides codant pour des polypeptides d'interleukine-12 (il12) ancrés et leurs utilisations
EP3638678A1 (fr) 2017-06-14 2020-04-22 Modernatx, Inc. Composés et compositions pour l'administration intracellulaire d'agents
EP3638292A1 (fr) 2017-06-14 2020-04-22 ModernaTX, Inc. Polynucléotides codant pour le facteur viii de coagulation
WO2018232357A1 (fr) 2017-06-15 2018-12-20 Modernatx, Inc. Formulations d'arn
US20210228738A1 (en) 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
EP3668833A1 (fr) 2017-08-16 2020-06-24 Acuitas Therapeutics, Inc. Lipides destinés à être utilisés dans des formulations nanoparticulaires lipidiques
WO2019036030A1 (fr) 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. Lipides destinés à être utilisés dans des formulations de nanoparticules lipidiques
JP7461872B2 (ja) 2017-08-17 2024-04-04 アクイタス セラピューティクス インコーポレイテッド 脂質ナノ粒子製剤における使用のための脂質
WO2019036028A1 (fr) 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. Lipides destinés à être utilisés dans des formulations nanoparticulaires lipidiques
CA3073211A1 (fr) 2017-08-31 2019-03-07 Modernatx, Inc. Procedes de fabrication de nanoparticules lipidiques
WO2019089828A1 (fr) 2017-10-31 2019-05-09 Acuitas Therapeutics, Inc. Nanoparticules lipidiques lamellaires
AU2018392716A1 (en) 2017-12-20 2020-06-18 Translate Bio, Inc. Improved composition and methods for treatment of ornithine transcarbamylase deficiency
CN111902397B (zh) 2018-03-27 2024-04-12 日油株式会社 改进了细胞内动力学的阳离子脂质
CN117430538A (zh) * 2018-05-24 2024-01-23 川斯勒佰尔公司 硫酯阳离子脂质
WO2020041793A1 (fr) 2018-08-24 2020-02-27 Translate Bio, Inc. Procédés de purification d'arn messager
CA3113025A1 (fr) 2018-09-19 2020-03-26 Modernatx, Inc. Lipides peg et leurs utilisations
US20220031631A1 (en) 2018-09-19 2022-02-03 Modernatx, Inc. High-purity peg lipids and uses thereof
EP3852728B1 (fr) 2018-09-20 2024-09-18 ModernaTX, Inc. Préparation de nanoparticules lipidiques et leurs méthodes d'administration
WO2020061426A2 (fr) 2018-09-21 2020-03-26 Acuitas Therapeutics, Inc. Systèmes et procédés pour la fabrication de nanoparticules lipidiques et de liposomes
US20230050672A1 (en) * 2018-11-21 2023-02-16 Translate Bio, Inc. Cationic lipid compounds
CN113474328A (zh) 2019-01-11 2021-10-01 爱康泰生治疗公司 用于脂质纳米颗粒递送活性剂的脂质
EP3962902A1 (fr) * 2019-05-03 2022-03-09 Translate Bio, Inc. Lipides cationiques di-thioesters
CN114423869A (zh) 2019-07-19 2022-04-29 旗舰先锋创新Vi有限责任公司 重组酶组合物和使用方法
JP2022544652A (ja) 2019-08-14 2022-10-20 アクイタス セラピューティクス インコーポレイテッド 核酸の送達のための改善された脂質ナノ粒子
CA3154618A1 (fr) 2019-09-19 2021-03-25 Modernatx, Inc. Composes lipidiques de queue ramifies et compositions pour l'administration intracellulaire d'agents therapeutiques
CA3147643A1 (fr) 2019-09-23 2021-04-01 Omega Therapeutics, Inc. Compositions et procedes de modulation de l'expression genique du facteur nucleaire hepatocytaire 4-alpha (hnf4?)
CN114391040A (zh) 2019-09-23 2022-04-22 欧米茄治疗公司 用于调节载脂蛋白b(apob)基因表达的组合物和方法
WO2021183720A1 (fr) 2020-03-11 2021-09-16 Omega Therapeutics, Inc. Compositions et procédés de modulation de l'expression génique de forkhead box p3 (foxp3)
AU2021244555A1 (en) 2020-03-24 2022-11-24 Generation Bio Co. Non-viral dna vectors and uses thereof for expressing factor ix therapeutics
WO2021195218A1 (fr) 2020-03-24 2021-09-30 Generation Bio Co. Vecteurs d'adn non viraux et leurs utilisations pour exprimer des agents thérapeutiques de la maladie de gaucher
JP2023520062A (ja) 2020-03-30 2023-05-15 バイオエヌテック エスエー クローディン１８．２を標的とするｒｎａ組成物
JP2023526422A (ja) 2020-05-20 2023-06-21 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー コロナウイルス抗原組成物及びそれらの使用
IL298363A (en) 2020-05-20 2023-01-01 Flagship Pioneering Innovations Vi Llc Immunogenic compositions and uses thereof
CN116018405A (zh) 2020-05-29 2023-04-25 旗舰先锋创新Vi有限责任公司 Trem组合物及其相关方法
CA3182026A1 (fr) 2020-05-29 2021-12-02 Flagship Pioneering Innovations Vi, Llc. Compositions a base de trem et procedes associes
TW202208630A (zh) 2020-06-15 2022-03-01 美國全美兒童醫院之研究學會 針對肌肉營養不良症的腺相關病毒載體遞送
EP4165012A1 (fr) * 2020-06-16 2023-04-19 Rhodia Operations Nouveaux composés d'ammonium utiles en tant que tensioactifs
JP2023535365A (ja) 2020-07-16 2023-08-17 アクイタス セラピューティクス インコーポレイテッド 脂質ナノ粒子に使用するためのカチオン性脂質
IL299925A (en) 2020-07-27 2023-03-01 Anjarium Biosciences Ag Compounds of DNA molecules, methods for their preparation and methods of using them
IL300111A (en) 2020-08-06 2023-03-01 Modernatx Inc The vehicles for the transfer of cargo molecules to the airway epithelium
TW202218669A (zh) 2020-09-03 2022-05-16 美商旗艦先鋒創新有限責任公司 免疫原性組成物及其用途
MX2023006056A (es) * 2020-11-25 2023-06-06 Akagera Medicines Inc Nanoparticulas lipidicas para suministro de acidos nucleicos y metodos de uso de las mismas.
EP4267732A1 (fr) 2020-12-23 2023-11-01 Flagship Pioneering Innovations VI, LLC Compositions de molécules effectrices à base d'arnt (trem) modifiées et leurs utilisations
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
EP4313109A1 (fr) 2021-03-31 2024-02-07 Flagship Pioneering Innovations V, Inc. Polypeptides de thanotransmission et leur utilisation dans le traitement du cancer
CN115197078B (zh) * 2021-04-08 2024-06-04 厦门赛诺邦格生物科技股份有限公司 一种聚乙二醇化脂质及其修饰的脂质体、含该脂质体的药物组合物及其制剂和应用
EP4319803A1 (fr) 2021-04-08 2024-02-14 Vaxthera SAS Vaccin à coronavirus comprenant une protéine mosaïque
EP4326860A1 (fr) 2021-04-20 2024-02-28 Anjarium Biosciences AG Compositions de molécules d'adn codant pour la beta-alpha-1, 6-glucosidase, 4-alpha-glucanotransférase, leurs procédés de fabrication et leurs procédés d'utilisation
WO2022232286A1 (fr) 2021-04-27 2022-11-03 Generation Bio Co. Vecteurs d'adn non viraux exprimant des anticorps anti-coronavirus et leurs utilisations
MX2023012643A (es) 2021-04-27 2024-01-05 Generation Bio Co Vectores de adn no virales que expresan anticuerpos terapéuticos y usos de estos.
CA3220351A1 (fr) * 2021-05-28 2022-12-01 Nanovation Therapeutics Inc. Lipides de type mc3 et leur utilisation dans la preparation de nanoparticules lipidiques
WO2023283359A2 (fr) 2021-07-07 2023-01-12 Omega Therapeutics, Inc. Compositions et procédés de modulation de l'expression génique de la protéine 1 du récepteur frizzled secrété (sfrp1)
WO2023001894A1 (fr) 2021-07-20 2023-01-26 Ags Therapeutics Sas Vésicules extracellulaires provenant de microalgues, leur préparation et leurs utilisations
EP4377457A1 (fr) 2021-07-26 2024-06-05 Flagship Pioneering Innovations VI, LLC Compositions de trem et leurs utilisations
CN115671025A (zh) * 2021-07-27 2023-02-03 中国医学科学院基础医学研究所 Fa类脂质化合物在制备核酸递送试剂中的应用及其相关产品
WO2023023055A1 (fr) 2021-08-16 2023-02-23 Renagade Therapeutics Management Inc. Compositions et procédés d'optimisation du tropisme de systèmes d'administration d'arn
WO2023026315A1 (fr) * 2021-08-23 2023-03-02 国立大学法人東北大学 Développement de technologie de contrôle de qualité pour formulation pharmaceutique ayant un arn encapsulé dans une membrane lipidique
JP2024534697A (ja) 2021-09-14 2024-09-20 レナゲード セラピューティクス マネージメント インコーポレイテッド 非環状脂質及びその使用方法
EP4402123A1 (fr) 2021-09-14 2024-07-24 Renagade Therapeutics Management Inc. Lipides cycliques et leurs procédés d'utilisation
JP2024534428A (ja) 2021-09-17 2024-09-20 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー 環状ポリリボヌクレオチドを生成するための組成物及び方法
AU2022370530A1 (en) 2021-10-18 2024-05-02 Flagship Pioneering Innovations Vi, Llc Compositions and methods for purifying polyribonucleotides
EP4426832A1 (fr) 2021-11-03 2024-09-11 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Édition précise du génome à l'aide de rétrons
IL312490A (en) 2021-11-08 2024-07-01 Orna Therapeutics Inc Fat nanoparticle preparations for the administration of circular polynucleotides
WO2023086465A1 (fr) 2021-11-12 2023-05-19 Modernatx, Inc. Compositions pour l'administration de molécules de charge utile à l'épithélium des voies respiratoires
WO2023091490A1 (fr) 2021-11-16 2023-05-25 Senda Biosciences, Inc. Nouveaux lipides ionisables et nanoparticules lipidiques et leurs procédés d'utilisation
MX2024006134A (es) 2021-11-22 2024-07-29 Sail Biomedicines Inc Lipidos ionizables novedosos y nanoparticulas de lipido y metodos para usar los mismos.
EP4436984A1 (fr) 2021-11-24 2024-10-02 Flagship Pioneering Innovations VI, LLC Compositions immunogènes de coronavirus et leurs utilisations
KR20240122785A (ko) 2021-11-24 2024-08-13 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 면역원성 조성물 및 이의 용도
EP4436983A1 (fr) 2021-11-24 2024-10-02 Flagship Pioneering Innovations VI, LLC Compositions d'immunogènes du virus varicelle-zona et leurs utilisations
EP4448485A2 (fr) 2021-12-16 2024-10-23 Acuitas Therapeutics, Inc. Lipides destinés à être utilisés dans des formulations de nanoparticules lipidiques
AU2022413687A1 (en) 2021-12-17 2024-06-27 Flagship Pioneering Innovations Vi, Llc Methods for enrichment of circular rna under denaturing conditions
AU2022417517A1 (en) 2021-12-22 2024-06-27 Flagship Pioneering Innovations Vi, Llc Compositions and methods for purifying polyribonucleotides
WO2023122789A1 (fr) 2021-12-23 2023-06-29 Flagship Pioneering Innovations Vi, Llc Polyribonucléotides circulaires codant pour des polypeptides antifusogènes
EP4452928A1 (fr) 2021-12-23 2024-10-30 Renagade Therapeutics Management Inc. Lipides contraints et procédés d'utilisation associés
WO2023135273A2 (fr) 2022-01-14 2023-07-20 Anjarium Biosciences Ag Compositions de molécules d'adn codant pour le facteur viii, leurs procédés de préparation et leurs méthodes d'utilisation
WO2023141602A2 (fr) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Rétrons modifiés et méthodes d'utilisation
WO2023147090A1 (fr) 2022-01-27 2023-08-03 BioNTech SE Compositions pharmaceutiques pour administration d'antigènes du virus herpès simplex et méthodes associées
WO2023144127A1 (fr) 2022-01-31 2023-08-03 Ags Therapeutics Sas Vésicules extracellulaires provenant de microalgues, leur biodistribution suite à leur administration, et leurs utilisations
WO2023154818A1 (fr) 2022-02-09 2023-08-17 Modernatx, Inc. Méthodes et formulations d'administration par voie muqueuse
WO2023161350A1 (fr) 2022-02-24 2023-08-31 Io Biotech Aps Administration nucléotidique d'une thérapie anticancéreuse
WO2023160702A1 (fr) * 2022-02-28 2023-08-31 深圳深信生物科技有限公司 Composé amino-lipide, son procédé de préparation, composition et utilisation de celui-ci
WO2023177655A1 (fr) 2022-03-14 2023-09-21 Generation Bio Co. Compositions vaccinales prime-boost hétérologues et méthodes d'utilisation
AU2023239151A1 (en) 2022-03-25 2024-10-03 Sail Biomedicines, Inc. Novel ionizable lipids and lipid nanoparticles and methods of using the same
AU2023251104A1 (en) 2022-04-07 2024-10-17 Renagade Therapeutics Management Inc. Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents
WO2023196634A2 (fr) 2022-04-08 2023-10-12 Flagship Pioneering Innovations Vii, Llc Vaccins et procédés associés
WO2023205424A2 (fr) * 2022-04-21 2023-10-26 Greenlight Biosciences, Inc. Compositions lipidiques et procédés de distribution d'acide nucléique
WO2023220083A1 (fr) 2022-05-09 2023-11-16 Flagship Pioneering Innovations Vi, Llc Compositions de trem et procédés d'utilisation pour traiter des troubles prolifératifs
CN117203186A (zh) * 2022-05-13 2023-12-08 南方科技大学 一种含有二硫键的脂质化合物及其组合物
WO2023218431A1 (fr) 2022-05-13 2023-11-16 BioNTech SE Compositions d'arn ciblant le vih
WO2023220729A2 (fr) 2022-05-13 2023-11-16 Flagship Pioneering Innovations Vii, Llc Compositions d'adn à double brin et procédés associés
WO2023230587A2 (fr) 2022-05-25 2023-11-30 Akagera Medicines, Inc. Nanoparticules lipidiques pour l'administration d'acides nucléiques et leurs procédés d'utilisation
WO2023230295A1 (fr) 2022-05-25 2023-11-30 BioNTech SE Compositions d'arn pour l'administration d'antigènes de la variole du singe et méthodes associées
WO2023232747A1 (fr) 2022-05-30 2023-12-07 BioNTech SE Complexes pour l'administration d'acides nucléiques
WO2023232976A1 (fr) 2022-06-03 2023-12-07 Ags Therapeutics Sas Vésicules extracellulaires provenant de microalgues génétiquement modifiées contenant une cargaison chargée de manière endogène, leur préparation et utilisations
WO2023239756A1 (fr) 2022-06-07 2023-12-14 Generation Bio Co. Compositions de nanoparticules lipidiques et leurs utilisations
WO2023250112A1 (fr) 2022-06-22 2023-12-28 Flagship Pioneering Innovations Vi, Llc Compositions de trem modifiées et leurs utilisations
WO2024030856A2 (fr) 2022-08-01 2024-02-08 Flagship Pioneering Innovations Vii, Llc Protéines immunomodulatrices et méthodes associées
WO2024035952A1 (fr) 2022-08-12 2024-02-15 Remix Therapeutics Inc. Procédés et compositions pour moduler l'épissage au niveau de sites d'épissage alternatifs
WO2024040222A1 (fr) 2022-08-19 2024-02-22 Generation Bio Co. Adn à extrémités fermées clivable (adnce) et ses procédés d'utilisation
WO2024049979A2 (fr) 2022-08-31 2024-03-07 Senda Biosciences, Inc. Nouveaux lipides ionisables et nanoparticules lipidiques, ainsi que procédés d'utilisation associés
WO2024064931A1 (fr) 2022-09-23 2024-03-28 BioNTech SE Compositions pour l'administration d'antigènes du stade hépatique et méthodes associées
WO2024064934A1 (fr) 2022-09-23 2024-03-28 BioNTech SE Compositions pour administration d'antigènes csp de plasmodium et procédés associés
WO2024063789A1 (fr) 2022-09-23 2024-03-28 BioNTech SE Compositions pour l'administration d'antigènes du paludisme et méthodes associées
WO2024063788A1 (fr) 2022-09-23 2024-03-28 BioNTech SE Compositions pour l'administration d'antigènes du paludisme et méthodes associées
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
WO2024074211A1 (fr) 2022-10-06 2024-04-11 BioNTech SE Compositions d'arn ciblant la claudine-18.2
WO2024074634A1 (fr) 2022-10-06 2024-04-11 BioNTech SE Compositions d'arn ciblant la claudine 18.2
WO2024088808A1 (fr) 2022-10-24 2024-05-02 Ags Therapeutics Sas Vésicules extracellulaires provenant de microalgues, leur biodistribution lors d'une administration intranasale, et leurs utilisations
WO2024097664A1 (fr) 2022-10-31 2024-05-10 Flagship Pioneering Innovations Vi, Llc Compositions et procédés de purification de polyribonucléotides
WO2024102762A1 (fr) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Lipides et compositions de nanoparticules lipidiques pour administration de polynucléotides
WO2024102677A1 (fr) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Compositions d'arn circulaire
WO2024102799A1 (fr) 2022-11-08 2024-05-16 Flagship Pioneering Innovations Vi, Llc Compositions et procédés de production de polyribonucléotides circulaires
WO2024102730A1 (fr) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Lipides et compositions de nanoparticules pour l'administration de polynucléotides
WO2024107906A2 (fr) * 2022-11-16 2024-05-23 Seawolf Therapeutics, Inc. Lipides ionisables et compositions de nanoparticules lipidiques pour l'administration d'acides nucléiques
WO2024119051A1 (fr) 2022-12-01 2024-06-06 Generation Bio Co. Nouveaux lipides conjugués à un polyglycérol et compositions de nanoparticules lipidiques les comprenant
WO2024119039A2 (fr) 2022-12-01 2024-06-06 Generation Bio Co. Nanoparticules lipidiques furtives et leurs utilisations
WO2024119103A1 (fr) 2022-12-01 2024-06-06 Generation Bio Co. Nanoparticules lipidiques comprenant des acides nucléiques et des polymères à ancrage lipidique
WO2024119074A1 (fr) 2022-12-01 2024-06-06 Generation Bio Co. Compositions de nanoparticules lipidiques furtives pour le ciblage cellulaire
WO2024129988A1 (fr) 2022-12-14 2024-06-20 Flagship Pioneering Innovations Vii, Llc Compositions et procédés d'administration d'agents thérapeutiques à un os
WO2024141955A1 (fr) 2022-12-28 2024-07-04 BioNTech SE Compositions d'arn ciblant le vih
WO2024151685A1 (fr) 2023-01-09 2024-07-18 Beth Israel Deaconess Medical Center, Inc. Molécules d'acide nucléique recombinant et leur utilisation dans la cicatrisation des plaies
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2024151673A2 (fr) 2023-01-09 2024-07-18 President And Fellows Of Harvard College Molécules d'acide nucléique recombinant et leur utilisation dans la cicatrisation de plaies
WO2024151583A2 (fr) 2023-01-09 2024-07-18 Flagship Pioneering Innovations Vii, Llc Vaccins et procédés associés
US20240269263A1 (en) 2023-02-06 2024-08-15 Flagship Pioneering Innovations Vii, Llc Immunomodulatory compositions and related methods
WO2024173307A2 (fr) 2023-02-13 2024-08-22 Flagship Pioneering Innovation Vii, Llc Lipides ionisables contenant un lieur clivable et supports lipidiques pour compositions thérapeutiques
US20240293582A1 (en) 2023-02-17 2024-09-05 Flagship Pioneering Innovations Vii, Llc Dna compositions comprising modified cytosine
WO2024173828A1 (fr) 2023-02-17 2024-08-22 Flagship Pioneering Innovations Vii, Llc Compositions d'adn comprenant un uracile modifié
WO2024192420A1 (fr) 2023-03-15 2024-09-19 Flagship Pioneering Innovations Vi, Llc Compositions comprenant des polyribonucléotides et leurs utilisations
WO2024192422A1 (fr) 2023-03-15 2024-09-19 Flagship Pioneering Innovations Vi, Llc Compositions immunogènes et leurs utilisations
WO2024205657A2 (fr) 2023-03-29 2024-10-03 Orna Therapeutics, Inc. Lipides et compositions de nanoparticules lipidiques pour administration de polynucléotides
WO2024216191A1 (fr) 2023-04-12 2024-10-17 Flagship Pioneering Innovations Vi, Llc Trem modifiées, compositions et procédés associés
WO2024216128A1 (fr) 2023-04-12 2024-10-17 Flagship Pioneering Innovations Vi, Llc Trems destinés à être utilisés dans la correction de mutations faux-sens
WO2024220746A2 (fr) 2023-04-21 2024-10-24 Flagship Pioneering Innovations Vii, Llc Agents d'arni ciblant la synthase d'acides gras et procédés associés

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US627711A (en) 1899-02-21 1899-06-27 Smith A Waterman Combined match-safe and cigar-cutter.
US3993754A (en) 1974-10-09 1976-11-23 The United States Of America As Represented By The United States Energy Research And Development Administration Liposome-encapsulated actinomycin for cancer chemotherapy
US4086257A (en) 1976-10-12 1978-04-25 Sears Barry D Phosphatidyl quaternary ammonium compounds
CH624011A5 (fr) 1977-08-05 1981-07-15 Battelle Memorial Institute
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4522803A (en) 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US4588578A (en) 1983-08-08 1986-05-13 The Liposome Company, Inc. Lipid vesicles prepared in a monophase
AU587989B2 (en) 1984-10-16 1989-09-07 Mitsubishi Chemical Corporation DMA fragments, expression vectors, proteins, hosts, and process for production of the proteins
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US5182364A (en) 1990-02-26 1993-01-26 The Scripps Research Institute Polypeptide analogs of apolipoprotein E
US5177189A (en) 1989-08-18 1993-01-05 The Scripps Research Institute Polypeptide analogs of Apolipoprotein E
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
US5473039A (en) 1989-08-18 1995-12-05 The Scripps Research Institute Polypeptide analogs of apolipoprotein E, diagnostic systems and methods using the analogs
US5168045A (en) 1989-08-18 1992-12-01 The Scripps Research Institute Diagnostic systems and methods using polypeptide analogs of apolipoprotein e
US5286634A (en) 1989-09-28 1994-02-15 Stadler Joan K Synergistic method for host cell transformation
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1993000443A1 (fr) 1991-06-26 1993-01-07 Bio-Technology General Corp. Purification d'apolipoproteine e recombinante tiree de bacteries
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
WO1993023011A1 (fr) 1992-05-18 1993-11-25 Minnesota Mining And Manufacturing Company Dispositif d'apport de medicament a travers des muqueuses
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5426039A (en) 1993-09-08 1995-06-20 Bio-Rad Laboratories, Inc. Direct molecular cloning of primer extended DNA containing an alkane diol
US5753613A (en) 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
US5785992A (en) 1994-09-30 1998-07-28 Inex Pharmaceuticals Corp. Compositions for the introduction of polyanionic materials into cells
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
AU701106B2 (en) * 1995-06-07 1999-01-21 Promega Biosciences, Inc. Novel carbamate-based cationic lipids
US5705385A (en) 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
ES2231819T3 (es) 1995-06-07 2005-05-16 Inex Pharmaceuticals Corp Particulas de lipido-acido nucleico preparadas a traves de un intermedio complejo de lipido-acido nucleico hidrofobo y uso para transferir genes.
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5672685A (en) 1995-10-04 1997-09-30 Duke University Source of apolipoprotein E and method of isolating apolipoprotein E
US5892074A (en) 1997-02-18 1999-04-06 Seidel; Michael C. Synthesis of conjugated linoleic acid (CLA)
DE69841002D1 (de) 1997-05-14 2009-09-03 Univ British Columbia Hochwirksame verkapselung von nukleinsäuren in lipidvesikeln
AU8428998A (en) 1997-07-24 1999-02-16 Inex Pharmaceuticals Corporation Preparation of lipid-nucleic acid particles using a solvent extraction and direct hydration method
US6320017B1 (en) 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
CA2335393C (fr) 1998-07-20 2008-09-23 Inex Pharmaceuticals Corporation Complexes d'acides nucleiques encapsules dans des liposomes
US6852334B1 (en) 1999-04-20 2005-02-08 The University Of British Columbia Cationic peg-lipids and methods of use
CA2370690A1 (fr) 1999-04-20 2000-10-26 The University Of British Columbia Lipides peg cationiques et methodes d'utilisation
US7189705B2 (en) 2000-04-20 2007-03-13 The University Of British Columbia Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
TW593427B (en) 2000-12-18 2004-06-21 Nektar Therapeutics Al Corp Synthesis of high molecular weight non-peptidic polymer derivatives
US7053150B2 (en) 2000-12-18 2006-05-30 Nektar Therapeutics Al, Corporation Segmented polymers and their conjugates
WO2002087541A1 (fr) 2001-04-30 2002-11-07 Protiva Biotherapeutics Inc. Formulations a base de lipides pour transfert genique
AU2003245160B2 (en) 2002-06-28 2009-09-24 Arbutus Biopharma Corporation Method and apparatus for producing liposomes
EP1604022A2 (fr) 2003-03-06 2005-12-14 Oligo Engine, Inc. Modulation de l'expression genetique au moyen d'hybrides adn/arn
US20050148531A1 (en) 2003-05-15 2005-07-07 Todd Hauser Modulation of gene expression using DNA-DNA hybrids
KR101168440B1 (ko) 2003-07-16 2012-07-27 프로티바 바이오쎄라퓨틱스, 인코포레이티드 지질 캡슐화된 간섭 ｒｎａ
WO2005026372A1 (fr) 2003-09-15 2005-03-24 Protiva Biotherapeutics, Inc. Composes conjugues lipidiques polyethyleneglycol-dialkyloxypropyle et utilisations de ces composes
CA2569645C (fr) 2004-06-07 2014-10-28 Protiva Biotherapeutics, Inc. Lipides cationiques et leurs procedes d'utilisation
CA2569664C (fr) 2004-06-07 2013-07-16 Protiva Biotherapeutics, Inc. Arn interferant encapsule dans des lipides
CA2587411A1 (fr) 2004-11-17 2006-05-26 Protiva Biotherapeutics, Inc. Silence arnsi de l'apolipoproteine b
US7404969B2 (en) 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
AU2006336384B2 (en) 2005-02-14 2010-12-16 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
JP5639338B2 (ja) 2005-07-27 2014-12-10 プロチバ バイオセラピューティクス インコーポレイティッド リポソームの製造システムおよび製造方法
US7838658B2 (en) 2005-10-20 2010-11-23 Ian Maclachlan siRNA silencing of filovirus gene expression
WO2007051303A1 (fr) 2005-11-02 2007-05-10 Protiva Biotherapeutics, Inc. Molecules d'arnsi modifiees et utilisations de celles-ci
WO2007056861A1 (fr) 2005-11-18 2007-05-24 Protiva Biotherapeutics, Inc. Attenuation de l'expression du gene du virus de la grippe par arnsi
US8598333B2 (en) 2006-05-26 2013-12-03 Alnylam Pharmaceuticals, Inc. SiRNA silencing of genes expressed in cancer
DK2068886T3 (da) 2006-10-03 2013-11-18 Tekmira Pharmaceuticals Corp Lipidholdige præparater
CA2710713C (fr) 2007-12-27 2017-09-19 Protiva Biotherapeutics, Inc. Silencage de l'expression de la polo-like kinase a l'aide d'un arn interferent
CA3044134A1 (fr) * 2008-01-02 2009-07-09 Arbutus Biopharma Corporation Compositions et procedes ameliores pour la delivrance d'acides nucleiques
WO2009129319A2 (fr) 2008-04-15 2009-10-22 Protiva Biotherapeutics, Inc. Réduction au silence de l'expression du gène csn5 au moyen d'arn interférant
JP5475753B2 (ja) 2008-04-15 2014-04-16 プロチバ バイオセラピューティクス インコーポレイティッド 核酸送達用の脂質製剤
WO2009132131A1 (fr) * 2008-04-22 2009-10-29 Alnylam Pharmaceuticals, Inc. Formulation lipidique améliorée à base d'amino lipide
EP2310440A4 (fr) 2008-07-10 2013-06-05 Serina Therapeutics Inc Polyoxazolines avec groupes terminaux inertes, polyoxazolines préparées à partir de groupes initiateurs protégés, et composés en rapport
EP2743265B1 (fr) 2008-10-09 2017-03-15 Arbutus Biopharma Corporation Lipides aminés améliorés et procédés d'administration d'acides nucléiques
EP2344639B1 (fr) * 2008-10-20 2015-04-22 Alnylam Pharmaceuticals, Inc. Compositions et procédés pour inhiber l'expression de la transthyrétine
US8722082B2 (en) 2008-11-10 2014-05-13 Tekmira Pharmaceuticals Corporation Lipids and compositions for the delivery of therapeutics
EP3284482B1 (fr) * 2008-11-10 2020-06-03 Arbutus Biopharma Corporation Nouveaux lipides et compositions d'administration d'agents thérapeutiques
EP2405921A4 (fr) 2009-01-26 2013-05-22 Protiva Biotherapeutics Inc Compositions et procédés d'inactivation de l'expression de l'apolipoprotéine c-iii
CA2751342C (fr) 2009-01-29 2019-05-07 Alnylam Pharmaceuticals, Inc. Formules lipides renfermant un lipide cationique et un lipide cible renfermant de la galactosamine n-acetyle pour la livraison d'acide nucleique
WO2010105372A1 (fr) 2009-03-20 2010-09-23 Protiva Biotherapeutics, Inc. Compositions et procedes d'inactivation de l'expression du virus de l'hepatite c
AU2010245933B2 (en) * 2009-05-05 2016-06-16 Arbutus Biopharma Corporation Methods of delivering oligonucleotides to immune cells
US20110071208A1 (en) 2009-06-05 2011-03-24 Protiva Biotherapeutics, Inc. Lipid encapsulated dicer-substrate interfering rna
CA3014827A1 (fr) 2009-06-10 2010-12-16 Jianxin Chen Lipide cationique ameliore de formule i
US8569256B2 (en) 2009-07-01 2013-10-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
IL292615B2 (en) 2009-07-01 2023-11-01 Protiva Biotherapeutics Inc Nucleic acid-lipid particles, preparations containing them and their uses
US8716464B2 (en) 2009-07-20 2014-05-06 Thomas W. Geisbert Compositions and methods for silencing Ebola virus gene expression
WO2011017548A1 (fr) * 2009-08-05 2011-02-10 Alnylam Pharmaceuticals, Inc. Compositions à formulation lipidique et procédés pour inhiber l'expression de gènes eg5 et vegf
CA2775092A1 (fr) 2009-09-23 2011-03-31 Protiva Biotherapeutics, Inc. Compositions et procedes pour reduire au silence des genes exprimes dans le cancer
EP2512449B1 (fr) * 2009-12-18 2019-08-07 The University of British Columbia Procédés et compositions pour l'administration d'acides nucléiques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2011141705A1 *

Also Published As

Publication number Publication date
CA2799091A1 (fr) 2011-11-17
JP2022163090A (ja) 2022-10-25
JP2018197239A (ja) 2018-12-13
US20130123338A1 (en) 2013-05-16
US20200282060A1 (en) 2020-09-10
US20170151333A1 (en) 2017-06-01
WO2011141705A1 (fr) 2011-11-17
WO2011141705A8 (fr) 2013-01-03
JP2013527856A (ja) 2013-07-04
EP2569276B1 (fr) 2021-02-24
JP2016222666A (ja) 2016-12-28
JP2020176135A (ja) 2020-10-29

Similar Documents

Publication Publication Date Title
EP2569276B1 (fr) Nouveaux lipides cationiques et procédés d'utilisation de ceux-ci
US20190106379A1 (en) Novel cyclic cationic lipids and methods of use
JP7110297B2 (ja) トリアルキルカチオン性脂質およびその使用方法
US8865675B2 (en) Compositions and methods for silencing apolipoprotein B
US9126966B2 (en) Cationic lipids and methods of use thereof
US20190032051A1 (en) Non-liposomal systems for nucleic acid delivery
WO2011066651A1 (fr) Préparations de snalp contenant des antioxydants
CA2767129A1 (fr) Compositions et procedes permettant le silencage de l'apolipoproteine b
JP2024161074A (ja) 陽イオン性脂質およびその使用方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20121206

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1183293

Country of ref document: HK

17Q First examination report despatched

Effective date: 20151125

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ARBUTUS BIOPHARMA CORPORATION

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/88 20060101ALI20200130BHEP

Ipc: C07D 249/04 20060101ALI20200130BHEP

Ipc: C07C 237/06 20060101ALI20200130BHEP

Ipc: C07C 229/12 20060101ALI20200130BHEP

Ipc: A61K 49/04 20060101ALI20200130BHEP

Ipc: C07C 271/20 20060101ALI20200130BHEP

Ipc: A61K 48/00 20060101ALI20200130BHEP

Ipc: C07C 217/08 20060101AFI20200130BHEP

Ipc: C07C 217/46 20060101ALI20200130BHEP

Ipc: C07D 233/60 20060101ALI20200130BHEP

Ipc: C07C 327/06 20060101ALI20200130BHEP

Ipc: C12N 15/11 20060101ALI20200130BHEP

Ipc: C07C 229/30 20060101ALI20200130BHEP

INTG Intention to grant announced

Effective date: 20200228

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602011070214

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1364262

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210315

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210224

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210624

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210224

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210224

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210525

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210524

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210524

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1364262

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210224

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210224

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210224

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210224

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210224

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210624

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210224

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210224

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210224

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210224

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602011070214

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210224

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210224

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210224

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210224

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210224

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210512

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210224

26N No opposition filed

Effective date: 20211125

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210224

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210224

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210624

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20110512

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210224

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230519

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20240315

Year of fee payment: 14

Ref country code: IE

Payment date: 20240312

Year of fee payment: 14

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210224

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240321

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240308

Year of fee payment: 14

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210224

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240319

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20240602

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20240422

Year of fee payment: 14

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210224